
R version 4.0.2 (2020-06-22) -- "Taking Off Again"
Copyright (C) 2020 The R Foundation for Statistical Computing
Platform: x86_64-apple-darwin17.0 (64-bit)

R is free software and comes with ABSOLUTELY NO WARRANTY.
You are welcome to redistribute it under certain conditions.
Type 'license()' or 'licence()' for distribution details.

  Natural language support but running in an English locale

R is a collaborative project with many contributors.
Type 'contributors()' for more information and
'citation()' on how to cite R or R packages in publications.

Type 'demo()' for some demos, 'help()' for on-line help, or
'help.start()' for an HTML browser interface to help.
Type 'q()' to quit R.

During startup - Warning messages:
1: Setting LC_CTYPE failed, using "C" 
2: Setting LC_COLLATE failed, using "C" 
3: Setting LC_TIME failed, using "C" 
4: Setting LC_MESSAGES failed, using "C" 
5: Setting LC_MONETARY failed, using "C" 
[R.app GUI 1.72 (7847) x86_64-apple-darwin17.0]

WARNING: You're using a non-UTF8 locale, therefore only ASCII characters will work.
Please read R for Mac OS X FAQ (see Help) section 9 and adjust your system preferences accordingly.
[Workspace restored from /Users/ras/.RData]
[History restored from /Users/ras/.Rapp.history]

> install.packages("pdftools")
--- Please select a CRAN mirror for use in this session ---
Error in if (res > nrow(m)) { : argument is of length zero
> install.packages("pdftools")
--- Please select a CRAN mirror for use in this session ---
also installing the dependency 'qpdf'

trying URL 'https://cloud.r-project.org/bin/macosx/contrib/4.0/qpdf_1.1.tgz'
Content type 'application/x-gzip' length 4523282 bytes (4.3 MB)
==================================================
downloaded 4.3 MB

trying URL 'https://cloud.r-project.org/bin/macosx/contrib/4.0/pdftools_2.3.1.tgz'
Content type 'application/x-gzip' length 6612979 bytes (6.3 MB)
==================================================
downloaded 6.3 MB

tar: Failed to set default locale
tar: Failed to set default locale

The downloaded binary packages are in
	/var/folders/74/mrvryffn70b7zp7d8n60t3t40000gn/T//RtmpCpPd3P/downloaded_packages
> library(pdftools)
Using poppler version 0.73.0
> library(pdftools)
> ls()
[1] "counties"                "kmPriced.res"            "nycDatNum1"              "nycDatNum1Priced.pca"    "nycDatNumToPrice.scaled" "plotCl"                 
[7] "predictedClust"          "var"                    
> ls()
[1] "counties"                "kmPriced.res"            "nycDatNum1"              "nycDatNum1Priced.pca"    "nycDatNumToPrice.scaled" "plotCl"                 
[7] "predictedClust"          "var"                    
> pwd()
Error in pwd() : could not find function "pwd"
> pdf_file = "US8080243.pdf"
> txt <- pdf_text(pdf_file)
> cat(txt)
                                                                       IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
                                                                                                   US008080243B2
(<U+00BB>)      United States Patent                                                  (io)   Patent No.:     US 8,080,243 $ 2
         Liang et al.                                                          (4s)   Date of Patent:     Dec. 20, 2011
(54)     ISOLATI(D ANTIBODY WHIC'H                                         Ilypercholesterolemia Mutantsy ihe Journo/ of Bioiog&r&d C'(ie<U+00AB>u<U+00BB>-
         SPEC'ii'ICALLY BINDS TO PCSK9                                     (ri; 2009, 1311-1321, vol 284, Vo 2
                                                                           C'han. J, et al, "A Propiotein Convcrtase Subtilisin Kes&n Type 9
                                                                           i&eat&ah(&n AntibodykeducesSerum(holesteiolinM&cean&IVon-
(73)     Iuva&iorsz    Hung I.iang, Snu Francisco. C'A (IJS).
                                                                           human P<U+00AB>matesy Prmeedi&i os of(he <U+00B9>uonai I cudemi of Sa nrei
                       Yasmina Noubia Abdiche, Mountain
                                                                           of iiie Lyin &ed S(o(e<U+00BB> ofrtiseiiru, 2009, &(8209825, sot 106, No 24
                       Y&ew, CA (US); Javier Fernando
                                                                           C:unninghanx D <U+201E>et al. "Structural and Biophysical Studies of
                       Chaparro Riggers. Sau Mateo, CA                     PCSK9 and &ts Mu&ants L&nked to I mrul&al Hypercholeste&olem&sy
                       (IJS): Bruce C'buries Onmes,                        Vonire,S&rurrvrni a .Vol ecsisr Bio iogi . 2007, 413-419, vol 14. Vo
                       Ashburuimm. iVLA (LIS): Juiie Jia Li                \
                       Hawhins. Old Lyme, Ci'(US): Jaume                   Grefhorst 5, e& al. "Plasma PCSK9 P&eferent&ally Reduces I ner
                                                                           LDL Recepiois m M&cey dos<U+00AB>in/ &i/'Lipid krieoi&/i, 2008, 1303-
                       Pons, Sau Bruno, CA (IJS), Yuii Wang,
                                                                            1311, vol 49
                       San 1)iego, ('A (US)                                Kwon. H, ct al, "Molecular Basis ioi I.DI. Racptoi Rsvognit&on by
                                                                           PCSK'JP I'rocee&iisg& of (h<U+00BB> Nvuonsi.&cad& mi oi'Science<U+00BB> of B&r
(73)     Assignees. Riuut Neuruscience Corp.. Swah Sau                     L'm(ed S(oies ofdsiemra, 2008. 1820-I 825, vol. 10(. No. 6
                    Francisco, CA (US). Pfizer Inc<U+00AB> New                    Pandit. S., et al, "I unctional Analysis of Sites wuhin P('SK9
                    York, NY (US)                                          Rmponuble fo& Hypacholesterolemisy,hi<U+00AB>rani o//<U+00BB>pid Reseoirh,
                                                                           2008, 17&1-1343 &ol 49
(    )   Notice        Subject to any d&sclsuuer. the teuu oi'this         Peter~on, A ei al, "P('SK9 I unction and Physiologyy Journo/ of
                       patent is exmuded or adjusted under 35              Lipid /(eseorcii, 2008. 1595-1599, vol 49
                       U.S.(2 154(b) by 0 days.                            Lhang, D, ct al '*St<U+00AB>&ct&ual Rcqu&remen&a t'or PCSK9-Mcd&ated
                                                                                             .
                                                                           Degradat&on of the I ow-Density I ipop&otein Receptor,*'mreed
                                                                           &sgi of (/ie.V&(iona/.(eadem& o/'Sae&ice<U+00BB> of (he (I<U+00AB>ied S(ore&
(21)
(22)
         Appl. No. 12/558,312
         Filed:        Sep. II& 2009                                                  o/'Imemco.
                                                                                     2008, 13045-13050, vol 105, No 35
                                                                           lrank-Kmnenetsky, et al.. '*Iherapeut&c RVA& target&ng P('SK9
                                                                           acutely lowers plasma choleste&ol &n rodents and I.DL choleste&ol &n
                                                                           nonhuman pmnatesy Pioceed&ngs of the Nat&onal Aciulemy of Sc&-
(65)                       Prior Publication Data                          ences of the L'mted States, Aug 2008. Pp 119i 5-11920, vol 105,
                                                                           No 13
         IJS 2010/0068199 A I             Mar. 18. 2010
                                                                           Grab&un, "Anusense mh&b&&&on of prop<U+00AB>&te&n convertase subt&l&s&n
                                                                           kex&n type 9 reduces semm LDL in hyperl&pidem&c nu cep Joami a i of
                    Related U.S. Appiicstiou Data                          Lipid Research, Apr 2007. pp 763-767, vol 48, No 4
         Prov&s&ouaiapphcauou No. 61(235.643, filed on Aug.                Horton et al, "Molcculm biolo yof PCSK9 its role in I DI mctabo-
(60)
                                                                           l&smy Trend<U+00BB> iii Bia hem&(oi Srien(er, 2007, pp 71-77, sot 32
         20, 2009, provisional application No. 61/232,161,
                                                                           Inrcrnational P&el&mmmy Fxaminat&on Repo&t issued Jun 30, 2010,
         Iiied on Aug. 7. 200'I, provisional application No.
                                                                           for Inte&national Patent Apphcat&on No PC:7'IB2009 053990
         61/096.716, iiled on Sep 12, 2008.
                                                                           Inta national Prclnn&na&y Fxam&nation Rcpoit &ssucd Dcc 15, 2010,
                                                                           for Inte&na&ional Patent Apphcat&on No PC'T 102009'053990
(5 1 )   Int. CI.
                                                                           International Search Report mailed Jun I, 2010, for International
         d 6IIC 392395                 (2006.01)                           Patent Spphcat ion No PC.'7'102009 051990
(52)     U.S. C:I..................... 424/130.1; 424/133.1                I opcz. D, lnlub&t&on of PC'SK9 as a novel stiatcgy foi thc ticatmcnt
(58)     Field of Classification Search............ None                   ofhipar/m/e&(em/esne, Dm Vev s g Perspectives, 2008, pp 321-
         Sec application file   Ii&r   complete search history             330, vol. 21
                                                                                                       (('outinued)
(56)                       Referenws Cited
                    I J S PATleNT      DOC'UMFNTS
                                                                           Prim<U+00AB>O Emminer Ciyau Chm&drn
        7,261,893 02  8 2007 Veldman et al
                       &
                                                           424 145 I
        7,456,264 B2'12008 Kclcretel                       530 3884
                                                                           (74) .Ikorue&, <U+00BB>Igeu(, or F/rm Pfizer iuc.
    2009 014<U+00BB>352 A I  C&'2009 Jackson et al
                FORFIGN PATI'.NT DO( UMI:,NTS                              (57)                        &&BSTR,ACT
WO            WOOI&57081      A2         8(2001
WO         IVO 2008 0(7457               I'&008                            The prmseut &us& i&i&ut& pu&sides autugo&uiing m&t&bod&es. m&ti-
WO         WO 2008&057458     A2         5 2008                            gen-binding portions thereof. und aptumem that bind tu pro-
WO         IVO 2008 057459    A2         5 2008                            pmiein convertmsc subtilisiu kcxin type 'I (PC'.SK9). Also
WO         W(J 2008&l<U+00C3>647     A2        11'2008
                                                                           provided ure ant&bodies d&rected to peptides, in v;hich the
IVO        WO 2009 0557&B     A2         4 2009
                                                                           antibodies bind tu P(JSK9. Tim invention further provides a
                      OTHF.R PUBLICATIONS                                  method of obtain&ug such m&t&bodies aud aut&body-encod&u
                                                                           nucleic acid. The invention f&irther relates to therapeutic
Albornet el., C1&n Chem 53. 1814-1819,2007P
C"ham&<U+00AB>and Ashkana(i, T&bterh 14 52-60, 1979(i
                                                                           nwthods for use of thesv. antibodies und antigen-binding por-
          "'ud&koff                                                        uous thereof to reduce LDL-chuiesteml levels aud/or for the
      'go
           et sl., Proc. Natl, Aced Sc& 79 1979-1983, 1982.<U+00BB>
Wells, 1990. B&ochanistiy 29 8509-8517                                     treatment mtd/or prevention of cardiovascular diseuse,
     et al . The Protein Folding Problem and Tenisry Stn&cture Pi e-       u&cludmg treatment of hypercholesterolemia
d&ct&on, pp 492-495. 1994 "
Bottomlcy. M . et al . "Stnictuiel and B&ochanical C'hmactcnzat&on
of ihe Vyild Iype PC.'SK&J-L('1(AB) Complex and Natural I mrulial                           3    Claims, 30 i)rawing Sheets
                                                          US 8,080,243         $2
                                                                   Page 2
                    OTHER PUB LIOATI 01&IS                              Otfic&al Conunun&cat&on issued h ov. I(, 2010, m connection volh
I open,  D, "pCSK9'n enig&natic piotcimscy Siorhemirc          oil&i    Internalmnal Pateni Application Vo Pi "I 'IB 2009,'053990
Bivphy&iin.tcm. 200S, pp 194-191, vol. 170 I                            (('<U+00AB>nen Opinion of thc ISA issued Slay 2 (, 2010. for Intenmtional
McKutt M C, ct al., '*Antagonism of sccicted PCSK9 increases lorn       Patent Application go, PC'I IB2009&tl(3990,
density lipoprotein rcccptor exp& cssion in HcpO2 cellsigiouruai of
II&olog&col i'ii&morrlv 2009,pp. 10561-10570, vol 2S4                     'ited bv cxanllllcr
 U.S. Patent          Dec.20,2011                              Sheet I of30             US 8,080,243 B2
 A mPCSK9                                                        8    hPCSK9
    (100nM)                                                           (100nM)
   mAb(nM)  800 40Q200100 50 25                        0 0           mAb(nM)  800 4002001QQ 50 25 0 0
 6F6.G10.3  QW     rt@.-::,:.,'.=:::-:.;.::,,::::;:;:: ~4          6F6.G10.3
      <U+00BB>44   WM4~+~4
    4A5.G3                                                            4A5G3   M@NeWuN
   5A10 88
                                                           Figure 1
 U.S. Patent          Dec. 20,2011       Sheet 2 of 30            US 8,080,243 B2
               Human PGSK9{0.4nM}- human LDLR Binding
                                       pH7.5
     o    I
     0
     O 0.5
          0
         1.0E-03  1.0E-02 1.0E-01  1.0E+00 1.0E+01 1.0Et02 1.0Ee03
                          mAb Concentration (nM)
                 Mouse PGSK9 {0.8nM)- human LDLR Binding
                                       pH7.5
        2.5
           2
      o
        1.5
      0
        0.5
           0
          1.0E 03 1.0E 02  1.0E 01 1.0E+00  1.0E+01   1.0E+02 1.0E+03
                        mAb Concentration {nM)
                                    Figure 2
 U.S. Patent  Dec. 20,2011    Sheet 3 of 30          US 8,080,243 B2
      40                                   + 4,i', IC50='?.I nM
      30
   CI
      20
      10
       0
         0.1       1           10             100            1000
                     rnAb concentration (nM)
                               Figure 3
 U.S. Patent Dec. 20,2011               Sheet 4 of 30                             US 8,080,243 B2
 A                       B        Normahxed binding by premixed 29.70M hPCSK9 and rgG
                           NPCGIIO
                                                                     U
                         8 F6  010 3
                               704 4
                                                                      ~ Fcx-6F6 G10      3
                            5410 08
                                                                      9 l c 3 = 641 0 36
                             4AF C3
                                                                      Bl c2=4A6643
                             GEI C4
                             'IF" FG
                              c6 HI 0
                           Gl  5 HI I
                             41.1 0I
                           56 610
                         %5 C4 41
                           40121 8
                           4E4   010
                                      0      20        40           0               PO     103 120
                                                           Ncr mzlizcd hlnding
                           Figure 4
 U.S. Patent   Dec. 20,2011   Sheet 5 of 30    US 8,080,243 B2
              4A5 5A10 6F6       6G7 7D4 42H7
       Human                                  ~     PCSK9
 Cyno Monkey
                                                    PCS K9
       Mouse
          Rat                                       PCSK9
                           Figure 5
 U.S. Patent       Dec. 20,2011      Sheet 6 of 30      US 8,080,243 B2
                                     ESI Control mAb {30rng/kg/day)
      150
                                                  g/kg/day)
  0   &oo
  O
  ttt
  O
  0
  o    5o
          pre total post total pre HDL post HDL
                               Figure 6
 U.S. Patent    Dec. 20,2011        Sheet 7 of 30               US 8,080,243 B2
            PCSK9 {6ug/ml)           <U+2014>      Hu     Hu       <U+2014>    Mu      Mu
       CRN6 pAb (100ug/ml)           <U+2014>       <U+2014>      +       <U+2014>     <U+2014>       +
  B B
                                                  I   Control mAb (30mg/kg/day)
                     150                                         /kg/day
                  o  100
                  sr
                  o
                 V    50
                       0
                          pratotal post total pre HDL postHDL
                                      Figure 7
 U.S. Patent         Dec. 20,2011       Sheet 8 of 30        US 8,080,243 B2
   A='a    100
                                                       C3 7D4 (10mg/kg i v)
      Vl
      E                                                R  Saline
      0
      Cl
            60
      Vl
      e     40
      0
     U
      C     20
      0
     I-
             0
               1day  2  day 4day   7 day 14day21day
            80
   B
            60
            40
         0
            20
               1 day  2 day 4 day  7 day 14 day 21 day
                           Figure 8
 U.S. Patent                Dec. 20,2011      Sheet 9 of 30                    US 8,080,243 B2
          ta
                                                              I        0
                                                              t((()t)t 0
                                                                         1mg/kg/day (n=at
                                                                         3mg/kglday (n =8)
   0                                                          %31mg/kg/day (n=8)
   et                                                         EZI 3mg/kgfday (ne8)
   Ie
   e  'U                                                      E310mg/kg/day (ne8)
   sots    5
                                                              IZB 30ntgfkgfday (n=8)
   o   E
   o
           2
                pre dosing       post dosing
            60                                           10.0
                                                          7.5
        st  Sa
                                                      ot
         E aa                                         E   5.0
                                                      cr
        cr 20
        X                                                 2.5
            "la
                                                          0,0
                pre dostng       post dosing                  pre dosing           post dosing
                                             Figure g
 U.S. Patent          Dec. 20,2011     Sheet 10 of 30        US 8,080,243 B2
                                                              "liijiii} 0.1
      I-I       80
  A             70
                                                             %30.3
         oL     60                                           E31
      ~~50                                                   [ZD3
          N  ot                                              IZ310
      r0        30                                           EZI saline
                20
                10
       I
                 0
                                                ~o   oe
                            Dose (mg/kg/day, 4x)
                110
                100                                            EE90.3
          t=     90                                            EKI1
          0
                 80
                 70
                                                               E33
          Cl
                 60
                                                               IZZI10
       <U+2014>         50                                            KZZI Sahne
             E
       D         30
                 20
                 10
                   0
                     0.3        1       3       10   Saline
                               Dose (mg/kg, 1x)
                                  Figure 10
 U.S. Patent           Dec. 20,2011       Sheet 11 of 30        US 8,080,243 B2
                                    4A5
              100
    C                                                           ml0.3
   Q                                                            ER91
    C          75
    0                                                           E33
    4i 'g                                                       CZ310
     ttj
           Vl  50
     ttt                                                        EZ3 Saline
           E
     0
   V
     t5
   I-0
                  0.3        1         3         10     Saline
                      Dose (mglkg, i.v. on Day 0)
                                   6F6
               90
               80
                                                               II0.3
               70                                              %31
               60                                              E33
        OU50                                                   62310
                                                               EZ3Saline
        o      30
       V       20
               10
       I-0      0
                  0.3                3         10      Saline
                      Dose (mg/kg, i.v. on Day 0)
                               Figure 11
 U.S. Patent    Dec. 20,2011          Sheet 12 of 30         US 8,080,243 B2
            4A5          5A10            GF6        7D4         PBS
   LDLR ~ ~ ~~~yeae          rtrrrrtrewee ~ ~ ews~      eww ""<U+00BB>
 GAPDH  ~
                             Figure 12
 U.S. Patent Dec. 20,2011  Sheet 13 of 30 US 8,080,243 B2
       300
       200
       100
            Total              HDL       LDL
                         Figure 13
 U.S. Patent  Dec. 20,2011    Sheet 14 of 30 US 8,080,243 B2
     100
  'V                                          C3 PBs
   E
      80                                      53   4A5
                                              E3   5A10
      60                                      [PD 6F6
   I
  -'0
   0
                                              IZ3 7I34
      20
   0
       0
            1mg/kg                10mg/kg
                          Figure 14
 U.S. Patent                   Dec. 20,2011                 Sheet 15 of 30                          US 8,080,243 B2
    A
        $4                                                   m'3
       0J
           2                                                Z
                DO   D2  D7  D9  D11 D14 D21 D28
                                                          D              DO  D2  Dr   D9 D11 D14 D21 D28
                                                                7
           1
                                                        III
       9   1
                                                        e
                                                       ra
         I 1
                                                                88
         0                                              III
         8                                             O.
         N
                                                       rc
                                                                2
                                                       Tll
       8                                                0
         0
                 DO  D2   D7 D9  D11 914  D21 D28                                          b+   bb
                                                                       0%   0S 08    0%
                                                                                         0     0 0      0
     E                                                          F         4
                                                                       Ul 3
           30
                                                                       E
        th                                                             e
        b
        tJ 28
                                                                       ;2
        c
       O.
           10
                                                                       01
       cI
       Z
             0
                                                                              DO  D2    D7    D9   D11 D14 D21 D28
               00   0&   04  0%   wb   bb
                                 0    0 0 0
                mhb Concentrations in Plasma                       H         PCSK9 Concentrations in Plasma
     G
                                                                        3800
       E                                                                2000
                                                                    Ol
       Ol                                                           c
       a
       cC
                                                                   Y
                                                                   or 1800
        E                                                          47
                                                                   c.
                 DO   D2  Dr  D9  D11 D14 D21  D28                            DO  D2    D7    D9 D11 D14 D21 D28
                                                 Figure 15
 U.S. Patent          Dec. 20,2011      Sheet 16 of 30              US 8,080,243 B2
              20 mg/kg TD4                                 3 mg/kg 7D4
   '0
                                            Vl
    E                                       E
   d                                        d
       00 02 D7   DS  011 D14 D21 D28            00   D2  D7  09  D11 D14 D21 028
               1 mg/kg 7D4                                0.3 mg/kg 7D4
    Ul
                                             Ot
    E
                                             E
   d                                         d
       DO D2 D7   DS D11 D14 D21 D28
                                                  DO   D2 D7   DS D11 D14 D21 D28
                                      Figure 16
 U.S. Patent           Dec. 20,2011     Sheet 17 of 30               US 8,080,243 B2
    100                                       100
 62                                       cr
 ~    60                                  ~    60
         o''e O'~ O'e         Oe
                                  o
                                                  D-2  Do  D1  D2   D4  D6  D9  D1 4
                    6F6                                           7D4
                                               1
    1
                                           g
 CI                                        CI
         D-2 Do D1 D2 D4   D6  D9  D14             D-2  D0  D1  D2   D4  D6  D9  D1 4
                                       Figure 17
 U.S. Patent        Dec. 20,2011       Sheet IS of 30  US 8,080,243 B2
               33.4% Keel fat, 0.1% cholesterol diet
     225
                                                       ~ saline
     200
  o 175
                                                       ~ 7D4
  I= 150                                                    N=3
  s  125
  g  100
      75
      50
      25
       0
                      oooo oooooooo oooooooooooo oooo
           o o ooooo
         o~ o~ c~
                   o o o o o o 'o o o o o o o o o
                                s nx nx+nx+n)+nx+nxo
                             Date
                               Figure 18
 U.S. Patent  Dec. 20,2011   Sheet 19 of 30    US 8,080,243 B2
                        +  +    +       +  + +    +
        (100nM)
      mAb (nM)         400 200100 50 25 12.5      0     0
 Human PCSK9
  Mouse PCSK9
                               Figure 19
 U.S. Patent             Dec. 20,2011         Sheet 20 of 30    US 8,080,243 B2
                          0,36nM Human PGSK9 pH7,5
                                                               O
                                                               ~
                                                                  L1L3
                                                                  5A10
                                                                * 42H7
              oo.  I<U+201E>s'%   so
                           0.35nM Human PCSK9 pH 5.3
        B
            1.5
                   Is'b
                     0      !b   o   e   4''         b  b'
                            0.31nM Mouse PGSK9 pH 7.5
      C
          1.5
          0.5
                             0.31 nM Mouse PGSK9 pH 5.3
           1.5
           0.5
                oo   oo
                         so'p'o
                          s~   oA   po o''''''
                                        Po  oo  o~   y   oA o&
                                      Figure 20
 U.S. Patent   Dec. 20,2011 Sheet 21 of 30  US 8,080,243 B2
           90
    0
           60
    01
    6
       2
       'Z$
    o   CS 45
    oE
           30
           15
              2-dBys         4-days       7-days
                           Figure 21
 U.S. Patent        Dec. 20,2011       Sheet 22 of 30          US 8,080,243 B2
            HDL                                      LDL
                                      150
                                                                     ~  5A10
                                                                        LIL3
  II                               Cl
  cs                               IS
  8 100                            s8 100
  II                                V
                                   g
     50                                50
  CI                               CI
  Z
                                        0
        0    10       20        30        -2       8       18    28
                Days                                  Days
                                   Figure 22
 U.S. Patent      Dec. 20,2011      Sheet 23 of 30       US 8,080,243 B2
       L1L3 F
                                           LOLR-EGF
                           PCSK9                            PCSK9
                        PCSK9
                                                          PCSK9
                                                    p
      L1L3 Epitoper                     LDLR EGF  Epitopo
                              Figure 23
 U.S. Patent        Dec. 20, 2011          Sheet 24 of 30              US 8,080,243 B2
             CJ O
             Cl (7
                o
                (0
         VI
                                       o      O     O          O  o o   O
          I(                            X                                Y
                                                                        (0
                                                 Vf m          (A           Cl       m
                                                                                0
             Cj       CJ                         Cj CQ  Cj  cj Cj cj cj cj  Cj O  Cj CJ
         m                                                  IK 6  Y  0. tll          x
         Z                                          (C            (C
             CL       IL                         CL 0.  0   CL    0. 0. IL  IL Q.    Q.
                                                 CC
                                                        CC
                                                        IJJ
                                                               IZ (0    IZ  CC       Z
             UJ       LJ                         IU UJ      UJ UJ ~J UJ QI  IU LL    IJJ
                             '0            IQ
             Vj       N   N  N         (0  N  CQ N
             v        O
                                    CQ
                                    Y      U.
                                                 Y
                                                 IL
                                              IL
             UJ           UJ
                                    Y      IU    UJ
                             LU IL  UJ UJ     IU
             Z        Z Z Z Z       Z Z Z Z      Z
             Z        Z Z Z Z       )
                                    Z  Z Z Z     Z
                          (0
                                    I-
             CC                     CC     CC    (0
                      C7  (7 CQ C"
                                    (7 Vl  Z N   U
             Y            (0 UI        o   CQ Vt
             N        0'I (0 N  0", Vj
                                    0
                                       N   N  N  N
             CL       0.  Q. (L Q.     0.  0. Q. IL
 CU
             Z        Z Z    Z Z    Z Z Z Z      Z
             UJ       LJ  IU UJ IL  UJ UJ  IU UJ UJ
 UJ
 IL'
 0                                               Z
             VJ       N                          N
             IL
                                                 (7
             CL       Q.
             Vj       Vj
             Cj       CI
             cj       Cj
                      0(
             CC       Z                          (0
             N        Vj                         N
             N        Vj                         N
             O        om                         (7
                   )
             N     N   N                         N
             Cj
             c( )
                N
                C! CQ
                       Cj
                       ci
                                                 Cj
             Vj c( CV
 U.S. Patent          Dec. 20, 2011           Sheet 25 of 30                     US 8,080,243 B2
         Y'K
                                        'I    7                '!
             O   o       O   C           o     O o              o         C      O   o
              I!          I!              if      I!             I!                   if
             N           N
                              X
                             Ll
                                                                           X
                                                                                 oIf IA
             n nI-   Q
             CL  CL
             K       K
             lij lli IIJ
                     IG
                     Y
                     I!
                     Y
                     llJ
                     Z
           N
           X         Z
                     ffi
  O3
  Cff
                     Z
                     tli
  CU
  0
                                                 N                               C!
                                                                                 f!      o  O
                             K                 K CC    K'  K    K   K         K  fL  K   K K
                     IL  C
                                                                                 Cf  ill    c(
                                                     0
                                                                                         0 0
                                                                    IL'IJ
                                    'JJ                                   ffi        IJJ
                     fCJ IIJ CIJ Di              f/i   IJJ fo   IJJ
                                                                                 III IIJ    ffi CIJ
                         IL
                     CC  C.  K   K  T          K     K K   CL'  K   K     K   K  K
                         0   0'     3'3          CC
                                                     0 0        0 0 0                    CE
                                         0 00 0
                                         0                                    0             CC
                                 0                                               CI  0'     0   I3
                                                 I3 0 0         CI 0 f3 0                CJ
                         Cf                                                      CI         f3
                     N
           N         K
                     flJ
                     <U+00C3>
                     )0
                      <U+00C3>
 U.S. Patent Dec. 20,2011 Sheet 26 of 30 US 8,080,243 B2 U.S. Patent             Dec. 20,2011         Sheet 27 of 30                 US 8,080,243 B2
                                         7
                O        O   O            O  O                O              O      CQ
             IC   X       X   X            X  CC                    X  X
                I                         O    I
                                      CJ
                                      Q.
                                      IU
                                      UJ
                                          CQ           Vf O        CC                     OC
                                                       CO                                   I
                                      CO
                                      N   N  VJ     CO
                                                       Vl N        N     N   N      N
                                      Y             Y  Y
                                                                      CO
                                                                             Y         K  Vi
                                                    IL                Y
                                      LL     IL  U     IL Y   LL   IL IL                  IL
                                                                             Y
                                      UJ     IU  UJ LU IU UJ          IU UJ  IJJ UJ UJ
                                      Z LUZ Z Z Z Z Z UJ
                                                                   LU
                                                                   Z Z Z Z Z Z Z
                                                                                       IL Ul
                                                          Y Z
          CC
                                                                                          Z
          Z                           Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z                       Z
                                          CC     IC CC
                                                    CI
                                                       Z CC   CL'Q
                                                                      Z IC IC CC CC
                                      CQ
                                          N CQ         CQ fQ       fQ N CQ CQ CQ CQ       CQ
                                      N
                                                    CO    CQ       Z  UI Z CO Y IQ        CJ
  Q                                   Q.
                                          rO        IL
                                                    CL
                                                          ICJ
                                                          UI
                                                              CQ
                                                              CL
                                                                   IU
                                                                   Q.
                                                                      IO
                                                                      Q.
                                                                             cf
                                                                                 Q.
                                                                                          rO
                                             Q.        Q                     fL
  CIJ                                     ei 2      CO
                                                       IO CI  VI   Z Z Z Y Z        fO
                                                                                          Cf
                                      LU            UJ        IU   Uj            IU    U. IU
                                          LU UJ        LU LU          LU UJ  Ul     UJ
  JJJ
  0                                   Z
                                      VJ
                                      CO
                O
                                   I-
                      CC     CC CQ IC IC
             Z  CL'/J
                      CO     CC IL Q  Q.
             CQ              Z     cf
                N     N  V&     N  0  CO
                                CC
                                      IU
                Cf
                      CC
                      C1
                         CC
                         CJ  U  Cf
                                   CC
                                   CJ
                                      0
                Cf    CJ     0  l3 CJ
                                      CJ
          CC
                                      N
                                      O
                                      CO
                                      CJ
                                      CJ
                                      VJ
 U.S. Patent             Dec. 20, 2011          Sheet 2S of 30                US 8,080,243 B2
                                                                             O
            O                       O     O                O   O   O
              X               IC           IC               CC  CC  X
            CO               Ct             t                  CO  CO
                                    O  IO                          CO     IA
                     Jj      IQ                                    CO IVI
                                                                          CO         CO
                                                               N
                                                                                  0 0 0M L0
                             IL'                     cf N
                 0   IQ
                         0M      0 0 0 0 0        0 0 0 0I- 0 0 0 0Z
                     M           2 Z Z N M           N Z       M Z x              Z N     N
         Z                                           *C               cC
                                                I
                 CL
                                    Q.    Q.  Q.  Q.    Q. Q.         Q.  C          Q.
                          Q  IL  IL    CL            Q         CL  Q              CL      Q
                 IC
                 Ul
                     X    CC     fL E  IC IC  CC
                                              IU     IZ IC         CC fL
                                                                          UJ
                                                                                  E  IC   IC
                     JJ   UJ tri LU UJ UJ IU      Ul LU LU IU  IU  Ul UJ     LU   Ul IU   IJJ
            CJ   ICI
            M    N                                                           N
                                                                             V
                 IL                                                          LL
            LL
            Z    IU                                                          UJ
            Lll
            Z    Z                                                           Z
         Ot
         Z Z     Z                                                           Z
                 CC                                                          CC
            IC
   UJ       I-   0
            0    LO
            0Q.  M
                 Q.
                                                                             Cjt
                                                                             Q.
   tJJ           Z                                                           Z
             Z
             ITI UJ                                                          IJJ
   6
   LL
                                                                             Z
         Z       N
                 LO                                                          I 'I
                 CC                                                          CC
                 CL                                                          Q
                 N                                                           'Jl
                 Cf
                 0                                                           0
                 Ot
         Ct                                                                  CC
                 N                                                           M
                 Cl
                 N                                                           Cri
                 O                                                           O
                 )0
                  N                                                          Cri
                                                                             Lj
                  0N
 U.S. Patent          Dec. 20,2011         Sheet 29 of 30           US 8,080,243 B2
                                                    Ch          ff Li Ih
                                                    N           P  I   I
                                                    N
              o     N
            I p     p                                                    p p p p
          Ih  x  Z
                 h'
                    X                                                    Ih ih Ih th
              Q     Q.                                                   Q. Q. Q. Q.
              LL    IU                                                   E     IU IU
          JJ                                                             IU UJ UJ LU
              UJ JJ UJ
                          Ih  Ih fh Ih (C                                   ih Ih
                          Y   Y  Y                                    LL    IL IL
                          U.     IL
                          Y                                           Ul    UJ Ul
                          LU  ~J       LL
                          Z Z Z Z Z
                                 UJ
                                                                      Z        Z
        Z                     Z Z Z Z                                 Z     Z Z
                          IL        IL IZ                             LL    IL LL
                          0 0 p                                       LQ    IQ
                                                                               p
                          Cf  0 0                                           Ig
                                                                            IL
                                    Q.                                Q.    Q  Q.
                                 Q. fh                                ih    Ih Ih
                          Z Z    lh    fQ                             Ul    UJ Ul
                          LLI ~J UJ    LL
                                                    C\       N
                                                    I-
                                             IU
                                                    x    III
                                                         ih
                                                             6
                                                 K  V,   Ih  Ih
                                                    7.
                                                 IU IU       E
                                             0'
                                                 p       8
        N
 U.S. Patent Dec. 20,2011              Sheet 30 of 30         US 8,080,243 B2
                          D
                  F                      IA
                                                         CD
                                                         o
                                                         CD
                   Qt  o
                       I                 CCI
                                                         CCD
                    Ct                                   CD
                          Cj
                       o                 0 o o                 o
                       CI    0 0 0           C5  CI Cj         0
                             N    Uj     Uj  Ut  N
                       t1    Q    Q          t1  LL Q.
                             E E E E             IU E          E
                       UJ    IU   Ul     Ul  IU  LU UJ         UJ
                             N    Uj
                                         Uj         N
                             IL   jL'L'J            LL         LL
                                         LL
                             LU                     UJ         UJ
                             Z Z UJ      Z          Z          Z
                  ICI
                  Z          Z Z Z                  Z          Z
                                                    I-         t-
                             IU   E E               E          E
                             0 0 0                  0          0
        0                    0IL 0IL 0              0          0
                                                               LL
                              Q.  Q.                LL
                              N          Q
                                         tlj        Z
        Ill                   UJ  LLI
                                         UJ         IU         UJ
        D
        0
                  Z                                            N
                                                    0          0
                                             E      tZ
                                             Uj     Q
                                             IL'
                                                    N
                                                    Z
                                  Ct                Ct
                                  0          Ct
                                             0      0
                                                       N
                  CCC                                  Z       E
                                                         Z     Uj
                                                       N N
                                                       0 Cj    Uj
                                                    N
                                                    Cj
                                                    0N
                                                                 tjs   8,080,243 B2
                                      1
                  ISOI.ATKH ANTIBODY YVHIC.'H                                     in individuals with mitosomal dominmu hypercholcster-
                 SPEC'IFICALLY Rl ~ HS TO PCSK9                                   olemia, v,bile other "loss-of-function" (LOF) nmtations are
                                                                                  linked with reduced plasma cholesterol. Morbidity and mor-
filed   This applicatmn claims priority, ulxler 35 IJSC'5119fc), to
     ilm liillou ing US provisional applications, IJ.S Appl No
     61/096,716, filed Sep. 12, 200K U.S. Appl. No. 61/232.161,
           Au. 7.   2009, and U S. Appl. No. 61/235 643, filed Aug.
                                                                                  ialiiy studio~ in Ibis group clearly dcmnnstratext thai riducing
                                                                                  PCSK9 I'unction significmltly diminished thc risk of cardio-
                                                                                  vascular disease.
                                                                                      Of sigiuficant importance to the treatment of CVD. a LOF
     20. 2009.                                                                    mutation may sensitize humans to statins, allouing for efii-
confimled
                                                                                  cacy nt a lower dose fhcncc, improving risks associatixI with
              RFFFRI',NC'I'. TO SFQIJFN('I'. I,ISTIN(i                      ln
                                                                                  safety and tolerance) and potentially achieving lower plasma
                                                                                  cholesterol levels than with current therapies.
       'Elis application is being filed electronically via EFSHVeb                    PC'SK 9 Is secreted into ilm plasma predomuinnilv by hei(a-
    and includes nn elcctrmiically submitted scqucncc listing
                                                                                  tocytes. Cienetic modulation of PCSK9 in mice                   th
    in ixi fomiat Thc.ixt lile contains a sequence listing entitled
                                                                                  ability of PCSK9 to regulate blood lipids, and suoogested tint
    "PC33713 A SequenceListing.txt" created on Sep 10, 2009                       lishedd. dou.n-regulate
                                                                                  it acts to                   hepatic LDLR protein levels.
    and having a size of 51 KB The scqucncc listing mmtaiimd in
                                                                                      Thc mechanism by which. and the site ai which, P( SK9
    this .txt file Is part of the spe ulication and is herein incorpo-
                                                                                  down-regulates I DI,R protein has not been clmlrly estab-
    rated by reference in its entirety.
                                                                                           (Vien over expressed. PCSK9 may act both witlun the
                      Ffiil D OF THI', INVEN1 ION                           "o    hap ate cyse and as a secreted li gaud for I,DI.R. There is strong
                                                                                  evidence that extracellular PC:SK9 binds io cell surface
       The present invention relates to antibodies. e.g.. full lenbuh             I,DLR and promotes LDLR degmdation at an intmcellular
    antibodies or antioen-binding portions thereof, pcptides, and                 site. I lou ever, It Is also possible that PCSK9 could uiteract
    aptamers that anta onize the activity of extracellular propro-                with the LDLR when the two proteins are translated witlun
    teln convertase subtilisin kexin type 9 ft'CSK9), including its               the endoplasmic reticulum fER) and traffic tlu'ough endoso-
    ( LDLR).     "-'nieraction
                with die lou density lipoprotein (I,DI.) receptor
              More  specifically. the invention relates to compos&-
    tions comprising antagonist PC'SK9 antibodie~, peptides,
    and/or aptamers uid methods of using these uitibodies and/or
                                                                                  mal compartnienms iimnrds the cell membrane Maxwell et
                                                                                  ul., 2005. Ciur. Opin. Lipidol. 16;167-172. showed that
                                                                                  P( SKI)-midiaticd I DI,R cndocytosis tmd degradation v;as
                                                                                  not altered by proteosome inhibitors nor was it modulatesf by
    peptldes and/or aptamers as n medicament. 1he antagonist ""                   different classes of lysosomal and nonlysosomal proteases.
    PC'SK9 mitibodicx peptides, aml aptamers can bc used thera-                   Two naturally occurring familial hypcrcholesterolmnia nuita-
    peutlmilly to lover I Dlocholesterol levels in blood, and can                 tions, S127R mid D I 29CJ, have beeo reported to be defective
    bc used in tfm prevention and/or treatment of cholesterol and                 in mitoprocessing and secretion as levels of tlmse nmtant
    lipoprotmn metabolism disorders, including fninilial hyperc-                  pmteins u erc greatly reduccxt or undetectable in lhe media of
    holesterolemim athemgenlc dyslipidenum atherosclerosis, ""                    trutsfectwf cells. Yet these mutants demonstrated an
    mid. more generally, cardiovascular disease (C'VD).                           enhanced ability to doiin-regulate I.DI,R, consistent widi
                                                                                  their identilicaiion ui individuals with high pissant I.DI.
                 BA('K(iROI JND OF THF, INVFNTION                                 fHomer et al., 200g, Athemsclerosis 196:659-(166: Cameron
                                                                                  ct al, 2006 Hummi Molecular Cienctics 15 1551-155g, I.am-
       Millions of people in tile U.S. are at risk for heart disease so           bert et al., 200 Cx TRENDS in Lndocnno logy and Metabolism
    tmd resulting cardiac events (JV D and underlying atheroscle-                 17 79-31. Since these mutants apparently do not get secreted
    rosis Is the leading cause of death among all demograpluc                     extracdlularly, and ivt do downregulate I DI R, this strongly
    groups, despite the availability of themspies directed at its                 suggests that an intracellufar site of action Is physiologically
    multiple risk lactors Atherosclerosis is a disease of the niter-              imponant.
    Ies and Is responsible for coronary heart disease associated 4.                   From the inliirmauon available in the ari, and prior to the
    with many deaths in industrialized countries. Several risk                    present Imention, it renmined unclear whether the Introduc-
    factors for comnary heari disease have nov, been identified:                  tion of'i      antibody-, peptide-, or apiamcr-based PC'SK9
    dysllpldemias. h)pertension, diabete~. snxiking, poor diet.                   antagoiust into the blood circulation to selectively antagonize
    uiaciivity and straws. The most clinically relevmit and com-                  extracellular PCSK9 would be effective to reduce hypercho-
    mon dyslipldenuas are clmractenzed by an increase in beta- o                  lesierolenun and the associnicd incidence of C'VD and. if so,
    lipopmtmns (very low density lipoprotein (VLDL) and LDL)                      uhat properties of a PCSK9 mit Igonist are needed for such In
    unh hypercholcsterolemia in theabsence or preselxe                            vive cffcctlvcniss
                               (Frednckson et al.. 1967, N L'ngl 1 Med.
                            ol'ypeitnglyceridemta
    276 34-42. 94-10'3, 143-1 56, 215-225. and 273-2g I ). I'here is                           SUMIVIARY OF THI, INVFNTION
    a long-I'elt sigmficmu unmet oined with respect to CVD with 1
    60-70Ao of cardiovascular events. heart attacks and strokes                      This invention relates to antagonist antibodies. peptides,
    occimillg despite illc ircaiirlcllt u itll staiiils (tlm cllrrcrli si ul-     and apiamers thm solcctivcly intcmcl with and inhibit P( SK9
    dard of care in atherosclerosis). Moreover, neiv guidelines                   funcuon. It is demonstrated for the first time that certaui
    suggest that even loiver LDI, levels should be achieved in                    P(:SK9 antagonists are effective in vivo to loumr blood cho-
    order to pmtect hi h risk patients from prmnature C.'VD [Na- mi               lesterol
    tional ('holesterol 1.'ducation I'rogram fNCEP). 2004].                          In one embodiment. the invention provides an isolated
       PCS K9, also known ns NAR(u I, was idenrified as a pmtcin                  antagonist of P( SK9 which comprises nn antibody. a peptide,
    wltll a gcilcilc illa t'Itloll 111 soillc forllls of filluillal hl'pci'cho-   or an aptamer, which interacts v, ith PCSK9 and when achnin-
    lestemlemia. I'('SK9 Is synthesized as a zymogen that under-                  istered to a subject lowers the LDL-cholesterol level in blood
    goes mitocatalytic processing at tlm niotif LVFAQ in the (                    of said subject. Tlm antagonist can be an antibody, for
    endoplasnuc reticulum. Population studies have shown tlmt                     example, a monoclonal antibody or human. Iuunaiuzed, or
    some PCSK9 mutations are "gain-of-function'* and are found                    chimeric antibody.
                                                         US 8,080,243 B2
   In another mrbodinwnt, the invm&tion provides an isolated        tive amino acid substitutions in ( DR I, ( BR2, and/or C'BR3
ant&-PCS K9   antibody tvluch specifically binds to PCS K 9 and     und further compris&ng a VH complementary detenmiun
wluch is a full antagonist of the PCSK9-mediated etTect on          region CDRI having the amino acid sequence shown in Sk.Q
I BI,R le&mls when nwasurcd in vitro using the 13)I,R down          ID NO:59, 60, or 8, a VH C:DR2 having the an&ino acid
regulat&on assay &n lluh7 cells d&sclosed here&n.                 s sequence shown in SEQ ID NO:61 or 9. and/or VH CDR3
   In yet another embodiment, the invention prov ides an iso-       having the amino acid sequence shown in SFQ ID NO:10, or
lated an rhody &v hich antagonizes the extracellular interact &on   a variant thereof lmv it&8 one or nulre conserve t&ve amino ac&d
of PCS K9 with the LDLR. as measured by PCS K9 bu&du&g to           subst&tutions in said sequences of CDRI, CDR2. und/or
the I BI.R in vitro. mxi. &vien administcrcdl to a subject,         C'DR'3. u herein thc variant retains essentially the sanlc bind-
louers the LDL-cholesterol level &n blood of sa&d subiect. nl u&g specitic&ty as the CDRI. CDR2. u&d/or CDR3 defined by
Preferably. the antibody recoyuzes an epitope on luunan             said sequences. Preferably. the variant comprises up to about
PC'SK9 that overlaps &vith tuore &ban about 75",z& of the surface   twenty mnino acid substitutions and, morc prclbrably. up to
on PCSK9 that u&temcts with the EGF'-hke dommn of the               about e&J&t amu&o acid subst&tutions. In another preferred
I,BI.R as described in Kwon et nl., 2008, PNAS, 105. 1820-          embodinwnt, the antibody of the invention h&ms n variable
1825                                                                heavy clmu& sequence con&prts&ng or consistu&g of SI.Q ID
   In yet another embodiment. the invent&on provides an anti-       NO: 54 and u variable fi&J&t chain sequence comprising or
body that recognizes a tirst epitopo of PC'SK9 that overlaps        ciulsisting of SEIQ IB NO: 53
w&th a second epitope that is recoguzed by a monoclonal                The invention also pmvides a humanized m&tibody mnu-
m&tibody selected from the group consisting of 5A10, which          prising polypeptides selected from the groups consisting of
is producod by a hybridoma cell line dcpositcdi with thc o SFQ ID NO 14. SFQ IB NO.15, or both SFQ ID NO 14 nnd
American Type Culn&re Collection and assigned accession             SFQ ID NO:IS, or a vanant thereof having one or more
number IzIA-8986; 4A5. which is produced by u hybridoma             conservative amino acid substitutions in said sequences,
cell l&ne deposited u ith the Amertc ul Type Culture Collect&on     where&nthevanantreta&nsessenuallythesamebind&n spec&-
and assim&ed accession number I'TA-8985; C&F6, which is             tic&ty as the ant&body defined by said sequence(s). It also
produced by a hybridoma cell linc dcpositcd u ith tl&o Ameri-       includes an antibody lacking a terminal lysinc on the heavy
can Type Culture Collect&on and assigned access&on number           chain, as tlus &s normally lost in a proportion of ant&bodies
PTA-8984, and 7D4. wlfich is produced by a hybridoma cell           during manufacture.
linedcpositedwiththeAmericm& TypeCultureCofiect&onand                  Preferably. the variant compnses up to about turn&ty amu&o
ass&y&ed accession number PIA-8983.                                 acid subst&tut&ons and more preferably. up to about eight
   hl anothcr clnbodiment, thc invention pmvidcs nn antibody lo amino acid substitution~. Prefi.rably, thc antibody furtlwr
to humm& PCSK9, ~herein the antibody recognwes an                   comprtses an unmunolog&cally u&ert constant re ion, and/or
epitope on luunan PCSK9 comprising anuno acid residues              the antibody has an &sotype that &s selected fmm the youp
153-1 &5, 194, 195, 197, 237-239, 367, 369, 374-379 nnd 381         consisting of'gC<U+00BB>,, lgCis. 18CI&aw 18CI<U+00AB>s, Ig(iszc IgCis
of the PCSK9 amu&o ac&d sequence ol'EQ ID NO: 53.                   S 228 P. IgG<U+00AB>s S 228 P and IRCis <U+201E>S22 8P. In another preferred
Preferably. the m&tibodv cpitopc on human PCSK9 does not "<U+00BB> embodiment, the constant region is aglycosylatcd Fc.
comprise one or morc oi'amino acid rcsiducs 71. 72, 150-152.           In onc mnboduncnk the invention provides a n&cthod for
187-192, 198-202. 212, 214-217, 220-226, 243. 255-258,              reducu&g a level ol LDL. LDL-cholesterol, or total cholesterol
317, 318, 347-351, 372, 373, 380, 382, and 383.                     in blood, serum, or plasmn of a subject in need thereof,
   In still unotber embodu&mnt, dw. invent&on prov&des un           comprisuig adininistcring to the subjcmt a therapeutically
ant&body which specifically binds PCSK9 comprising a VH so efibctive amount of an antagonist of the invention.
con&pten&cntary detem&ining region one (( BR      I)   having thc      In ime embodinwnt, the invention provides a therapeuti-
anuno acid sequence shown in SL&Q ID NO:8 (SYYNIII). a              cally effect&ve amount of an antagonist of the invention for
VH C'DRZ having the amino acid sequence shou n in SLQ ID            use in reducing a level of I.DL, LDI.-cholesterol, or total
NO 9 (IIISPF(i(iRTNYNFKFKS), and/or VH CBR3 having                  cholostcrol in blood, serum, or plasma of a subjoct in need
the anuno acid sequence shown u& SL'Q ID NO:10 (ERI'L-              thereof. The u&venuon further provides the use of a therapeu-
YASi)1 ), or a variant therm&f having one   antor more conserva-
                                                &body               tically etTective amount of an antagonist of the invention in
trte mn&no acid substitutions in said sequences of CDRI,            the manufacture of a medicament for reduc&ng a level of LDI.,
CDR2, and/or CDR3, wherein the variant retains essentially          LDL-cholesterol, or total cholesterol in blood, sertuu, or
thc same binding specitimty as the CBR defined by said              plasma of a sub)cct in need thereof.
sequences. Preferably. the vanant comprtses up to about ten u          In yet another embod&ment, the invent&on provides a
anuno acid substitut&ons and, more preferably, up to about          metlald of preparing an ant&body wluch specifically binds
I'our mnino ac&d substituuons.                                      PCSK9. which comprises: a) prtlviding a PCSK9-negative
   The invention &s further d&rec ted to an           comprt s&ng   host aiumal: b) imnuuuzu&g sa&d P( SK9-ne at&ve host a&u-
a VI, C'BR I having the an&inn acid svqucncc six&w n in S I',Q IB   n&al with P('SK9; and c) obtaining an tmtibody An m&tibody-
NO 11 (RASQCiISSAI,A). a C'DR2 hav&ng the am&no amd s pmducmg cell, or an anubody-encodu&g nucleic amd from
sequence shown in SFQ ID NO:12 (SASYRYTk and&or                     amid p( SK9 negative host animal. and preparing an antibody
CBR3 having thc mnino acid sequence shown in SFQ IB                 from said antibody-producing cell or said antibody-cnm&ding
NO.13 (QQRYSI.WRT). or a vartant thereof lmvmg m&e or               nucleic ac&d.
more conservative muino acid substitutions in said sequences           The invention also comprises a method t'or reducing the
oi'(. DRI. C'.DR2. and.'or CBRS, uhclehl thc varimlt retains m& level of I.BI, in bk&od of a subject in nccd thcreol'. comprismg
essent&ally the same binding specitic&ty as the CDRI defined        adnunistering to the subject a therapeutically effective
by said sequences. Prefembly, the variant comprises up to           amount of the m&tibody prepnrcd according to tl&o invention.
about ten mnino ac&d subst&tut&ons and, more preferably. up to      The sub&act can be further treated by arhuimsteru& a stern. In
about four amino ac&d subst&tutions.                                a preferred embodiment, the subject is a lorn&an subject.
   In another embodiment, the invention pmvides an m&tibody            In onc cmbodimem. thc antibody is adn&inistcred in u for-
comprisu&g specific VL CDRI. CDR2. and/or CDIL)                     mulation as a sterile aqueous solution lmving a pit that ranges
sequences, or a variant thereof lmving one or more conserva-        from about S.O to about 6.5 m&d compris&ng from about I
 I
mg/nil to nbout 200 nig/ml of antibody. front about I milli-
molar to about 100 mill imo far of histidine buffer, from nbout
0.01 mg/ml to about 10 mg/ml of polysorbate 80, from about
100 nli I limo far ur aboui 400 ill i molar of treha lose. and I'rom
about 0.01 millumilar to about I 0 millimolm ol'disodmm
EDIA dihydrate.
DR
                               m
                                   5
    In uiother embodunent, the invention pmvides a thempeu-
tically elTective unount ol'the antibody prepared accorduig to
the invention for use in reducing thc leiml of I DI in blood of
a subfect in need thereof. The invention further provides the
use of a thempeutically effective amount of the antibody
prepared uccording to the invention in the mmiuiacture ol'a
medicament for rixfucing the level of LDI in blood of a
subject in need thereof. 'fhe thempeutically effective amount
can optionally be combuied ivith a thempeuncally effective
aniount of a suitin.
    111 aliothcr clnbilifilnclit, tlm inventioll provides a hybri-
doma cell line that produces a I'CSK9-specific antibody or an
anti en-bmding portion theresrf. wherem the hybridomn cell
       ol'AS
line is selected from the group consisting
          having an AT('(: Accession No. of PTA-8985:
    5A10 lmving an ATCC Accession No. of PTA-8986:
    61'6 having ml ATCC Accession No of PTA-8984; and
    7D4 havuig an ATCC Accession No. of PTA-8983.
    In miother emboduuent, the invenuon promdes cell luis
tluit recombulantly pmduces an mitibody wluch specifically
binds to P('SK9 mid comprises a heavy chain variable region
(VI I)  complementary      d el ann i lung region  one  (C
                                                          US 8,080,243 B2
the amino acid sequence shown ui SFQ ID NO;8. 5'&, or 60, a ""
VH CDR2 having the mnino ncid sequence shown in SFQ ID
                                                               ) havulg
                                                                         1 (1
                                                                                 FKi. 4 illustrates comparative cpitope binding of anti-
                                                                              PCSK9 antibodies.
                                                                                 FICi. 5 illustrates Western blots of binding of anti-I'('SK9
                                                                              antibodies to scnim P('SK9 front diffi:rent species
                                                                                 11Cr. 6 illustrates the effect of anti-PCSK9 monoclonal
                                                                              antibody 7D4 on blood clxilesterol levels in mice.
                                                                                 FICi. 7 illustrates (A) the effect of a pariuil anuigonist
                                                                              polyclonal anti-PCSK9 mAb CRN6 on LDLR doivn regula-
                                                                              uon mid (B) the lack of'clif:ct mi cholestcnil levels in micm
                                                                                 FICi. 8 illustrates the time course of the cholesterol lower-
                                                                              ing effect obtained using anti-PCSK9 antagonist antibody
                                                                              7D4 ill nliCe
                                                                                 FIG. 9 illustrates the dose dependence of the anti-PCSK9
                                                                              antagonist mAb 7D4 on the reduction of serum total choles-
                                                                              teml. IIDI, and LDI, in mice.
                                                                                 FKi. 10 illustrates the dose dependence of the cftofesterof
                                                                              lowering etTi.ct of anti-PC'SK9 antagonist mitibody 5A10 in
                                                                              tutee.
                                                                                 FICi. 11 illustrates the dose dependence of the cholesterol
                                                                              loss cring cfli:ct of'anti-PCSK9 nntagmiist mltibixlies (A) 4AS
                                                                              and (B) 6F6 in nuce.
                                                                                 FICi. 12 depicts Western blots of anti-P('SK9 antagonist
                                                                              atuibodies etl'ect on liver LDLR levels.
                                                                                 FBI. 13 illustrates the lack of effect of anti-I'C SK9 antago-
                                                                              nist antibody 4A5 in an I.DI,R-/- mouse model
                                                                                 FIG. 14 illustrates the effect on total serum cholesteml of
                                                                              nuiltiple administrations of anti-PCSK9& antagonist mitibod-
                                                                              ies ul nues over a longer tune course tlmu seen is ah a single
                                                                              dose.
                                                                                 FKi. 15 illustrate the tinw. course. of the elTimts of mlti-
                                                                              PCSK9 autagomstic mubodv 7D4 on lipid parameters in a
NO 9 or 61. and/or VH CDR3 having the amino amd                               cynomolgus monkey model.
sequence shown in Sk Q ID NO.10. or a variant therixif hav-                      FICi. 16 illustrates lhe dose- and time-response of anti-
iilg.  Cnc  or  iliore cotlsurvativc     amiil&1 acid  substitutions iil      PCSK9     mltagonistic auubody 7D4 on serum cholestenil lev-
CDRI, CDR2. mid/or CDR3, ulrpor compnses a light chain "" els in thc cynomolgus monkey
variable region (Vf,) ('DR I Imving the amino acid scxfuence                     FICi. 17 illustrates a compmison of anti-PC SK9 antagonis-
shown in SFQ ID NO I l. a VI CDR2 having the mnino acid                       uc antibodies 4AS, SA10. 6F6 and 7D4 on serum cholesterol
sequence shown in SEQ ID NO:12. and/or VL (.'DR3 having                       lcimks in the cynomolgus monkey.
the mnino acid sequence shown in SFQ ID NO:13, or a                              FICi. 18 illustrates thc time course oi'he sfl'ecl of'ui-
vanant thereof havulg one or more conservative amino acid sn I'('SK9 mitagonist antibody 7D4 on plasma cholesterol liw els
substitutions in Cf&RI, ('DR2, anipor CDR3. Preferably, the                   of cynomolgus monkeys fed a 33A% kcal fat diet suppli-
cell line riecimibinmitly produces an antibody comprising                     mented with 0.1% cholesterol.
SF Q ID NO: 53 anChor 54, and, more preferably, SF Q ID NO;                      FICi. 19 illustmtes the effect of LIL3 (lnunanized anti-
14 and/or 15                                                                  P('SK9 monoclonal antibody) on down regulation of I J&I,R
                                                                              in Huh7 cells.
                  BRIkl'l'.S(.'RIPTION OF 1HE                                    FICf. 20 illustrates the dose-response of LIL3 fnimanived
                       FIGLIRES!DRsrWINGS                                     antibody. the mouse precursor SA10, and negative control
                                                                              antibody 42H7 on b le ckuig the binding of recombinant bioti-
    FKr'     illustratms the efTect ol'nti-PC'SK9 antagonistic                nylated human PCSK9 (A and B) and mouse PCSK9 (C'nd
monoclonal antibodies 7D4.4. 4AS.C13. 61'6.G103 and u D) to immobilized recombinmit LDLR extnscellulur domain
SAIO.BS on the ability of mouse PCSK9 (A) and lnunan                          in vitro at pll 7.5 (A and C) and pH 5.3 (B and D).
PCSK9 (B) to down regulate I,DI R ui cultured 1luh7 cells                        FICr. 21 illustrates the elTiect on serum cholesterol of trmit-
61'CxG10,3 is a subclone of 6F6, 7D4.4 is a subclone of 7D4.                  ment ofmicewith 10mg/k LIL3.
4AS (13 is a subclone of 4AS, and SA10 BS is n subclone of                       FKi. 22 illustrates the elTimt ol'dministration of 5A10
5A10.                                                                      :r antibody or L11,3 to cynomolgus monkeys and measurement
    FKi. 2 if lastmtes the dose-response of anti-P( SK9 antago-               of changes in serum HDL (A) and serum L1&1. (B) as a
nist mmioclonal antibodies 6F6(il03. 7D44. 4AS C13.                           function of liam.
SA I 0.BS, negative control antibody 421 17. and PBS to block                    I'ICI. 23A depic(s the crystal structure of the PC'SK9 (hght
the binding of recombinant biotinylated Inunan P('SK9 (A)                     gmy surface representation) bound to the LH 3 antibody
and nxrusm PC:SK9 (B) to immobilixml ricombinmit I,DI.R ai (black caruion rcqrrcscntatton) FKi 23B depicts ihc crystnl
extracellular domain in vitro.                                                stnicnire of the I'CSK9 (light pay surface representation)
    FKi. 3 illustrates the dose-response of anti-P('SK9 mono-                 bound to the fkil'-like domnin ol'lm I.DI,R (black cartoon
clonal antagonist antibodies 61'6.G10.3. 7D4.4. 4AS.G3 and                    representation) (Kwon et al., PNAS, 105, 1820-1S25, 2008).
SAIO.BS to block binding of recombinant biotinyfated                          FICi. 23('hoivs tile surface area representation of PCSK9
humnn PC'SK9 (30 nM) to Furopium labeled rccombinmit ( with the f,l I 3 cpitopc shown in dark gray. FKi 23D shows
LDLR extmcellular domain (10 CM) ui solution at neutral pH                    the surface area representation of PCSK9 with the LDLR
in vitro.                                                                     ECrp-like domain epitope sluiwn in dark gvray.
                                                         US 8,080,243 B2
   I'1(IS 24 A-(i dh7ict the substitutiims made in the ( DRs of           prises an nnrigen recognition site. An antibody includes m&
antibody 5A10 in thc course of affinity maturation and opti-              annbody of any class, such as IgO. IgA. or IgM (or sub-class
mization and to aclu eve particular properties. PCS K9 bu&du&             thereof) and the antibody need not be of any part&cular class.
assocmted w&th antibi&dies having these C'DR substitutions is             Depending on the antibody amino acid sequm&ce of the con-
also reprcsvnted The number following each svqucnce is thc                stant doma&n of &ts heavy cha&ns. immunoglobulins can be
SL'Q ID NO desi~a&ed for each sequence.                                   assigned to difTerent classes. There are five major classes of
                                                                          u&ununoglobuln&s: IgA, IgD. IgE. IgCI. m&d lgM. u&d several
    DETAILED DESCRIPTION OF TIIE INVL'NTION                               of these may be further div&ded into subclasses (iso&&T&es),
                                                                          c.g, IgCil. IgC12, Ig()3, Ig(14. IgAI and ISA2 Thc lmavy-
   The present invention relates to antibodies, pep&ides, anil ia         chain constant domau&s that correspond to the difierent
aptamers that antagonize the iiu&ct&on of extracellulm PCS K9             classes of &nununoglobulins are called alplm, delta, eps&ion,
including its interaction with tlm I J&I,R. More specifically.            gamma and im&, respcctivcly. The auburn& structures a&xl
the invi:ntion relates to methixis oi nmking nnta onist PC'SK9            tluee-dimensional conti urat&ons of diferent classes of
ant&bodies, peptides, and aptamers, compositions comprising               &&ainu&&ogl(lbu1ins are well known
tlmsc m&tibodies, peptidcs, and/or aptamers. and nwthods of la               As usvd hereu&. '*monoclonal anl&body*'eli:rs to an mui-
us&ng these antibodies, peptides. and/or nplamers as a med&-              body obtained from a population of substantially homoge-
cament 11&e antagonist VCSK9 antibodies and peptides can                  ncoms antibodiew i c., tlm individual antibodies comprising
bc usod to lower blood I DI -clx&lcstcrol levels, and cm& bc              the population are identimd except lor possible naturally-
used in the prevent&on and/or treatment of cholesteml and                 occurring mutations that may be present in minor amounts.
lipopmtein metabolism disordem, including familial hyperc- zc             Monockmal antibodies nre highly spccilic., being directed
holesterolemi &, athemgen&c dyshpidem&a. atheroscleros&s.                 against a single m&tigenic site. Furthermore. &n contrast to
and. more generally, ('VD.                                                polyclonal antibody prepamtions, which typically include
Cienc& sl Teclmiquas                                                      d&fferent antibod&es directed s ainst d&fferent detenn&nants
    The pract&ce of the present invent&on w&11 employ, unless             (ep&topes). each monoclonal antibody is d&rected against a
othenvise ind&cated, conventional techniques of molecular                 single determinant on the nntigcn. '11&e modifier "mono-
        "-'iology
           (including recombinant techniques). m&crobiology,
cel I biology, biochenu stry and inuuuno logy, winch are witlun
tlm ~kill of the art Such tcchniqucs nre explained fully in thc
literature. such as, Molecular C'loning A I.abomtory Manual.
second ediuon (Sambrook et al., 1989) Cold Spnn llarbor              ""
                                                                          clonal" u&d&cates the character of the anubody as be&n
                                                                          obtmned from a substantially homogeneous populat&on of
                                                                          a&uibodics, m&d &s nol to be coustrucxI as requ&ring producuon
                                                                          of the ant&bodv by any particular method. 1&or example, the
                                                                          monoclonal antibodies to be uscxI in accordmlcc with thc
Press, Oligom&cleotide Syntlmsis (M. J. Ciait, ed, 1984),                 present invention nuiy be made by the hybridoma method lira&
Methods &n Molecular B&ology, I lumana Press, C'ell B&ology:              described by Kohier and Milste&n, 1975, Nature 25Cx495, or
A I aboratory Notebook (J. I'I Ccllis, ed., 1998) Academic                may bc m&xle by r&vombinant DNA methods such as
Press, Animal Cell C'ulture (R I Frcshncy, ed . 1987), Intro-             described u& U S. Pat No. 4.816.567. The monoclonal anti-
ducuon to Cell and Tissue Culture (J. P. Mather m&d P. Ls            ""   bodies may also be isolatscd from phage libraries genernted
Robert~. 1998) Vien&un Press: (.'ill and Tissue ('ulture I.abo-           using thc techniquca dcscribcd in McCaiTerly cl al, 1990.
I dtory Procedures (A. Doyle .I B. C&'rifiiths. and D. C& New&all.        Nature 348. 552-554. for example.
eds.. 1993-1998) J. Wilev and Sons; Methods in Enzvmology                    As used herein, "lnunanized'ntibody refers to filnns of
(Acadmnic Press. Inc ): Handbook of Fxperimcntal Immu-                    non-lummn (e g, im&rine) mitibodies ihal are chuu eric immu-
nology (D. M. We&r and C. C. Bluckv ell, eds.); C&ene Transfer       sc   noglobulins, inununoglobulin clm&ns, or fraynents thereof
Vectors for Mammalian (.'ella (J. M. Miller and M. P. ('alos.             (such as Fv. Fab. Fab'. F(ab')s or other antigen-binding sub-
cds.. 1987), ( urrent Protocols in Molecular Biology (F M                 sequences of ant&bod&es) that contain m<U+00BB>umnl sequence
Ausubel et al., eds., I')87); PCR: The Polymerase Chain                   derived from non-human inununoglobulin. Preferably,
Reaction, (Mullis et al.. eds., 1994); ('urrent Protocols in              humnnizcd antibodies me humnn immunoglobulins (recipi-
Immunolo y(J E Col&gauetel.. eds..1991): ShortProtocols              ss   ent ant&body) in wluch res&dues from a complementary deter-
&n Molecular Biology (Wiley and Sons, 1999): Inumu&obiol-                 mining region (CI&R) of the recipim&t are replacsxl by residues
ogy (C'. A. Jancway and P. Travers, 1997), .Antiboilics (P                from a CDR of a non-human spec&es (donor ant&body) such as
Fu&ch, 1997): Annbodies; a pnsctical approach (D. Catty.. ed.,            mouse, mt. or rabbit hav&ng the des&red specific&ty, affinity,
IRL Vress. 1988-1989); Monoclonal antibodies: a practical                 and capacity. In some instiu&ces, F& I'ramev'ork reg&mt (FR)
apprmich (P. Shepherd and C De m, eds, Oxli&rd IJni&vrs&ty           su   residues of the hmnan inununoglobulu& are replaced by cor-
Press, 2000); Using antibodies. a laboratory manual (E. Ihu-              respond&ng non-human res&dues. Furthermore, the human-
low and D. Lm&c (('old Spring Harbor Laboratory Press,                    ized m&t&body may comprise residues thai are found neither u&
 1999), The Anubodics (M. Panetu and J. D Capra. cxls.                    the recipient antibody nor in the imported C DR or framework
Ha&wood Academic Vublishers, 1995).                                       sequcnccs, but arc included to furtlmr refine and optimize
                                                                          antibody perfonnance. In general. the humanized antibody
                        l&EVINI1IONS                                      will comprise substantially all of at least one, and typically
                                                                          two. variable dmnains. in hich all or substantially all oi'he
                                                                                                     &&
   An '*ant&body" is an inm&umiglobulu& inolecule capable of              CDR reg&ons correspi&nd lo those o I'a non-human unnn&no-
specific binding to a target, such as a carbohydrate. poly-               globulin and all or substantially all of the FR regions are those
nucisx&tide. lipid. polypcptickx ctc, thmugh at least onc ant&- m&        of a human immunoglobulin consensus sequence The
gen recognit&on site, located in the vanable region of the                human&zed antibody optimally also w&11 comprise at least a
immunoglobulin molecule As used herein. the tenn encim&-                  portion of an imnnu&oglobulin consmnt region or domain
passes not only u&tact polyclonal or monoclonal ant&bodies,               (Fc), typically that of a luunan immunoglobulin. Preferred are
but also fragments thereof (such as Fab, Fabk F(ab')s. Fv),               antibodies having Vc regions mod&fied as described u& WO
single chain (ScFv) m&d domain antibodies), and fusion pro- (             99/58572. Othm fonna of hmnanizixI nntibodics have one or
te&ns comprising an antibody portion, and any other mod&fied              more CDRs (CDR L i. CDR L2, CDR L3. CDR I I I. CDR 1 12.
configuration of the inununooJobufin molecule that com-                   and/or CDR H3) which are altersxI w ith respect to the original
                                                       US 8,080,243 B2
                                                                                                          10
mitibody. which are also termed one or morc Cl&Rs "derived                 V(   SK9 signaling, including PCSK9-mediated down-regula-
from" one or more CDRs from the oriynal antibody.                          tion of the LDLI&, and PCSK9-mediated decrease ui LDL
   As used herein, "human antibody" means an antibody hav-                 blood clearance. A VCSK9 antagonist antibody encompasses
ing an mnino acid scqucncc corresponding to tlu&t of an anti-              antibodies that block, antagonize, suppress or reduce (to any
body that can be produced by a human and/or which has been         s       dree including significantly) PCSK9 biological activity,
made using any of the teclmiques for making Inunan antibod-                including downstream pathways mediated by PCSK9 signal-
ies known to those sloiled in the an or disclosed herein. This             uig. such as I,DI R uiteraction andior elicitation of a cellular
definition of a lnunan antibody includes antibodies compos-                response to PCSK9. For purpose of the present uivention. &t
ing at least one human hcavy chain polypeptide or at least onc             will be explicitly understood that the tern& "PCSK9 antago-
hunt ut light chain polypepude. One such example is an anti-       ui      mst antibody" encompasses all the previously identified
body comprismg nninne light chain and human heavv clmin                    terms. titles, and functional states and clmracteristics
polypcptidcs I lumen mitibodies can bc pmduccd using ven-                  v, hereby the PCSK9 imvli. a PCSK9 biological act&Cloy (in-
ous teciuuques intown in the art. In one embodiment, the                   cluding but not hmited to its ability to mediate any aspect of
lnunmi antibody is scicctcd from a phage library, where tlmt               interaction with the I JJI.R, down regulation of I DI.R, and
phage library expresses human mitibodies (Mmighan et nl .                  dcmrexsed blood LDI. clearance). or the conscxluences ol'he
1996. Nature B iotechnoloay. 14: 309-314; Sheets et al., 19(J8,            biological activity, are substantially nullified, decreased, or
Proc. Natl Acad. Sci (IJSA) 95:6157-6162: Hoogcnboom                       neutralized in any nieaningful degree In some embodiments,
and Winter, 1991, .1. Mol. Bml,, 227:381: Mnrks et al.. 1991.              a PCSK9 uttag(mist mitibody buids PCSK9 and preven1s
J. Mol. Biol., 222 581). Human antibodies cmi also be made                 interaction with the LDLR. 1)xampfes of VCSK9 antagonist
by immunira1ion of aninials into which bun(an immunoglo-           io      alulbodlLs are provided bc&el&1
bulin loci have been trmisgenically introduced in place of the                 Asusedhereina "fullanta onist"isanantagonistwhich,at
endogmiom loci, e.g., mice in which the endogenous inumi-                  an eifective concentmtion, essentially completely blocks a
noglobulin enes have been partially or completely uiacti-                  measurable effect of PCSK9. By a partial mits omst is meant
va ted. This approach is des cubed in U.S. Pat. N os. 5,545,807;           an antagonist tltat is capable of partmlly blocking a measur-
5,545,80(i: 5,569,825, 5,(i25,126; 5,633.425; and 5,661,016&               able eifect, but that, even at a hivhest concentration is not a
Alternatively, the lnunan antibody &nay be prepared by                     ii&11 antagomst. By essentially completely is meant at least
immortalizing lmnmn B lymphocytes that produce an anti-                    about 80%. preferably, at least about ()0(%(s more preferably, at
body (irected against a tar et antigen (such B lymphocytes                 least about 95%, and most preferablv, at least about 98% or
may be recovered from an individual or may have been immu-                 99% of the measurable effect is blocked. The relevant "mea-
niz(d in vitro) Scc, e g, Cole et al Monoclonal Antibodies         io      surable cfii:cts" arc dcsscribmi hcrcin mid include down regu-
and Cancer Therapy Alan R. I isa, p. 77, 1985. Boerner et al,              lation of I.DI.R by a PCSK9 antagomst as assayed in Huh7
1991. J. Inuuunol., 147 (I):86-95: and U.S. Pat. No. 5,750,                cells in vitro, in vivo decrease in blood (or plasma) levels of
373                                                                        total cholcsn.'rol and ill vlvo dcclcasc ln I.DI, ICYLL( ill blood
   A '*vanable region" of an antibody refers to the vera&hie               (or plasma).
region of the antibody light chain or the variable region of the   "<U+00BB>          As usLVI herein. tlm term "clinically meaningful'* means at
antlb(xlv heavv'fraul, el&be( alone or u1 co&nbinatlon As                  least a 15% rcdiuction in bio&xi I,DI,-cholesterol levels in
known ut the a&t. the venable regions of the heavy and light               h&unans or at least a 15% reduction ui total blood cholesterol
chain each consist of f(iur fmmework regions (FR) connected                in mice It is clear that mcasurcmcnts in plasina or senim can
by three complementarity determining regions (C'DRs) tlmt                  serve m surrogates I'or nicasuremmit of levels in blood
contain hypervariable regions. The ( DRs in each chain are         so          As usLVI herein, the term "PCSK9 antagonist peptide" or
lmld togetlmr in close proximity by tlm FRs and, with thc                  'PCSK9 antagonist aptamer" includes any conventional pep-
CDRs from the other chain, contribute to the fomiation of the              nde or polypeptide or aptamer that blocks, antagonizes, sup-
antigen-binding site of antibodies. There are at least two                 presses or reduces (to any degree including sigotificantly)
techniques for determining CDRs: (I) an approach based on                  PCSK9 biological activity, including downstrcnm pathways
cross-species sequence vanability (i.e., Kabat et al.              4.      mediated by VCSK9 sig(&Cling, such as LDLR interaction
Sequences of Vroteins of Immunological Interest, (5th ed.,                 and(or elicitation of a cellular response to i(CSKO. IK'SK9
1991. National Institutes of I iealth. Bethesda Md.)k and (2)              antagoiust peptides or polypeptides include I c fusions com-
an approach based on c&ystalloyaphic studies of antigen-                   prising the LDLR and soluble portions of the LDLR, or
antibody complexes (Al-lazikani ei al, 1997, I Molec Biol                  mutants thereol'with higher ailimty to P( SK9
273:927-948). As used herein. a CDR may refer to CDRs                  o       The terms "polypeptide". "ohgopeptide", "peptide" and
defined by either approach or by a combination of both                     "protein" are used intercliangeabiy herein to refer to elm ins of
approaches                                                                 amino acids of any length. preferably, relatively short (e.g,
   As known in the art u "constmit re@on" of an antibody                    10-100 iuruno acids). 11&e clmin may be linear or branched. &t
refers to dw. constant region of the antibody light chain or tlm           niay comprise modified aniino acids, and/or may bc inter-
constant region ol'the mtibody heavy cluiin, either alone or in 1          rupted by non-amino acids The terms also encompass an
colllbination.                                                             amino acid chain that has been modified naturally or by
   As used herein. thc tcmi "PCSK9" refers to any form                     intcrvmition, for example, disuliide bond liinnation, glyco-
       oi'CSK9
          and vanants thereol'hat retaui ai least part of the
activity of PCSK9 Unless indicated differently, such as by
spccilic refcrmicc to human PCSK9. P('SK9 includes all ni
manunaiian species of native sequence PCSK9, e.g., human.
canine, feline, equiim, mid bovine. Onc exemplary human
                                                                           sylation. lip&dation. acetylatmn. phosphorylation. or uiy
                                                                           other manipulation or modification, such as conjugation with
                                                                           a labeling component Also inc iud(d withui thc dclinition arc,
                                                                           for example, pc l)3(Opt&des containing one or more ana logs of
                                                                           an amino acid (including, for exnmple, unnatural amino
PCSK9 is found as Un&prot Accession Number QSNBP7                          acids. etc ), as well as other modiiications known in the an. It
(SLQ ID NO:16().                                                           is understood tlmt the polypeptides can occur as single chains
   As used lmrein, a "PCSK9 mitagonist" refers to an anti-         &       or associated chains
body. pepude. or aptamer that is able to inlubit PCSK9 bio-                    As loiov;n in the art, "polynucleotide," or "nucleic acid," as
logical activity and(or downstremn patlnvay(sj mediated by                 used interchangeably herein, refer to chains of nucleotides of
                                                           US 8,080,243 B2
                                                                                                           12
wly length. and include DNA and RNA The nucleotides can                    morc prefcmbly less than about 1 nM, most prcti.rably less
be deoxyribohhuclcothdes, ribonucleotldes, modified nucle-                 than about 0.2 nM, as measured by the methods disclosed
oti des or bases. and/or their ana logs. or any substrate that can         herein in Example 2.
bc incorporatcxl into a chain by DNA or RNA polymcrase. A                     An epitope that "prefcrcntially binds" or "specifically
polynucleotide may compnse modified nucleotldes, such as                I  buids" (used ulterchangeably herein) to an antibody or a
methylated nucleotides and their analogs. If present. modifi-              polypeptide is a tenn ii el 1 understood in the art. and methods
cation to the nucleotide structure may be imparted before or               to deiernune such specdic or preterentud binding are also
after assembly of the chain. The sequence of nucleotldes may               well known ln the art. A molecule is said to exlublt "speci bc
be uucmipted by non-nucleotide components A polynucle-                     binding.'r *'pret'Lrential binding*'t't reacts or associates
otlde may be further modified after polymerization, such as            ni  more frequently. more rapidly, uith greater duration and/or
by conjugation with a labeling component. Other types of                   with yester affiiuty with a particular cell or substance than it
nllxiificmiOns inClude. for example. *'caps'*. substiuition ol             does with altcrnatilw cells or substances An antibody "spe-
one or more of the naturally occurnng mlcleotides uith an                  cifically bulds" or "preferential ly binds" to a target lf it buids
wlalog, intcrnuclcotide modificarions such as. I'or example,               with greater atfinity, avidity, more readily, mid/or with greater
those 111th uncharged hnkages (e g.. methyl plmsphonates.                  duration Ihnn il binds to other substnnces. For ex uuple. Wi
plmsphotriesters, phosphoamidates. carbamates, etc.) and                   antibody that specificallv or preferential ly binds to a I'(.'SK9
with charged linkages (e g., phosphorothioates, phospho-                   epitopc is an antibody that binds this epitope with greater
roditlnoates, etc ). those contauung peudmit moieties, such                afiimty, avidity. more readily, and/or lvith grwiter duration
as, for example, proteins (e.g., nucleases, toxins, antibodies.            than it binds to other V( SK9 epitopes or non-p(.'SK9
s~gnal PePtidcs. Polv-l.-lyslnL. i'Ic ), Ihosi: with lillLlcilliltol's so  epitopcs. It is also understood by reading this definitiml that,
(e.g., acridine, psoralen, etc.). those containing chelators               for example, an antibody (or moiety or epltope) that specif-
(c.g.. metals, mdioactive metals, boron. Oxidative metal~,                 icall or preferentially binlLS to a first target may or may not
etc.), those contaimn alkylators. those with modified luik-                specifically or preferentially bind to a second target. As such,
ages (e.g.. alpha anomeric nucleic acids, etc.). as well as                "specific binding" or "preferential binding" does not neces-
umnodified fonna of tlm polynucleotide(s). Further, any of             "   sarily require (although it can include) exclusive binding.
the hydmxyl youps ordlnartly present in the sugars may be                  Generally. but not necessartly. reference to binding means
replaced. for exmnple, by phosphonate woups, phosptmte                     preferential binding.
grolips, prohccIPLI by sIBlxlald prtllcctnlg gl'oops, oh'lctlvaIPd            As usexf lmrein, '*substantially pure*'efi:rs to matertnl
to prepare additional hnkages to additional nucleotides. or                uhich is at least 50% pure (i.e.. free from contaminants),
may bc conjugated to solid supports. Thc 5'nd 3'erminal                so  morc preferably, at least 90% pure<U+201E>morc prefi:rably. at least
OII can be phosphorylated or substitutsxl 111th amiues or                  95% pure. yet more preferably, at least 98% pure. and most
orgaruc capping group moieties of from I to 20 carbon atoms.               preferably, at least 99% pure.
Other hydroxyls may also bc derivatil,cd to standard protect-                  A "host cell" includes an individiwl cell or cell culture Ihat
uig groups. Polynucleotides can also contain analogous                     c m be or has been a recipient for vector(s) for incorporation
fortns of ribose or deoxyribose sugars that nre gmlemliy               "<U+00BB>  of polynucleotide inserts. Host cells include progeny of a
knou n in Ihc arL including<U+201E> for example, 2n0-methyl-. 2u0-                single host cell mid the progeny may not necessartly be
allyl. 2uthioro- or 2uazido-ribose. carbocychc sugar uialogs,              completely identical (in morpholog) or ui genonuc DNA
alpha- or beta-anonmric sugars, epinwric sugars such as am-                complement) to thc original parent cell due to natural. acci-
buiosc, xyloscs or lyxoscs. pyr Bio st.'ugal s. fwalulsc sugals,           dental. or deliberate mutation A host cell mcludes celL~ trwis-
sedoheptuloses, acyclic analogs and abasic nuclsmiside ana-            sc  fected in vivo with a polynucleotide(s) of tllis invention.
logs such as methyl riboside. One or morc phosphodiester                       As know n in the art. rim term "Fc region" is used to dctinc
linkages may be replaced by alternative linking aroups. These              a C-ternunal region of an utuuunoglobulin heavy clmsln. The
alternative linking groups include, but are not limited to,                'Fc region" may bee native scsquence Fc region ore variant Fc
embodiments lvhcrein phosphate is replaced by P(0)S("tbio-                 fcgl 011. Although hie boundaries of the Fc region of an imnni-
ate"). I'(S)S ("dkthioate"), (0)NRi ("anudate"). V(0)R, P(0)           4.  noglobulul heavy chain might vary, the human IgCh heaiq
OR'. (.'0 or CHC ("fonnacetal'). in which each R or R's                    chain Fc region is usually defined to snatch from ml amino
uidependently I I or substituted or luisubstltuted alkvl (1-20             acid residue at position Cys226, or from Pro230. io the car-
(:) optionally containin an ether ( 0 ) hnkage, aryl, alk-                 boxyl-terminus thereof. The numbering of the residues in the
enyl. cycloalkyl. cycloalkenyl or araldyl. Not all hnkages in a            Fc region is that of Ihc FIJ index as in Kabat Kabai et al,
polynucleotide need be identical. The preceding descnptlon               c Sequences of Proteuis of Immunological Interest, 5th Ed.
applies to all polynucleotides referred to herein. including               I'ublic Ifealth Service. National lnstlmtes of lfealth,
RNA and DNA                                                                Bethesda Md, 1991 The Fc region of an immunoglobului
   A "PCSK9ants onlstaptamer,"wluchcomprisesamicleic                         enemslly comprises two constant domains. CI12 and CII3.
acid or pmtein sequence. is, for example, selected from a                      As used in tlw art, 'Fc receptor" and "FcR'* describe a
large pool of rwidom sequences and specifically binds                    I receptor that binds to the Fc re ion ol an uitibody. The pre-
Vt SK9. I'he nucleic acid of the aptamer is double-stranded                ferred FcR is a native sequence lnuuml FcR Moreover, a
DNA or single-strmid RNA Nucleic acid aptwncrs can                         prcfcrrel FcR is onc which hinds an I (i antibody (a gmnma
uiclude moditied bases or functional groups, uicluding but                 receptor) and includes receptors of the Fcyki, FcyRII. aod
not limited to 2ufluorine nucleotides and 2LO-methyl nucle-                Fc/RIII subclasses. including allelic variants and altcma-
otidcs Aptamcrs can include hydrophilic polymers. for                  ai  tivcly spfhCLXI Iorms of thisC reCeptnr. FcyRH recLPIors
example, polyethylene glycol. Aptamers may be made by                      include FcykllA (an "activating receptor") and FcykllB (an
methods known in the art and selected for Vt SK9 antagonist                'itdfibiting receptor*'). which have similar amino acid
acuvity by routine modification of the methods ihsclosed in                sequences that hhtfer prunarily in the cysoplashuic domains
the Examples.                                                              thereof. Fcks are reviewed in Ravetch and Kinet. 1991, Ami.
    As hhssxf herein, an mltibody, peptide, or aptahucr "interacts     r   Rcv. hnnuinol.. 9457-92, I apcl et al.. 1994. Imnni-
with" PCSK9 when the equilibrium dissociation constant ls                  nomethods. 4:25-34: and de 1 lass et ul.. 1995. J. Lab. Clin.
equal to or less titan 20 BM, preferably less than about 6 BM,             Med.. 126:330-41. "Fck*'lso includes the neonatal receptor,
                                                        US 8,080,243 B2
                               13                                                                     14
FcRn, which is responsible for the transfer of mnternal IgCis         about one to about five mnino acid substitutions in a native
to the fetus (Ciuyer et al.. 1976 I. Inuminol., 117: SS7; and K&m     sequence Fc region or in the Fc region of the parent polypep-
et al.. 1994, .l. Inununol.. 24:249).                                 t&de. The vanant I'c reg&on herein w&ll prefemsbly possess at
   The term *'compete*h as used hcrcin with regard to an              lmcst abiiul g0'is sequence identity u ilk a native svquence Fc
ant&body. means that a first antibody. or an antigen-buid&ng s region mid/or with mi Fc region ol'a parent polypepiidc, and
ponion thereof, binds to an epitope in a manner sufficiently          most preferablv. at least about 90% sequence identity there-
sinular to the b&nd&ng of a second antibody. or a<U+00BB> u&ugen-            u&tin more prefemsbly. at least about &95%. at least about 96%,
b&ndm portion thereof. such tlmt the result of binduig of the
                                                                      at least about 97"!u at lemst about 9g%. at least about 99bv
firsl m&nbody u ilh ics cognate epitopc is dclcclnbly do:re&i&md
                                                                      sequence identity therewith.
&a the presence of the second ant&body compared to the buid- n&
                                                                          As used herein. "treatment" is an approach for obtai&ung
&ng of the first antibody in the absence of the second antibody.
                                                                      benefic&al or desired ch&ucal results. I&or purposes of this
The altcmative. where thc binding ol the second anlibixly n&
                                                                      invent&on. bencticial or desired clu&ical resulcs include, but
&ts epitope &s also detectably decreased in the presence of the
tirst antibody, cnn, but need not be the case Thnr is, a tirst        are not limited to, one or more of the folio&& ing: enhancement
anl&body can udiibil lhe binding of a svcond antibody lo ils
                                                                      of LDL clearance and reducing incidence or mnelioration of
epitope u:ithout that second antibody inhibiting the binding of       aberr uit cholesterol and/or lipoprotein levels resultu&g from
the first antibody to its respective cpitopc. However, where          metabolic m&d/or cating disorders. or including I'amilial
each antibody detectably inlnb&ts the binding of the other            hypcrcholesterolemia, athcrogenic dyslipidemia, atlmrosclc-
m&tibody with its cognate epitope or ligand, whether to the           rosis, and, naire generally. cardiovascular disease (CMD).
same, grcalcr. or lesser oxtcnh tlm antibodies are snid to sc             **Reducu&g mmdence" means any of reducuig severity
"cross-compete" v;ith each other for bind&ng of their respec-         (which can utclude reducing iuwd for and/or ammmt of (e g.,
tive epitope(s). Both competing and cross-competing anti-             exposure to) other drugs and/or therapies generally used tiir
bodies are encompassed by the present invent&on. Regardless           tlus condition. As &s understood by those skilled u& the art,
of the meclianism by &vhich such competition or cross-com-            ind&viduals may vary in terms of their response to treatment,
petition occurs (e.g, steric hindrance, confonnational " and, as such, for example. a "nmthod of reducing
change, or bind&n to a conunon ep&tope. or port&on thermA,
the skilled art& san would appreciate, based upon the teachings
                                                                              incidence*'etlects
                                                                                admuustenng the PCSK9 ants onist annbody, pep-
                                                                      t&de. or aptamer based on a reasonable expectat&on that such
provided here&n. that such compeung and/or cmss-competing             aihmni ~ t ration may l&kely unuse such a reduction in me&dence
ant&bodies are encompassed and can be useful for the meth-            ui that part&cular ind&vidual.
ods disclosed hcrcin.                                             "(1     *'Ameliorating*'eans a lcsscning or improvement of onc
    By  an   mu&body    with   an  c7&tope that  *'overlaps*'v&th     iir  nlore sv'&lip&ellis as co&i&pareil lo ilol ail&i&i&i&slat&i& a
another (second) ep&tope or iv&th a surface on PCSK9 tlmt             PCS K9 antagon&st antibody. peptide. or ap tamer. "Amel&orat-
interacts with the FCiF-bkc donuiin of the I.DI,R is meant lhc        ing'* also includes shortening, or rnluction in duration of a
shanng of space in tern&a of the PCSK9 residues that are              symptom.
interactcd with. To calculate the percm&t of overlap. for "<U+00BB>              As used herein, an "effi:ctive dosage*'r "cffi:ctive
example, tlm percvnt overlap of ibe claimed m&t&body*a                amoum" ol'drug. compound, or pharmaceutical compositmn
PCSK9 ep&tope w&th the surface of PCSK9 uhich interacts               &s an amount sutlic&ent to effect uiy one or more beneficial or
with thc HiF-like domain of tfm I,DI R, thc surface area of           dcsircxf results. For prophylactic use, bencticial or desired
PC'SK9 buried when in complex u ith the I DI R is calculated          results u&elude eliminating or reducing tbc nsh, lessening thc
on a per-residue basis. 'Bie buried area is also calculated for sc severity, or delaying the outset of tl&e disease. including bio-
these residues in the PCSK9 nntibody complex To prevent               clmmical, histological ancUor behavioral symptoms ul'lm
more than 100% poss&ble overlap. surface area for residues            d&sense, its compl&cat&ons and &ntermedmte pathological phe-
that i&ave hind&er buried surface area in the FCSK9:antibody          notypes presenting during development of the disease. For
complex thm& in I,DLR PC'SK9 con&plex is sel to values from           therapeutic use, beneficial or dcaimd results include clinical
the LDLR:PCSK9 complex (100%). Percent surface overlap 4. results such as reducing hypercholesterolemia or one or more
is calcu latcxl by sununing over aff of thc LDI,R:PC'SK9 inter-       symptoms of dyslipidemia, atherosclerosis. I'irlk or coro-
act&ng residues u&d is v, eig&ed by the uiteraction ares.             nary heart disease, decrees&ng the dose of other med&cations
   A "functional Iic region" possesses at least one effector          required to treat the disease, enhancing the efTect of another
I'unction ol'a native sequence Fc region Fxen&phuy "elT&wtor          med&cat&on, and/or delaying lhe progression of&he disease
fiu&ctions*'include Clq hindu&g,complement dependent cyto- u
toxicity; Fc receptor binding; ant&body-dependent cell-medi-
ated cytoloxicity: pluigocytosis, down-regulation of cell sur-
face receptors (e.g., B cell receptor), etc. Such effector
                                                                                ol'atients.
                                                                                 An effective dosage cmi be ad&u&mater&xf &n one or
                                                                      more administmtions. For purposes of this invention, an
                                                                      effeclive dosage of dn&g. compound, or pharmaceutical com-
                                                                      posiuon is iu& amount sufficient to accomplish prophylact&c or
functions genernl ly rcquirc thc Fc region to bc combined with        thempeutic treatment effect     directly or indirectly As isundcr-
                                                                                               either&ve
a bindn&g domai<U+00BB>(e.g, ananubody vnriabledomau&) andean s stood in the clinical context. u& eti'ective dosage of a drug,
be assessed using vnrious assays kno&vn in the art for evalu-         compound. or pharmaceutical composition may or may not
ating such antibody effi.ctor functions                               be achieved in cmfilunction u i&h m&other drug, compomid. or
   A 'native sequence Tc region*'ompnses mi amu&o amd                 phannaceutimd composition. Thun ui "ell'ecuve dosage"
sequence idm&tical to tlm amino acid scequm&cc of an Fc region        may be considered in the context of administering one or
1'om&d in imturc A "vanmu Fc region" comprises ail a&stille s&1 morc therapeutic agents. and a smgle agent may be consid-
acid sequence wh&ch differs from that of a native sequence Fc         ered to be g&ven in an             amoiuit f, in conjunct&on with
                                                                                                                &
region by virtue of at least one nmino acid moditication, yet         onc or more other ngents. a desirable result may be or is
retains at least one effector h&ncnon of the native sequence Fc       achieved.
rey'on. I'referably. the variant Fc region has at least one amino         An "individual" or a "subject" is a manunal, more prefer-
acid substitution con&pared to a native sequence Fc region or r ably. a luunan Mnnm&als also include, but are not limited to,
to the I'c reg&on of a parent polypeptide. e.g.. from about one       farm an&mals. sport anunals. pets, pnmates, horses, dogs.
to about ten amino acid substin&tions, m&d preferably, from           cats. mice and rats.
                                                          US 8,080,243 B2
                                 15                                                                     16
    As uscxI lmrcin, "&veto&" nwans n construct, which is               blood I,I/I is at least about 20% lower than bcf&ire adminis-
capuble of del&venng. and. preferably. expressing, one or               tration of the antibody Yct more preferably, blood cholesterol
more gene(s) or sequence(s) of interest in a la&st cell.                and/or blood LDL is at least 30% lower than befnre a&hnin-
Fxan&ples of vsictors include, but arc not limited to, viral            istration of ibe &u&tibndy. Advantageously. blood cholesterol
vectors. ooked DNA or RNA expression vectors. plasmid,                  and/or blood I,DI is a& lmist 80% lower than be(i&re o&huin-
cosmid or phage vectors. DNA or RNA expression vectors                  istrati on of tine antibody. More advantageously, blood cho1es-
assocuued with cationic condensing a ants. DNA or RNA                   teml and/or blood LDL is at least 60% lower than before
expression ~actors encapsulated in liposomes. and certain               adm&mstration of the antibody. Very preferably, blood cho-
eukaryotic cells, such as producer cells                                lesterol ond/or blood LDL is ot least 60% le&vcr tlmn betiirc
    As used herein. "expression control sequence" means a           &&1
                                                                        adm&nistmntion of the antibody. Most preferably. blood cho-
nucleic acid sequence that directs transcnption of a m&cleic
                                                                        lesterol ond/or blood LDL &s at least 70&/8 lower than before
acid An expression control svqumiee can bc a promoter. such
                                                                        ad&a&ala&ration of the mtibody
as a constitutive orat& inducible pmmoter. or an enhancer. The
expression control sequence is opembly linked to the nucleic                With respect to all methods described herein, reference to
acid svquence to be transcribed                                      ,  PCSK9 antagonist antibodies, peptides, and aptamers also
    As used herein. "plmrmaceutically occeptable carrier" or            uiclude compositions compris&n one or more additional
            subject 'sacceptable excipient'* includes any n&aterial
*'phanuaccutical                                                        agents Tlmsc compositim&s moy fintlmr comprise suitable
winch. &shen comb used with mi active &ngredi ant, allows the           excipients, such os plmrmaceutically acceptable excipients
ingredient to retain biological activity and is non-reactive            including buffers, wluch are well knov;n ui the ait. The
with the               in&mune systmn. Fxamp les include, but orc n     present invention ran be used alone or &n combi&rntion with
not limited to, any of the standard pharmaceutical carriers             other conventional methods of treatment
such as a phosphate bufferixI saline solution. water. emulsions            The P(JSK9 antagonist antibody. peptide, or aptamcr can
such as o&l/water emulsion, and various types of &vettut                be a&bnimstered to an u&C&vidual via any suitable route. It
agents. Preferred d&luents for aemsol or parenteral adnunis-            should be apparent to a person skilled in the on tint the
tration ore phosphate buffered saltlm (PI)S) or normal (0 9%n)          examples Ccscribcd herein are not intended to be limiting but
saline. Compositions comprising such carriers are fornn&lated           to be illustrative of the tecluuques ac ulable. Accordingly. ui
by well known conventional methods (see. for example. Rem-              some embodiments, the I'('SK9 antagonist antibody, peptide,
uigto&i's Pharmaceutimd Sciences. 18th edition. A Gem&aro.              or optamer &s adm&ni ~ tered to an individual ui accord &&ith
ed., Mack Pubhslung Co.. L'aston. Pa.. 1990: and Remington,             known methods. such as &ntmvenous a&hn&n&stration. e... as a
The Science m&d Pmctice of Plmrmacy, 20th Fd <U+201E>Mack Pub- sn              holus or by mmtinunus inl'usion over a period of tinm, by
lisluog. 2000)                                                          &nuamuscular. mtraperitoneal, &ntracerobrospu&al. uansder-
    Tl&e tenn "K<U+201E><U+201E>". as used herein, refers to the rate constant        mal, subcutaneous. &ntmn-articular, subhnguolly, intrasyn-
I'or association of an muibndy to on 'mtigen Specilicnlly, thc          ovial. via insufflation, intmthccal, &mil, inhalatim& or &opicol
rate constants (k<U+201E>, and k.y) md eq&ulibuum dissociation con-            mutes. Ad&ouzo&rat&on can be systemic, e.g., us&ravenous
stants are measured using~ Fab antibody fmgmmits (i.e, uni- "<U+00BB>          administration, or localized. Conuneiciolly available nebu-
voiel&t) aud P( SK9.                                                    hzee'or bquid fom&ulations, including jct ncbuli!ers and
    The term "k,f'2 as used herein. refers to the rate constmtt         ultrasonic nebul&zers are usefi&1 for admimstmnt&on. Liquid
for dissociation of an m&tibody fron& the antibody/antigen              f&irmulations can be directly nebulized and lynphilizcd pow-
col&&plex                                                               der cun bc nebuli!ed alter reconstitutim& Alternatively,
    'lite tern& "Kr", as used herein. refers to the eqmlibrnuu sn       I'('SK9 antagonist antibody. peptide. oraptamer con be aero-
dissociation constant of m& antibody-antigen interaction                snli!ed using a fluorocarbon fnnnulation and a metered dose
,A. Methods for Preventing or Treating Disorders Associated             uihaler. or uilialed as a lyophilized and nulled powder.
with Hypercholesterolemia                                                   In one embodiment, o P('SK9 antagonist antibody, pep-
    In one aspect. the invention provides a nmthod for treating         tiCe. or aptan&ur is administered via site-spccilic or targeted
or preventing hypercholesterolenna. and/or at least one                 local delivery techniques. Examples of site-specific or tor-
symptom of dyslipidemio. atherosclerosis. ('VD or coronary              getixI local delivery techniques include varinus implontable
heart disease. u& an u&dividual comprising adnunistering to             depot sources of the PCSK9 antago&ust antibody. peptide. or
the individual an effective amount of a PCSK9 antagonist                aptamer or local delivery catheter~. such as mfu sion catheters,
antibody nr peptide or aptmucr tlvu antagonizes circuloiing             indwelling catheters. or ncvdle catheters. syntheuc grafts<U+201E>
PCSK9.                                                               n  advennt&al wraps. shunts and stents or other &mplontable
    In a t'urther aspect, the imention provides an effective            devices, site specific carriem, direct in)ection, or direct appli-
amnunt of a PCSK9 antagonist antibody. peptide. or apiamer              cation See c g., PCT Publ No. W000/63211 andi).S Pot.
that ants oiuzes c&rculat&n PCSK9 for use in treatin or                 No. 5.981,668.
preventing hypercholestcrolemia, and/or at least one symp-                 Various liinnulotions nf a PCSK9 antagonist antibody,
tom of dysl&p&demia, athemsclerosis, CVD or coronary heart s            peptide. or optamer may be used for administration In some
disease. in an individual. The invention further provides the           embodiments, the P('SK9 antagonist antibody. peptide, or
osv. ol'an e(Tcetive muoont of a P(.SK9 antagonist antibody.            aptamcr nt 9 bc administered neat In sonw. embodiments,
pepude. or ap tamer that antagomzes extracellular or circulat-          PCSK9 antagonist u&tilxidy, peptide. or apt uner mtd a phar-
ing PCS K 9 in the manufacture of a medicament fnr treating or          maceutically acceptable cxcipient may be in various formu-
prevm&ting hyperchnlcsterolemi i, and/nr at lmist nnc symp- ro          latmns Pharnraceutically acceptable cxcipients are known m
tom of dyslipidemia, atherosclerosis, CVD or coronary heart             the a&t. and are relatively inert substances tint facihtate
disease. in an individual.                                              administration of a pharmacologically effective substance.
    Advantageously, therapeuuc odmuustration of the ann-                I'or exmnple, an exc&pient can give fomi or consi stency. or act
body. peptide. or optamer results in lower blood cholesterol            as o diluent. Suitable excipients include but are not hmited to
m&d/or lower blond I,DI Preferably, blrxid cholesterol mid&or           stabilizing agents, wcuing and emulsifying agm&ts, salts f&ir
blood LDL &s ot least about 10% or 16%a lower than befnre               varying os&nolo&sty, encapsulating agents. butTers. and skin
administration. More preferably, blood cholesterol andcir               penetmtion enhancers. Fxcipients as well as formulations for
                                                          US 8,080,243 B2
                               17
parenteral and nm&parcnteral dnig delivery are set le&th in            given incremm&tal dosages of a PCSK9 antagonist antibody,
Rmuington, The Science and Vmctice of Phamiacy, 20th L'd.,             pepnde. or aptamer. To assess eiiicacy. an &nd&cator of the
Mack Pubhshing (2000).                                                 disease can be follow ed.
   These agents can be cou&bh&e<U+00BB>I ivith phannaccuiically                   Administration of a P(.'SK9 antagomst antibody, peptide,
acceptable vi:hiclcs such as saline, Ringer's solution, dex-           or aptmuer &n accordance w&th the method in the present
trose solution. and the like. I'he particular dosage regimen,          invention can be continuous or intermittent, depending, for
&.e.. dose<U+201E> t&m&ng and repetit&on, w&ll depend on the part&euler
                                                                       example.    upon the recip&ent's phys&clog&cal cond&tion,
nuliv&dual and thnt u&div&dual's med&cal lustory.                      whether the purpose of the administrat&on is therapeut&c or
   PCSK9 antibodies can also bc adn&inistered via inhalation,          pmphy lactic, and ot lier fee airs known to ski l lcd p rue utioncrs.
                                                                   &(1 The xhnin&strat&on of a PCSK9 antagoiust anubody<U+201E>peptide<U+201E>
as descnbed hereu&. Generally, for administration of PCSK9
                                                                       or aptamer may be essent&ally cont&nuous over a presefected
ant&bodies. an iiutial candidate dosage can be about 2 mg/kg.
                                                                       per<U+00BB>id of tmw. or may be in a si:ries ol'paced dose~
For the purpose ol'the present invention, a typical daily dos-
                                                                           In some embod&ments. more than one antagoiust antibody,
age mice range from about any of about 3 gg/kg to 30 gg/kg             pcq&tide, or aptamcr may bc present. At lcasr onc. at least two,
to 300 Pg/kg to 3 mg/kg. to 30 u&gvkg, to 100 mg/kg or nlole
                                                                       at less& three. at least four. at least live dilferenk or more
depend&ng on the factors ment&oned above. For example.                 antagonist antibodies nnd/or peptides can be present. (Iener-
dosave of about I mg/kg. about 2 5 mg/kg, about 5 mg/kg,               ally, those PC'SK9 antagonist nntibodies orpcptidcs n&ay have
about 10 mg/kg, and about 25 mg/kg may bc used. For                    complementary activities that do not adversely alfcct each
repeated admin&strations over several days or longer. depend-          otlmr A VCSK9 m&tagonist antibody, peptide, or aptamer can
ing on &he condition. the treatment is sustnu&ed unt&l a desirtnl o also bc used in conjunction with otlmr PCSK9 anuigonisis or
suppression of symptoms occurs or until suifiment thernpeu-            VCSK9receptoranta on&sts.forexample.oneormoreofthe
tic levels are achieved, for example. to reduce blood LDI.             following P(JSK9 antagonists may be used: mi ant i sense mol-
levels. An exemplary dosing regimen comprises adnunister-              ecule directed to a PCSK9 (&nclud&ng mi anti-sense molecule
&ng an iiutial dose of about 2 mgkg, folloiied by a v,eekly            directed to a nucleic acid encoding P('SK9), a PCSK9 inhibi-
maintenance dose of about I ing!kg of thc PCSK9) antibody, " tory compound. and a PCSK&J stnicmral analog A P('SK9
or folio&red by a ma&ntenance dose of about I &ugkg every              antagoiust antibody, peptide, or aptamer can also be used &n
other week. However, other dosage reg&mens may be useful.              conjunct&on with other agents that serve to enl&ance and/or
dependu&g on the pauern of phanuacok&netic decay &hnt the              complement the elfect&veness of the ngents.
pmctitioner wishes to ac lu eve. I'or example, in some embod&-             Acceptable camera. exc&picots, or smb&1&zers are nontox&c
mcntx dosing fmm oim to liiur times a week is conte&<U+00BB>plate<U+00BB>I "o to rivipiems a<U+00BB> hc dos~gas and concentrations mnploycd, ilflil
In other emboduuents dosu&g once a month or ooce every                 mav a<U+00BB>npnse bulIers such as plmsphate, citrate. and other
other month or every three months is contemplated. The                 organic acids; salts such as sod&um chloride: ant&oxidants
progress of this tlmrapy is easily monitored by conventional           including ascorbic acid and methim&inc, prese&vatives (such
teclm&ques and essays The dosu&g rein&en (including the                as octadecyldnnethylbenzyl mnmonium chloride: hexam-
P( SK9 antagonist(s) used) can vary over tinm.                         ethonium chloride: benzalkonium chloride, benzethonium
   For the purpose ol'hc pit.'Ni:l&t &I&vcl&&101&, tlm appfoplla&c     chloride, plmnol. butyl or bcnzyl alwihol, alkyl parabcns.
dosage of a PCSK9 antago&ust ant&body. peptide, or aptamer             such as methyl or propyl p arab en: ca tee hob resorcinol: cyclo-
will depend on tlm PF'SK9 m&tagonist m&tibody, peptide, or             hcxanol, 3-pentanol, and m-cresol), low molecular weight
aptamer (or compos&tin&&s the&L00 en&ployexI, &bc type and             (less than about 10 residues) polypeptides, pro&el&&s. si&ch tls
severity of symptoms to be treated, ivhether the agent is 4o senun albumin. gelatin, or inuuunoglobulins: hydrophilic
administered fit r preventive or themapeuti c purposes, pres ious      polymers such as polyvinylpyrrolidone, amino acids such as
therapy. the patient's eh<U+00BB>ical history and response to the             glyc&ne. glutamu&e. asparagine, lustidu&e, arg&n&ne, or lys&ne;
agent, the patient's blood V('SK9 levels. the patient's synthe-        monosaccharides. disaccharides. and other carbohydrates
sis and clearance rate fiir Pf'SKR the patient's clem ance rate        including glucose. mannosc, or dcxtrins, chelating agents
for the admin&stered agent, and the discretion of the attending 4. such as L&DTA: sugars such as sucrose, mann&tol, trehalose or
physician I'ypically the clinician will administer a V( SK9            sorbitok salt-fern&ing counter-iona such as sodium; metal
an&agon&st antibody, pep&&de. or aptamer unt&l a dosage is             complexes (e.g.. Zn-prote&n complexes): and/or non-&on&c
reached tlmt achieves the desired result. Dose and/or fre-             surfactants such as T)&/L&LN&<U+00BB>, PLL&RONICS'u or polyeth-
quency ciui vary oivr course ol'treauuent I.mpirical consid-           ylene lycol (PFG)
emtions. such as the half-l&fe. genemlly v;ill contribute to tire o        Liposomes containing the PCSK9 antagon&st ant&body,
determination of the dosage. For example, antibodies that are          pept&de, or aptamer are prepared by metliods lo&own in the am
compatible with thc human inununc system, such as human-               such as described iu Epsteu&. et al.. 1985, Proc Natl. Amid.
ized m&t&bodies or fiilly luunan antibodies, iuay be used to           Sc&. IJSA 82:3688; I hvang, et al.. 1980, Pmc. Natl. Aced. Sci.
prolong half-life of thc antibody m&d to prevent the antibody          IJSA 77:4030. and IJ.S. Pat Nos 4.485,045 and 4.544.545.
beutg attncked by the host's imnuu&e system. Frequency ol'             I.&posomes with enhanced circulat&on tnne are d&sclosed in
administration may be determined and adjusted over the                 I I S. Pat No. 5 013 556. Particularly useful liposomes can be
course el'herapy. m&d is generally, but not accessarily, based         gcneratedi by the reverse plxisc evaporat<U+00BB>m nwthod with a
on treatment and/or suppress&on and/or amehoration aud/or              l&pid compos&t&on ci&mpnsu&g phiisphatidylchohne, chiiles-
delay of symptoms, e.g., hypcrcholesterolemia. Alterna-                terol and VF,(i-dcrivatizcxI phosphatidylethanolaminc (PHJ-
lively. sustained contmuous relcasi: fiinuulations of PCSK9 ui PF) I,iposomes are extruded through tiltcrc ol'defini:d pore
antagon&st ant&bodies may be appropriate. 3/ai&ous formula-            size to yield liposomes with the desired d&ameter.
tions and devices fiir achieving suits inc<U+00BB>I release are known in          The active ingr&xlicnts may nlso be entrapped in microcap-
the art.                                                               sules prepared. for example, by coacervat&on teclm&ques or by
   In one embodiment. dosages for an antagonist antibody,              interfacial polymenzation. for example, hydroxymethylcel-
peptide, or aptamer may be detcm&ined empirically in indi- 4 lulosc or gelatin-microcapsules and poly-(methyhnethacry-
v&duels who have been g&ven one or more adnun&stmt ion(s ) of          late) microcapsules. respectively. &n collouk<U+00BB>1 drug dehvery
an antagonist antibody, peptide, or aptamer. Individuals are           systems (for example. Iiposomes. albumin microspheres,
                                                         US 8,080,243 B2
                               19                                                                       20
micrommds iims, nano-particles and nano capsules) or in mnc-                 A P('SK9 nntagonist antibody, PCS&tide, or aptmner should
roemulsinns. Such tecluiiques are disclosed in Remington,                 exlub&t Bny one or more of the folloiv&n clmractenstics: (a)
The Science and Pmicuce of Pharmacy. 20th Ld.. Mack Pub-                  bind to PCSK9; (b) block PCSK9 interaction with the LDLR;
lishmg (2000)                                                             (c) block or decrease P( SK9-mcdiatcd doivn-regulation of
   Sllstan<U+00AB>XI"IclcBSC pl'ipali&110&IS mal'li pl'i."Pitied Sultablc        the LDLR; (d) inlublt the PCSK9-mediated decrease ui LDL
examples of sustained-release prepamtions include semiper-                blood clearance, (e) increase LDL clearance in mcxfia by
meable matnces of sohd hydmphobic polymers containing                     cultured hepalocy tea, (0 increase blood I,DI. clearance by the
the antibody, winch matnces are in fiie form ol shaped                    liver ui v&vo, ( ) sensiuze to statins, and (ti) block PCSK9
                                                                                                                                    inhibi-
                                                                          in&cree&ion with other yei to bc identified ihctors.
articlcx e g.. film~. or microcapsules Fxamplcs of sustaiiwd-
                                                                     &o       For purposes of llus nivent&on, the milibody. peptide. or
release niatrices include polyesters, hydrogels (for example,
                                                                          aptamer preferably reacts with I'C'SK 9 in a maiuier that
poly(2-hydroxyethyl-methacrylate), or 'poly(vinylalcohol)),
                                                                          tss P(. SK9 signaling functmn and I,DI,R mtcraction In some
polylamides (IJ.S Pat No 3,77'3,919), copolvmers
                                                                          embodiments. the PCSK9 antagomst antibody specitically
            ol'-glutamic
              acid and 7 ethyl-L-glutanmte, non-degradable
ethylene-vinyl acetate, degradable lactic acid-glycolic acid
copolymers such as the LIJPRON DFPOTI" (uijectable
                                                                     <U+201E>
                                                                          recognizi:s prllnate P(.'SK9 In sonw. embodiments. the
                                                                          PCSK9 uitagonist antibody binds primate and rodent
                                                                          I'CSKOJ.
microsplmrcs composed of lactic acid-glycolic acid copoly-               Thc antibodies useful in the present invention can encom-
mer and leupmlidc acetate), sue<U+00AB>isa acetate isobutyrate. Bnd          pass monoclonal md&bodies. polycloiml mtibodies, mitibody
poly-D-(-)-3-hydroxybutyric acid.                                     fragments (e.g., Fab, Fab', F(ab')<U+201E>Fv, Fc. etc.), chimeric
   The fonuulations to be used lorin vivo administration must       o antibodies, bispccific mitibodics. hctcroconjugate antibodies,
be stemle, This is readily accomptisticxt by. I'or example, fil-      sm~JC chain (ScFv), nu&tants thereol'. i&sion proteins com-
tration through sterile filtration membmnes. Therapeutic              prising an antibody portion (e.g., a dnmain antibody), Inunan
PCSK9 antagonist antibody, peptide. or aptamer compos&-               atuibodies, hunmn&zed antibodies, and any other modified
tions are generally placed into a container having a sterile          config&umtion of the inmuinoglobulin molecule that com-
access port, for example, an intmvenous solution bag or vial       " prises an antigen recognition site of the required speciticity,
havingsstopperpierceableby ahypoderm&c intecuonneedle.                uicludin glycosylat&on variants of antibodies.8'Ill&la&&Clog&call-
                                                                                                                              amino acid
   Suitable emulsions may be prepared using commercially              sequence variants of antibodies. and covalently moditied
Bvailiiblc fal clil&llsloilm such Bs IBIIBtlp&d<U+2122>. I,lposynru.         a&uibodica. The uitibod&es may be murine, rat. hummi. or any
Infonutrol'", Lipohuidinru and Llpiphysani", The active               other ofigtn (including ctumenc or humanized antibodies).
ingredient may be cilhcr dissolved in a prc-mixed cmutsion io            In some embodiments. the P(.'SK9 antagonist antibody is a
composition or alternatively ll may be dissolved &n an o&1            monoclonnl anubody The PCSK9 muagonist antibody can
(e.g.. soybean oil, saftloiver oil, cottonseed o&l. sesame oil,       also be lnunanized. In other embodiments, the aimbody is
corn oil or almond oil) Bnd an emulsion fiirmcd upon mixing           human
ivlth a phospholip&d (e.g.. egg phosphohp&ds, soybean phos-              In some emboduuents, the antibody composes a moditied
pholipids or soybean limithin) nnd water. It will bc appreci- "<U+00BB> c oils tant ri'glori, sllcli Bs a cons&alit regin&1 &liat Is
atcdt that other ingredients may be aifdcd, for cxmuple glyc-         yally inert, that is, havulga reduced pomntia1 iiir provoking an
erol or lucose. to adlust fiie toiucity of the ennilslon. Suitable    uunnuie response. In some embodiments, the constant region
ennilsions will lypically contain up to 20%v oil, for cxaniple,       is modified as described in I ur .1. Inummoi.. 1999. 29:2613-
belween 5 and 20%. Thc I'at emulsion can cmnprise fat drop-           2(124, PC:T Publ. No WO99/58572: anti'or UK Pulent Appli-
lets between 0.1 and 1.0 um, particularly 0.l and 0.5 pm, and sr& cation No. 98099S1.8. 'the I'c can be human lg()2 or hilluain
luive a PH in tlm range of 5 5 to 8 0.                                IgCis The Fc can be human lgCi2 contain&flu thc nlillaltlol'I
   The emulsion compositions can be those prepared by mix-            A330P331 to S330S331 (Idiom), in which the Bnuno acid
ing B P( SK9 antagonist antibody. peptide, or aptamer with            residues are munbered with reference to the wild type IgCi2
Intralipidr" or the componmils thereof (soybean oil, egg              sequence Iiur J Inununol. 1999. 29 2613-2624. In some
phospholipids. CPycerol and water).                                   emboduuents. the antibody comprises B constant region of
   Cmmpositions for inhalation or insuffiation include solu-          Ig(14 comprising the following nu&tations (Armour et al.,
tions and suspensions ui pharmaceut&cally acceptable. aque-           2003. Molemdar Inununology 40 585-s93): 0233F234L235
ous or organic solvent~. or mixtures thereof, and powders.            to P233M234A23S (Igni<U+00AB>). in which the numbering &s with
Thc liquid or solid composit&mis may contain suitable phar-           rel'erence to wild type tg(i4 In yet another embodiment. the
maceutlcally acceptable excipients as set out above. In some o            is human IgCJ4 02331'234L235 to P233V234A235 with
embodiments, the compositions are Bdmmistered by the oral             deletion C&236 (tgOB <U+201E>,). In another embodiment the Fc is any
or nasal respiratory route fiir local or systemic e fleet. Com-       lnunan IgC14 Fc (Ig(is. IgCI<U+00AB>s or Ig(i<U+00AB>,.) contaimng hinge
positions in prefembly stenle pharmaceut&cally acceptable             stabihzuig mutation S228 to P228 (Aalberse et al., 2002,
solvent~ may be ncbuliscd by usc of gases Nebulised solu-             Immunology 105, 9-19) In anotlmr cmbodimmit. Iho Fc cmi
tions may be breathed directly I'rom the nebulising device or 1 be aglycosylnted I c
the nebulising device may be attached to a face mask, twit or            In some embodiments, the constant region is ag lycosyl ated
intcrmiltcnt positive pre<U+00AB>sure breathing machine. Solution.           by mutating lhc oligosaccharide attaclmmnt rcsiduc (such as
suspens<U+00AB>in or poivder compositions may be administered,               Asn297) aod,'or itankuig residues tlrat are pan of the glyco-
prefembly orally or nasally, from devices which deliver the           sylation recognition sequence in the constant region. In some
formulation in an appropriate manner                               so cmb&idimcnts. the constant region is aglycosylatcd Ior
IL PCSK9 Antagonists                                                  N-linked glycosylation enzymatically. The constant region
   11m methods of the invention use a P('SK9 antag(mist               may be aglycosylatixl for N-linked glycosylation cnzymati-
antibody. peptide. or aptamer. w tuch refers to miy peptide or        cally or by expression in a glycosylat&on deficient host cell.
nucleic acid molecule tlmt blocks, suppres sea or reduces (in-           The binding BSnity (Kol of a PCSK9 antagonist antibody
cluding significantly reduces) P(.SK9 biologimil nctivity. ( to P(.SK&J (such as Inunmi P(.'SK9)) can be about 0 002 to
&ncluduig doivnstream patt<U+00AB>vays mediated by PCSK9 signal-             about 200 BM. In some embodiments, the buiding affinity is
inc, such as elicitation of a cellular response to PCSK9.             any of about 200 nM. about 100 nM, about 50 nM, about 10
                                                       US 8,080,243 B2
                              21                                                                     22
nM, about I nlVL about 500 pM, about 100 pM, about 60 pM,        ing but not lin&ited to X63-Agg 6&53 m&d those from the Salk
about 50 pM, about 20 pM. about 15 pM, ubout 10 pM, about        Institute. ('ell 1)isuibution (Jcnter, San Diego. I alif.. i ISA,
5 pM, or about 2 pM. In some embodiments, the binding            may be used in the hybrtd&zat&on. (Ienerally. the teclm&que
affinity is less than any of about 250 nM. about 200 nM, about   involves fusing n&yeloma cells and lymphoid cells us&ng a
100 nM. about 50 nM, about 10 nM, about I nM, about 500 s fusogcn such as polyethylcnc glycol, or by elcmtrical means
pM, about 100 pM, about 50 pM. about 20 pM, about 10 pM.         well knot&n to those skilled in the art. After the fiision. the
about 5 pM. or about 2 pM.                                       cells are separated from the fus&on medium and gn&wn in a
   One way of deternuiung binding ailimty of antibodies to       selective growth mednun, such rwv hypoxanth&ne-uninop-
P('SK9 is by n&easunng. binding aginity ol'monofunctiwml
                                                                 tcrin-thymidiim (HAT) medium, to eliminate unhybridized
Fab fmgments of the antibody. To obtain monofunct&otu&1 I'ab 8&
                                                                 parent cells. Any of the media described herein. supple-
fragments, an antibody (for example, IgCI) can be cleaved
                                                                 mented w&th or &vithout serum, can be used for cultunnv
w&th papaii& i&r expressel recombu&ni&tlv Thc affit&ify of a
                                                                 hybridomas lira& secrete monoclonal untibodies. As miother
PCSK9 I'ab fmyuent of an at&tibody can be deternuned by
sari'ace plasmon resonance (Biacore3000<U+2122> surface plasmon         altcmative to the cell fiision technique, EB&/ immortalized B
resonance (SPR) svstcm. B&score, INC, P&scatav ay NI )           cells may be used to produce the PCSK9 monoclonal anti-
                                                                 bod&es of the subject invention. The hybrtdomas are expanded
equipped &vith pre-inunobilized streptavidin sensor chips
(SA) using HBS-FP nmning buffi.r (0.01M HFPFS. pH 7 4,           and subcloned. if desired. and supcrnatants are assayed for
0.15 NaCI. 3 mM EDTA. 0,005%         v/v Suriacxaut P20). Riot&- af&t&.in&n&un(igen act&vlrt'lv'iinvcntun&al immunoassay pro-
nylated luunan VCSK9 (or any other VCSK9) cm& be diluted         cedures (e.g., rad&oimmunoassay, enzyme inununoassay, or
into HBS-FP butferus a conccntmtion ol'less tlum 0.5 pg/mi a           lluorescence &m&mmoassay)
and injected across the u&dividual clup channels usu&vg van-              Hybridomas that may be used as a source of nnt&bodies
able contact times, to achieve tvvo ranges of m&tigen density,         encompass all derivatives, progeny cells of the parent hybri-
e&ther 50 200 response umts (RU) for data&led kmet&c studies           domas tlmt produce nionoclonal ant&bodies specilic for
or 800-1,000 RU for screenmg assay&. Regenerat&on studies              I'C SK9. or a portion thereof.
have shown tlrat 25 mM NaOH in 25% v/v ethanol ctfi:ctively "             Hybrido mes that produce such antibodies may be grown in
removes the bound I'ab wlule keep&ng the actwity of PCSK9              v&tro or in vwo usia known procedures. The monocku&al
on the clup for over 200 injections. Typically, serial d&lutions       antibodies may be isolated from the culture media or body
(spin&&ln&g conceal&i&t&(ii&s iif 0 I-10x est&mated Ko) ol'un-         lluids. by coinvent&oral immunoglobului purilication proce-
fied I'ab samples are injected for I min at 100 I&L/n&inute and        dures such as anunon&wn sulfate precipitation, gel electro-
dissociation times of up to 2 bo&lrs alc allo'wcvf. Thc c(incor. &(i   phorcsis, dialysis. chromatography. m&d ultrafiltration, if
&rations of the Fab prole&ns are determined by ELISA and/or            desired. IJndesired aciivity, &f present, can be rmnoved. for
SDS-PAUL elec trophores is using a Iinb of lo&own concentra-           example, by rnm&u&g the preparation over adsorbent s made of
tion (ns dcti:rtnincd by amiw& acid analysis) as a standard            the immunogcn attachedto asolidphascandclutingorrclcas-
K&netic assoc&anon rates (k,<U+201E>) u&d d&ssociation rates (k,z) are        u&g the des&red m&tibodies off the immunogen. Inunumrtit&on
obmined simultaimously by titting the data globally to a I: I          of a host animal with a human PCSK9, or a fragment con-
I,angmuir bindin inodcl (Karla&a&n, R Roos, H Fagerstmn.               &ainuig the target amino acid scquencc conjugated to a protmn
L. Petersson. B, 1994 Methods Enzymology 6. 99-110)                    that &s &numu&o eric in the spec&es to be immumzed. e.g.,
using tlm BL&.evaluation program. I;quilibrium dissociation            keyhole limpet lmmocyanin, serum albumin, bovine thyro-
constant (K<U+201E>) vului:s are calculated i&s k.~'k<U+201E>,. This protocol        globulin, or soybean tryp sin inhibitor usu&g a b&li mctional or
is suitable for use in detem&ining bind&ng affinity of an anti- sr&    dertvat&z&ng agent, for example, maleinudobenzoyl sul fosu-
body to any PCSK9, including human Pt SK9. PCSK9 of                    ccinimi ester (conjugation through cysmine residues), N-hy-
another mammahan (such as mouse PCSK9. rat PCSK9,                      droxysuccin&mide (thmugh lysine residues), glutaraldehyde,
primate I&CSK9). as &veil as different forms of I&CSK9 (such           succinic anhydride, SOLq<U+201E>or R'N          I'R,       where R and
as o and $ fom&) Binding nliinity of an antibody is gencmlly
          &
                                                                       R're dilferent alk31 groups. can yield n population oi'anti-
measured at 25" C., but can also be measured at    37'.                bod&es (e.g., monoclonal antibod&es).
    11&e V(:SK9 antagonist antibodies may be made by any                  If desired, the V(.'SK9 antagonist antibody (monoclonal or
method known in. the ait uicludu&g the method as prov&ded &n           polyclonal) ol interest may be sequenced and the polym&cle-
Example l. 'I'he rome and schedule of immun&zat&on of the              ot&de sequence n&ay then be cloned u&to a vector fiir expres-
host animal are generally in keeping with es&abi&shcxl and             sion or propagation Tbe sequence encoding tbe &mubody
convennonal techmques for ant&body stimulat&on and pro- u
duct&on, as further described here&n. Oeneral techniques for
product&on ol'human md mouse ant&bodies are known in thc
ait and/or are described herein. A currently preferred method
                                                                              ol'&terest
                                                                                may be mau&tau&ed u& vector &n a host eel I and the host
                                                                       cell can then be expanded and frozen for future use. Produc-
                                                                       t&on of recombu&mu n&wuiclonal antibod&es in cell culture can
                                                                       be cerned out tlu ough c luring of ant&body enes from B cells
of n&ak&ng the antibodies con&prises tlm immuniwition of               by means knmvn in thc art. See, e g., Tiller ct al.. 2008, .I.
PCSK9 knockout (P('SK9-/-) annuals as disclosed herein s               Imnuu&ol Methods 329. 112: US Pat. No 7,314,622.
    It is contemplated that any manunalian subject including              In an al ten&ative. the pol you cleotide sequence may be used
humnns or muibody pmducing cells thercl'rom can bc                     for genetic nianipulation to "humanize" tlm antibody or to
man&pulated to serve as the basis for producuon ol'mamnui-             improve the aiffimty. or other charactertst&cs of the antibody.
lian, including human. hybridoma cell lines Typically, the             For example, the constam rey'on may bc engineered to more
lliisi animal is inoculated intrapcritoneally, intra&miscularly, R&    nearly resemble human constant regions hi avoid immune
orally, subcutaneously, intraplantar, and/or u&tradennally             response if the ant&body is used in cl&nical trtals and treat-
with an amount of in&munogen, including as described herein            ments in hunuins. It mny be desirable to genetically manipu-
    Hybndomas cm& be prepared from the lymphocytes and                 late the ant&body sequence to obtain greater aiiimty to PC SK9
inunortalized myeloma cells using the geneml somat&c cell              and greater efficacy u& inlubiting PCSK9). It will be apparent
hybridizatiw& technique of Kolder. B. m&d Milstcin, C . 1975. r        to one of skill in tlm art that one or more polynuchx&tide
Nature 256:495-497 or as mod&fied by Buck, D. W.. et al..              changes can be made to the PCSK9 antagonist ant&body and
I&982, In Vitro. 18:377-381. Available myeloma lines, includ-          still maintain its binding ability to VCSK9.
                                                           US 8,080,243 B2
                                23                                                                          24
   'IJmre are filar general steps to humanize n n&onoclonal                based on the functiimal prope&ties of thc m&tibody also result
anubody. 'Ihese are: (I) determuung the nucleotide mid pre-                ui selection of the ene encoding the antibody exlub&un
d&cted amino acid sequence of the starting antibody li Jv&t and            those properties. Thus, the plmge mimics some of the prop-
hcavy variable domains, (2) designing tlm Inimanizcd anti-                 cnies of thc B cell Phage display can bc pcrfornwd in n
body, i.e.. decidu&g v;hich mit&body frmnessork reg&on to use          s vanety of formats; see, e.g.. Joluison, Kevin S. and Cluswell,
during the humanizing process; (3) the actual luunanizing                  l&avid J., 1993, ('urrent Opinion in Stnicnira1 Bioloht) 3:5(i4-
Illelllodologlesl tech&i&clues: iilltl (4) tile trail&feet&(ill alltl      571. Several sources of V- ene segments can be used for
expression of the humaruzed antibody. See. for example. U S.               phage display. Clackson et al., IWI. Nature 352;624-628
Pa( N(is. 4816,5C&7, 5.80771 3; 5,86C&692, 6331 415, 5<U+201E>530,                isolated a diverse. array of nit&i-oxazt&lo&tc ant&bodies froin a
101: 5.693,761: 5.693.762; 5,585.08&J; and CI.180.370                 ui small nsndom combuuttonal hbrary of V enes derived from
   A number of "humanized" antibody molacu les compr&sing                  the spleens of umnunized mice. A repertoire of V genes f'rom
ml at&ligen-binding sile dcrivcd fret&& n i&on-1&im& nl itlunuilo-         unimnnmi ted Iunuan dm&or, can bc constntctcxf and antibod-
globul&n have been descnbed. &ncludin clumenc antibod&es                   ies to a d&verse array of ant&gens (including self ant&gens) can
having rodent or modified rodent V regions and their associ-               be isolated cairn&tially follow:ing tlm teclmiqucs described by
ated CDRs fles&xi ttl hill&lail et&list&lilt iklmallls Sl:e, fol           Mark et al.. 1991, I Mol B&ol 222:581-597, or Ciriffith et nl.,
example, Winter et al., IWI. Namre 349:293-299: Lobuglio                   IW3. L'MBO J. 12:725-734. In a natural inunune response,
ct al., 1989. Proc Nat Aced Sci. USA 86 4220-4224. Shat&                   antibody genes accuimilate mutations at a high rate (somntic
ei al . 1987. 1 Immiu&ol 138 4534-4538, and Brown et al..                  hypenmnat&on). Some of the ch mges introduced w&ll confer
1987. ('sneer Res. 47:3577-3583. Other references describe                 higher afhnity, mid B cells displaying high-affmity surface
rodent C'DRs grnfted into a humm& supporting framcvork                  n immunoglobulin are prefercntially replicated and diffi:rm&ti-
re@'on (FR) prior to fissio with mi appropriate human ant&-                ated dunng subsequent antigen challenge. Tlus natural pro-
body constant domain See, for example, Ricechmann et ai.,                  cess can be mimicked by employing tl&e teclmique known as
1988. Nature 332.323-327, Verhoeyen et al.. 1988. Sc&ence                  "chain shufiiingy (Marks et al.. 1992, Bio/Teclmol. 10:779-
23&J&1534-153 G: and Jones et al.. 1986, Nature 321:522-52 S.              783). In this method, the affinity of "primary'* lmman anti-
Another refi:rcncc describes rodent ( DRs supponcxl by                " bodies ohtaiiwd by
                                                                                                 phage display can be improved by sequen-
recombinantly eng&neared rodent fmmework reg&ons. See,                     tially replac&ng the heavy and 1&ght chain V region enes w&th
for example, European Patent Publ. No. OS1959G. These                      repertoires of naturally occu&ring variants (repertoires) of V
"humalllzetf ill(ilecllles are designed ni mlllltlllli: nllwiillletl       domaui genes obtained from unimnnm&zed donors This lceeh-
&mmunolog&cal response tou ard mdent anti-human ant&body                   mque allow s the pmduction of ant&bodies nnd antibody frag-
molt:culcs which limits thc duration and efTcvtiivncss of             lo ments with affinities in the pM-nM ange A stmtcgy for
therapeutic applm mons ol'hose moiet&es in hunuin rec&pi-                  maku& very large phage au&&body reperto&res (also knoivn as
cots. I'or example. the ant&body constant reg&on can be eng&-              "the mother-of-sll 1&branes") has been described by Water-
ncercd such that u is immunologically inert (e . docs not                  house et al, 1993, Nucl Acids Res 21.22C&5-2266. (ienc
trigger complement lysis). See. e.g., PCT Publ. No WO99/                   shulf1&ng can also be used to derive luuu m antibodies from
&8572; I.&K I'atm&t Application No. 98099&1.8. Other meth-            "<U+00BB> mdent antibodies, where the human antibody has similar
ods of In&manizing antibodies that may also be utilized arc                afiimtics aml spccilicities to tlm sinrting mdent antibody.
d&sclosed by Dmigherty et al.. 1991. Nucl. Ac&ds Res.                      Accorduig to tlus method, uluch is also referred to as
19.2471-2476 and in U S. Pat. Nos. 6,180377; Ci,054,297;                   "epitopc imprinting", the hcavy or fight chain V donmin cene
5.997 867: & 866 692. 6 210 671: and 6 350 861: and in PC'                 of rodent muibodics obtuini:d by phage display ant    technique is
Publ. No. WO 0 1i27160.                                               st replaced v;ith a repertoire of Inunan V domain genes, creating
                                                                         t
    In yet another alternative. fully hill&la&& alltibodies mny bc         rodent-human chimeras Selection on antigen results in iso-
obta&ned by us&ng commerc&ally available m&ce that have                    lat&on of human vanable regions capable of restoring a func-
becca engineered to express specific human inununoglobulin                 tional antigen-binding site. i.e, the epitope governs (im-
proteins Transgonic m&imnls tlrat are designed to produce a                prints) thc choice of panner Whmi thc process is repeated in
more des&rable or more robust &nunune response may also be            4. order to replace the remaining rodent V domain, a luunan
used for generation of humanized or human antibodies.                      antibody is obtained (see PCT Publ. No. WO 93i06213).
Ex unples of such technology are Xenomousel&'mm                            Unl&ke traditional hiunanizat&on of rodent antibodies by CDR
Abgen&x, lnc. (I'reniont, Calif.), lfuIVL&b-Mouseic and 'I'C               gmfting. this tecluuque provides completely luunan antibod-
Mouseru iron& Medarex, Inc. (Princeton, N Jl), imd the                     &~es, uhich have no I'rameuork or C'DR residues of rodent
Veloclnunune*'k mouse from Regeneron Phannaceuticals, o 0&I gill.
Inc. Cfanytown. N.Y).                                                          It &s apparent that al thous+ the above discussion pertains to
    In nn nltcrimtivc. antibodies may be made rcwomb&nantly                lnunau&zed nnubodies. the general principles d&scusssed ime
and expressed usuig any method known in the art. In another                nppl&cable to custom&zuig ant&bodies for use. ftir exmnple, &n
altcrnativc. antibodies may bc made rccombinantly by phage                 dogs, cats, primate, equi&ms m&d bovines. It is furiher apparent
d&splay leclu&ology See, for example. U.S. Pnt. Nos. 5,565, s that one or more aspects of human&zuig an                       &body des cn bed
332: 5,580.717; S,733,743; and t&,265,150: and Winter et al.,              herein may be con&bine&I, e g.. ('DR grafting. framesvork
1994. Annu Rev lmmunol 12 433-455 Alternativelv thc                        nuitation and C'DR mutation
phage display teclmology (McCalTerty et al.. 1990, Nature                      Ant&bodies may be made recoinb&n u&tly by first &solauog
348:552-553) can be used to produce human antibndics and                   the antibodies and antibody producing cells from host ani-
ant&body frag&neat& in v&tro, I'rom immunoglobulin vnriable ai mals, obtaining tlm gene sequence. and usia ihe gene
(V) dommn gene repertoires from un&mmunized donors.                        sequence to express the antibody recombinantly in host cells
According to this tecluiique, mitibody V domain genes nre                  (e g., ( HO cells) Another method which mny bc employcxl is
cloned in-frame into e&ther n major or conor coat prole&n gene             lti express the antibody sequence &n plants (e.g.. tobacco) or
of a filamentous bacteriophage. such as M13 or fd, and dis-                trm&sgenic milk. Methods for expressing antibodies recombi-
plnycxl as fiinctional antibody fmgments on thc surface of the r nantly in plams or milk lmvc been disclosed. Sox for
phage particle. Because the filamentous part&cle contains a                example, Peeters, 2001. et al. Vaccine 19:2756: Lonberg, N.
single-stranded DNA copy of the phage genome, selections                   and D. Huszar, IW5, Int. Rev. Inununol 13:6S: and I'ollock,
                                                              (js 8,080,243 B2
                                                        25                                                26
et al, 1999, I Immunol Merhods 231:147. Methods for mak-                   P( SK9 antagonist antibodies nu&y bc characterized using
ing derivatives of antibodies. e g., humanized, single chain,           methods weil knovn u& the art. I or example, one method is to
etc. are known in the art.                                              ident&fy the epitope to which it binds, or "epitope
   hnmunoassays m&d liow cytomctry sorting techniques such
as fiuorcscencc acti&a&ed cell sorting (FA('8) can also bc
                                                                                mapping.*'lmre
                                                                                arc many methods known in thc a&t for mapping nnd
                                                                        charactenzu&g the location of epitopes on pmte&ns, includ&ng
employed to isolate antibodies that are specific for PCSK9.             solving the cry sta I structure of an m&tibody-antigen complex,
   The antibod&es can be bound to many d&fferent camera.                con&pent&on      assavs, gene fragulcirt cxprcsslon &&ss&&vs. &&&xi
Carriers can be acnve and/or u&ert I.xamples of well-known              synthetic peptide-based assays, as descnbed, for example, &n
                                                                        ('haptcr 11 ol'liar)on a&xi I,anc, Using Antibodies, a I.abo-
carriers include polypropylcne, polystyrene, pe)yeti&')cue,
                                                                    Ia mtory Manual, (Cold Sprmg Ilarbor Labomtory Pres~. Cold
dextran, nylon, amylases, glass, nan<U+00BB>al and modified cellu-
                                                                        Spring I h&rbor N Y., 1999). In an add&ti one 1 example, ep&tope
loses, polyacrylmnides. Sgaroses and magnet&te. 'Il&e nature
                                                                        mappuig cm& bc used to determine the sequence to wluch a
oithcc                                                                  erlands
                                                                        PCSK9 antago&ust ant&body b&nds. Ep&tope mappu&g is com-
   uriercanbeeitlmrsolubleoruisolublcforpurposesol'he
      invention. fhose skillcxI in the an will know of other            mercinlly avnilnblc from various sources, filr example, Pcp-
suitable carriers for binding antibodies. or &vill be able to           scan Systems (Lie)her&wc 15. 8219 PH l,elystad, The Neth-
ascertain such, usu&g rounne experuuenlation. In some                            ). 'II&e epi tope can be a linear epito pe, i e., contained in
en&bodimcnts, tlm carrier comprises a moiety that targets the           a single stretch of amino acids, or a confimnational epitopc
myocnrdnun                                                              fonncxl by a tinea-din&ensional interactmn of muino wids 01st
   DNA encoding the monoclonal ant&bodies is readily iso-               may not necessarily be contained in a single stretch. Peptides
la&ceil and sequenced using convent&onal procedures (e g.. by         c of var) ing lengths (c.g, at least 4-(i mnino acids king) cm& bc
using oligonucleotide probes that are m&pable ol'bind&ng spe-           isolated or synthesized (e... recombinantly) and used for
ciiically to genes encoding the heavy and light chnins of the           binding essays with a P('SK9 antagonist antibody In another
monoclonal m&tibodies). The hybndoma cells serve as a pre-              example. the epitope to wh&ch the PCSK9 ants onist m&t&-
ferred source of such DNA. Once isolated, the DNA may be                body bu&ds can be detem&ined in a systematic screening by
placed u&to express&on vectors (such as expression vectors " using overlapping pcptides derived from the P('SK9
d&sclosed &n PCT Publ. No. WO 87/04462). v,hich are then                sequence and detennu&u& binding by the PCSK9 antagon&st
transfected into host cells such as E. co/i cells, simian COS           antibody. According to the gene fragment expression assays,
cells, (.hinese hains&er oven (CIIO) cells. or myeloma cells            the open reading frame encod&ng PCSK9 is fragmented either
that do not otherwise produce immunoglobuhn protein, to                 mndomly or by spec&fic genetic construct&ons and the reac-
obtain tlm syntlmsis oi'nxmoclonal antibodies in the rccmn- &a tivity of thc express&cd I'ragmcn&s ol'PCSK9 with tlm antibody
bn&anthost cells See.e.g.. PCTPubl No WO87/04462. The                   to be tested &s detennu&ed. The gene ikagmen(s n&ay. for
DNA also may be modified. for example. by substitut&ng the              example, be produced by PCR and then tmnsc rib ed and trans-
coding scqum&cc filr human heavv aml light ch&un constant               lated into protein in &'itro, in thc presence o fradioactivc amino
domains in place ol'&he homologous murine sequences, Mor-               acids. The bu&du& * of the u&tibody to the radioactively labeled
rison ct al.. 1984, Proc Nat Aced. Sci. 81:6861, or by "<U+00BB> PCSK9 fragments is then determined by inummoprecipita-
covalently joining to the immunogkibubn wlding scxiucncc                tion and gel clectroplxlresi&. ('crtain epitopes can also be
all or part of the coding sequence for a non-&nununoglobulin            &dent&fied by using large 1&bm&nes of random pept&de
polypeptide. In that manner. "chinmric" or "hybrid" antibod-            sequences displayed on tlm surface of phage particles (phage
ies are prepared thut have the binding spec ifimty o I'a PCSK9          hbraries) Alten&atively, a defined hbrary of overlapping pep-
monoclonal antibody herein.                                         st t&de frag&neo&a can be tested for binding to the test antibody in
                                                                        &
   P( SK9 antagonist m&tibodies and polypcptides dcrivcd                simple binding essays. In nn additional example. mutagenesis
from m&tibodies can be Identifie or clmracterized us&ng                 of an ant&gen bu&d&ng domau&. domain swapp&ng experiments
methods known in the art. whereby reduction, amelioration,              and alanine scaiufing nuitagenesis can be perfonucxI to iden-
or ncutrali&ation of P('SK9 biologicnl nctivity is detected             ti6 residues required, sufficient, and/or nocessary for cpitope
and/or measured. In some embodiments. a PCSK9 antagonist ss binding. For exmnple, domain swapping expenments can be
antibody or polypeptide is identificxI by incubating a cm&di-           performed using a mutant P('SK9 in u hich various fragments
date agent w&th PCSK9 and mon&tonng bu&ding &&n&L'or atten-             of the PCSK9 polypept&de have been replaced (swapped)
dm&t reduction or neutral&zation of a biological activity of            with sequences from VCSK9 from another species, or a
P('SK9. The binding assay may be performed with puniied                 closely related, but antigenicnlly distinct pmtein (such as
PCSK9 polypepude(s). or w&th cells naturally expressing, or c another member of the proprote&n convertase fanuly). I)y
transfected to express, I'CSK9 polypeptide(s). In one                   assess&ng binding of the m&tibody to the mutant I'CSK9. the
emb&xliment, the binding assay is a compet&tive binding                 in&portance of tbe p aticular P(:SK9 I'ragment to antibody
assay, where the abihty of a cund&date ant&body to compete              bindino can be assessed.
with a known P('SK9 antagonist for P('.SK9 binding is evalu-               Yet snot)mr nlcthod wl'lich can bc &ised to chamcterize a
ated The aswiy may be performed in venous formats, inc iud- 1 PCSK9 &Intagonist ant&body is &o use competit&ou essays with
ing the L'LISA fern&at. In other embodiments, a P('SK9                  other nntibodies known to bind to the same antigen, i.e.,
m&tagonist antibody is identified by incubating a mmdidatc              vtmlous hagnlcn(s on PCSK9, to dctcm&inc if thc P( SK9
agent w&th P( SK9 and nu&nitoru&g bn&du&g aud attendant                 an&agoms& ant&body bu&ds to the same ep&tope as other mti-
inhibition of LDI,R expression and/or blood cholesterol                 bodies. Competition essays are well known to those of sl ill in
clmirm&ce                                                           sa th&. art
   I&ollov, ing initial identificat&on. the activity of a candidate         I'he crystal structure of the ant&body and antibody:ant&gen
P('SK9 antagonist antibody can be further confinncxI and                complex cm& also be nsed to chamacterize the m&tibody 'II&c
refined by b&oassays that are known to test the targeted b&o-           residues are identiiied by calculating the d&fierence &n acces-
logical activities. Alternatively. bioassays can be used to             sible surface area between the LI L3:I'('SK9 crystal strucnire
screen candidates directly Some of thc methods for identify- I and P(.SK9 stn&cturc alone. PCSK9 residues that show buried
&ng and characterizing PCSK9 antagonist antibodies. pep-                surface area upon complex formation w&th Li L3 ant&body are
tides, or aptamers are descnbcxl in detail in the Examples.             included as a part of the cpitope. 'I'he solvent accessible
                                                           US 8,080,243 B2
                                    27                                                                  28
surf'ace of a protein is defined as tlm Incus of the emit re ul'          Pntent No 0 345 242), alphavinis-bswsed vectors (e g., Sindbis
probe sphere (represennng a solvent molecule of 1.4 A                     virus vectors. Semhlo forest vinls (ATCC VR-67; ATCC
radius j as it rolls over the Van der Waafs surface of the protein.       VR-1247), Ross River virus (ATCVC VR-373: ATCC
Thc solvent accessible surface area is calculated by gcncrat-             VR-1246) and Venerniclmi equine encephalitis vinis (ATCC
uig surface points on an extended sphere about each atom    equival-
                                                                 (at  5   VR-923; ATCC V R-1250: ATCIC VR 1249: ATCC VR-532)),
a distance from the atom centre equal to the smn of the atom              and adeno-associated virus (AAV) vectors (see, e.g., PCT
and probe nldli). and eliminating those that he 11 ithin                  Publ. Nos. WO 94/12649, WO 93/03769; WO 93i'19191, WO
entt spheres associated with neighboring atoms as imple-                  94/2893K WO 95/11984 and WO 95/00655) Achniiustration
mented in pnrgram ARBAIMOI (Brings, P J., 2000, CC'P4                     ol'DNA linked to kifftxf adenovirus as dcscnbcd in C:uriel,
Newsletter No. 3R CCLRC, Daresbury).                                  1(1 1992. Ihun. Ciene liter. 3:147. can also be employed.
   An expression vector can be used to direct expression of a                Noll-viral delivery vehicles and methods can also be
PC'SK9 antagonist mitibody Oiw. skilled in the art is fmlihnr             employed. includmg. bul not limited lo. polycationic con-
with administration of expression vectors to obtain expres-               densed DNA linked or unlinked to killed adenovirus alone
sionofmlexogenousprotcin invivo. Sec, e g,US Pat.Nos.                     (sce, c g., ('uriel, 1992, Hum. (iene Ther 3:147), ligand-
6.436.908: 6,413,942, nnd 6,376.471 Administration                ol'.    lmked DNA (sep, eg, Wu..l.. 1989, Biol C'liam 264.16985),
expression vectors includes local or systemic administration,             eukaryotic cell dehvery vehicles cells (see, e.g., U.S. I'at. No.
includino injoction, oral adtninistration. pnrticle gun or cath-          5,814,482, PC:T Publ. Nos. WO 95/07994, WO 96/17072,
eierized adnumstration, and topical admuuslration In                      WO 95/30763: mul WO 97/42338) and nucleic charge neu-
miother embodiment, the expression vector is acbninistered                tmiizmtion or fusion with cell membranes Naked DNA can
directly to thc sympathetic tnmk or angfion. or into a coro- o also be employcdl Pxmnp fary naked DNA introduction ml th-
nary artery, atrium, ventrical, or pericardium.                           ods are descnbed ln PCT Publ. No. WO 90/11092 and U.S.
   Targeted delivery of therapeutic compositions containing               Pat. No. 5.580,859. Liposomes tliat cmi act as gene delivery
an expression vector, or subgenomic polynucleotides c ui also             velucles are described in U.S. Pat. No. 5,422,120; PCT Publ.
be used. Receptor-mediated DNA dehvery techniques are                     Nos. WO 95/13796; WO 94/23(i97; WO 91/1444S: and BP
described in, for exmnplc, I'indeis ct aln 1993, Trends Bio- " 0524968. Additional nppmaches are described in I'hilip,
teclmol. il;202, Cluou et al., 1994. Gene liierapeutics:                  1994. Mol. Cell. Biol o 14. 2411, and in Wolfendin, 1994 Proc.
Methods And Applications Of Direct (iene Transfer (J. A.                  Natl. Aced. Sci. 91:1&81.
Wolff.ed 8 Wuetal..1988..1 Biol C'hem. 263:621,Wuetal..                      This invention encompasses compositions, lncludui phar-
1994, .f. Biol. Chem. 269:542; Zenke et ale 1990. Proc. Natl.             maceutical compositions. comprising antibodies descnbed
Aced Sci. IJSA 873655; Wu cl al, 1991. I Biol Clmm so iwrcin or made by lhc nwt bode and hnv ing the chmaclcri sties
266:338. Therapeutic coinpositions containing a polynucle-                described hereui. As used herein, compositions comprise one
otide are admi iu stered in a range of about 100 ng to about 200          or more antibodies, peptides, or aptamers that antagonize the
mg of DNA f'o r local administration in a gene therapy proto-             inlernction of PCSK9 v,ith tlm I,DI.R, nnd/or onc or morc
col Concentration ranges of about &00 ng to about &0 mg,                  polynucleotldes composing sequences encoding one or more
about I pg to about 2 mg, about 5 pg to about &00 pg. and "<U+00BB> these antibodies or peptides Illese compositions may further
about 20 pg lo about 100 pg of'DNA can also bc use&I during               comprise. suitable excipicnts. Such as phannaceutically
a gene thenspy protocol. The therapeutic polynucleotides and              acceptable excipients lncludin buffers, lvluch are lvell
polypeptides can be dclivcrcd using gene delivery velgcles                kl iowa lu thl'. Rift
The gene delivery vducle cml bc ol'iral or non-viral ongin                   The PCSK9 antagonist antibodies and peptidcs ol'hc
(see generally, Jolly, 1994, Cancer (rene Therapy I;Sl; so invention are cliaracterized by any (one or more) of the fol-
Kimura, 1994, Hunmn (icne Therapy 5 845: ('onnellyi 1995,                 lowing characteristics (a) bind to PCSK9: (b) block P('SK9
lhunan Gene 111erapy I:185; and Kaplitt, 1994, Nature                     uiteraction with the LDLR; (c) decrease PCSK9-mediated
(ieneti ca 6: 148 j. L'xp ress i on of such coding sequences can be       down-regulation of the Lf&LR: and (d) inhibit P('SK9-medi-
induced using endogenous mmmnalian or heterologous pro-                   ated inhibition of I.DI, blood clearance. Prcfi.rably. PCSK9
moters. Lixpresslon of the coding sequence can be either 4. antibodies have two or more of these features. More prefer-
constitutive or regulated.                                                ably, the antibodies have three or more of the features. Most
   Viral-based veciors for delivery of a desired polynncle-               prefensbly, the antibodies have all four charactensucs.
otide mid expression in a desired cell are well know n in the art.           Accordingly, the invennon pmvides any of the follow ing,
Bxemplmy viral-based vehicles include bnl are nol limited                 or compositions (ulcluding pharnulccuiical compositions)
to. recombuiant retroviruses (see. e.g. PCT Publ. Nos. WO o compnslng any antibody havurg a partial light chain sequence
c90/07936; WO 94/03622; WO 93/256198; WO 93/25234: WO                     and a partial hery clmin sequence as found in 'Iable l. The
93/11230, WO 93/10218. WO 91/02805, US Pat. Nos                           underluicd sequences are CDR sequences according to Knbnl
5.219.740 and 4.777,127; CiB Patent No. 2.200.6Si: and L'P                and in bold according to Chothia.
                                                                                                TABLE   I
                                                            mAb    Light Chatn Vattable Regton Heavy Chain Variable Regton
                                                            SIS    DIVI'ITQSQKPNSTSVGDRV               EVQ'QQSGPELVKPGASVKISCKAS
                                                                   SVTCKASIINIIGTNVAICIQ               GYTFTDYYININVKQSHGKSLRNIG
                                                                   QKPGQSPIGILIYSASYRYSG
                                                                   VPDRPTGSGSGTDPTLTISN                YSTKCHELR LTSED A'1YYCARNL
                                                                   VLSEDLAEYPCQQFYSYPYT                LPAYtIGQGTLVTVSA ISEQ ID
                                                                   PGGGTKLEIK lsEQ ID No         I I   No   Ecl
                                                            US 8,080,243 B2
                              29                                                                          30
                         TABLE     I-continued
WAb    Light Claarn Variable Regron Heavy Chain Variable Pegion
5AZO DIVI6TQSHKFNSTSVGDRVS                QVQLQQPGAELVKPGASVKLSCKAS
       ITC~KAS DVSTAVAIvYQQK              GYTPTSYWMHtmKQRPGQGLEWIG
       PGQSPKLLZYSASYRYTGVP               EINPSNGRTNYNEKFKSKATLTVDKS
       DRPTGSGSGTDFTPTISSVQ               S S TRY) )QL S 5 LT 5 5 D 5 AVYYCARER
       AEDLAVYYCQQRYSTPRTF                PLYAMDY)GQGTSVTVSS
       GGGTKLEIK )SEQ ID No      17)      )SEQ ZD      HO     21)
6P6    DIQHTQTTSSLSASLGDRVTZ              EVQLQQSGPELl.'KPGASVKISCKAS
       SC~SAS   ZSNYlbclYQQKP             GYTFTDYYMNlh)KQSHGKSLKWIG
       DGTVFLLIYTrssLHsGVPs
       RFSGSGSGTDYSLTISNLEP               SSSTAYMELPSLTSEDSAVYYCAGG
       EDIPTYYCQQYSKLPPTPGS               GIYYRYDRNYPDYWGQGTTLTVSS
       GTKLEIK lsEQ ID No      15)        )SEQ ZD      HO     22l
7D6    DIVI'ITQSHKPNSTSFGDRVS             EVKLVESEGGLVQPGSSHKLSCTAS
       ITCHES   DVSNALMiYQQK              GFTPSDYYID<U+00C3>VRQVPEKGLEWVA
       PGHSPKLLI5'SASYRYTGVP              NINYDGSMTSYLDSLKSRFIISRDNAK
       DRFTGSGSGTDPTFTISSVQ               NILYLQMSSLKSEDTATYYCPPEKPA
       AEDLIVYYCQQHYSTPNTF                AMD1WGQGTSVTVSS
       GGGTKLEIK lsEQ ID No      19)      ISEQ ZD      NO     23)
LZL3 DIQHTQSPSSLSASVGDRVT                 QVQLVQSGAEVKKPGASVKVSCKAS
       ITC~RAS GZSSALAIvYQQKP             GYTPTSYYMHtmRQAPGQGLEWM
       GKAPKLLIYSASYRYTGVPS               GEISPPGGRTNYNEKFKSRVTHTRD
       RFSGSGSGTDFTFTISSLQP               TSTSTVYHELSSLRSEDTAVYYCARE
       EDZATYYCQQRYSLWRTFG                RPIYASDLWGQGTTVTVSS
       QGTKLEIK )SEQ ID No      531       (SEQ ID Ho 56)
   The unention aiso provides CDR portions of'lmtibodies to as                 In another alternatilja the antibodies and peptides cml be
V( SK9 (including I'.hothia and Kabat   ('DRs). Dctcnnination               made recombinantly using procedures tlmt are well known in
ol'F.'DR reg<U+00AB>ms is lvell within thc skill of thc art It is under-           the art. In one embodiment, a polynuclcotlde compnses a
stoodthatinsomeembodimonta( DRscanbeacombination                            sequence encoding the heavy chain and/or the I)pit chain
ol'he Kabnt lmd Chothia CDR (also termed "colnbined                         vmiablc regions of antibody 4A5, 5A10, 6F6. 7D4 or 1.11 3.
CDRs" or "extended CDRs"). In some embodiments, the 5
                                                                            The sequence encoding the antibody of interest may be main-
CDRs are the Ka bat CDRs. In other embodiments, the b 'DR s
                                                                            tained in a vector in a host cell and the host cell can then be
are the Chothia CDRs In other ~ords. ul embodiments la 1th
                                                                            expanded and froyen for future use VLT)ors (including
more tlmn one CDIL the CDRS may be any of Kabat, Chotlua.
conlbination CDRs, or combinations thereof                                  expression vectors) and host cells are fluther described
   The ulventlon also prov)des methods of making mly                  ol'   herein.
these antibodies or polypeptides. The antibodies of this inven-                The im ention also encompasses scl'v of ant)bod)ca of this
lion can bc made by procedures known in tlm ar) Thc                         invcnnon    Single chain vanablc region fragments al'6 njadc
polypeptides cml be produced by proteolytic or other degra-                 by  linking light and)or heavy chain variable regions by using
dation of the mltibodics, by rccombinmlt methods (i.e, sinoJe               a short linking peptide. Bird et al.. 19gg, Science 242:423-
or fusion polypcplidcs) Rs described above or by chmnical N) 426. An example of a lulking pcqltide is (Cifif)C)S), (SIIQ ID
synthesis. Volypeptides of the antibodies, especially shorter               NO.24), which budges appmximately 3.5 nm bet~can the
polypeptides up to about 50 amino acida are conveniently                    carboxy terminus of onc variable region and the amino ter-
made by chenucal synthesis. 37lethods of chemical synthesis                 m)Due of the other variable region. L uikers of other sequences
are known in the art and are commercially available. For                    have been designed and used. Bird et el., 193 g, supra. Linkers
example, an antibody could bc produced by an mltomated 6 should be short, tlexible polypeptidcs and prcfbrably com-
polypeptide synthesizer employing the sohd phase method.                    p)Ised of less than about 20 anuno acid residues. Llnkers can
See also, U S. Vat. Nos. 5 g07 715; 4 g16 567: and 6 331,415.               in turn be modified for additional functions. such as attach-
                                                         (js 8,080,243 B2
                                31                                                                   32
ment of drugs or attachment to solid supports Tlm single            of His/ infection    (P&  T Publ Nos WO 91/00360 and WO
chaui vanants can be produced either recombinantly or syn-          92i200373: EP 03089). Ileteroconjugate antibodies may be
thetically. For syntlietic production of scFv, an mitomated         made using any convenient cross-linlong methods. Suitable
synthesizer can be used For rccombinmit production of scFv,         cross-linking agents nnd tcwiutiques are well Ioutwn in the an,
a suitable plasnud contauungpolymicleotide that encodes the       1 and are descnbed in U.S. Pat. No. 4,676.980.
scpv can be introduced into a suitable host cell. either eukary-        Chimeric or hybrid antibodies also may be prepared in
otic. such as yeast, plant. uisect or mammalian cells. or           vitro using kno(vn methods of synthetic protein chemistry,
prokaryotic. such as Fd co/i. Polynucleotides encodmg the           uicluding those involving cmss-linking agents. For example,
scF v o fintcrcst cnn be made by routine manipulations such as      intmunotoxins may bc constructed using d di sulfide cxchangc
ligitionofpolynucleotides. Theresultantscl'vcanbeisolated lo reaction or by fornung a tlu cether bond. Examples of suitable
using standard protein purification techniques known In the         reagents for tlfis purpose include iminotluolate mid methyl-
'irt                                                                4-nIercapiobutyrimidatc
     Other forms of sin le chain antibodies. such as diabodies          Iiumanized mtibody compnsuig one or more CDRs of
are also encompassed Dinbodics are bivalent. bispeci tie miti-      antibodies 5A10 or 7D4 or one or nxire & DRs derived from
bodicsinwhtchVIlandVl.domainsareexpressedonasin le                  antibodies 5A10 or 7D4 can be made. for example. using any
polypeptide chain. but using a linker that is too short to allow    metlmds know in the art. For example. four general steps may
for pairing bct(recon the two domains on the same chain,            be used to humanize a monoclonal antibody Thcsc nre (1)
thereby Rircing the donuuns Io pnir (vith cmuplementary             determining the mmleotide md predicted amino ncid
domains of another chain and creating nvo antigen binding           sequence of the starting antibody light and heavy variable
sites (sce e g.. Holligcr. P. ct al . 1993, Proc Natl Acnd Sci o d(lluallls, (2) ilcsigl1i!I ihchulniu11zLd dlltlbody. i.c, deciding
USA ')0:6444-6448; Poljak, R..l., et al., 1994. Structure           which mitibody framework region ui use during the human-
2:1121-1123).                                                       izing process; (3) using the acmal humanizing methodolo-
     For example, bispeciiic antibodies, monoclonal mttibodies      giesitechniques; and (4) transfecting mid expressing the
that have binding specificities for at least t(vo different anti-   humanized antibody. See, for exaniple. U.S. Pat. Nos. 4.816,
gens, m n be prepmed using thc antibodies disclosed imrein          567, 5.807,715; 5,86&1,&i92; 6331,415; 5.530,101; 5,693,7&11,
Methods for nmkuig bi specific antibodies are known In the art      5,693,762; 5.585,089: uid 6.i 80,370.
(see, e.g., Suresh et al.. 198&x Methods in Enzymology 121:             In the recombinant humanized antibodies, the Fc portion
210). Traditnmnlly, the reeombuinnt production of bispemiic         can be modilied to avoid interaction with Fc( receptor aud the
antibodies was based on the coexpression of two Inuuunoglo-         complement and uumune systems. The tecluiiques for prepa-
bulin hcavy chain-light chain pairr, (1 ith the two hcavy chains io mtion of'such antibodies are dcscrib(xl in WO99/58572 For
having dilperent specifimties (Millstein and Cuello. 1983,          ex unple. the cousIant region may be enguieered to more
Nanire 305. 537-539).                                               resemble human constant regions to avoid immune response
     According to one npproach to mnking bispecilic SIItibod-       if thc antib(xly is uscxl in clinical trials and treatments in
Ies, antibody venable dom nns with the desired b uiding speci-      humans. See. for example, U.S. Pat. Nos. 5.997,867 and
iicities (mitibody-antigmi combining sites) are fused to "<U+00BB> 5,86&i,692.
uumunoglobulin constant domaut scqumices. The liision                   Huntanizedi antibody comprising the bght or hmivy clmin
preferably is with an immunoglobulut hery ch un constmtt            variable regions or one or more CDRs of mi antibody or Its
domain, coniprising at least part of the hinge. CH2 and H3  &       variants shown in Table I, or oiw or more & DRs derived from
regions It is prcfi.rrcd to have the iirst bca(T chaui amstmit      tbc mitib(xly or its vananm sho(vn in Table 2 can be made
region (&'H1), containing the site necessary for fight chain do using any methods known in the art.
bindino, present in at least onc of tlm fusions l&NAS encoding          Hunmnizcxl antibodies indi'IL In ada by any nwt bod know n
the inununoglobului heavy chain fusions and, if desired. the        111 tile an.
inuuunoglobulin light cliai, are insened into separate                  The invention encompasses modifications to the antibodies
cxprcssion (mciors, mid are cotmnsfi.ctcd into a suitable host      and polypeptidcs of the invention vmiams shown in Table 1,
orgarusm. Iliis pro~ides for peat fiexibility in adjusting the d. including functionally eqiuvalent antibodies which do not
mutual proportions of the three polypeptide fravgntents in          significmitly affect their propenies and variants which have
embodiments when unequal ratios of the three polypeptide            enhanced or decreased activity andior afiinity, I'or example,
chains used in the construction provide the optinuuu yields. It     the amino acid sequence may be mutated to obtain an anti-
Is, la(waver, possible to htscn tlm coding sequences for Iwo or     body with the desired buiding alIiuity to PCSK9 Modiiica-
all tluee polypeptide chains In one expression vector when tlie o non of polypeptides is routine practice in the art and need not
expression of at least two polypeptide chains in eqiml nitios       be described in detml herein. Modification of polypeptides is
results In hi h yields or when Ibc ratios are of mi particulnr      exempli lied in the Fxmnples Fxamp les of modilied polypep-
sigiuiicance.                                                       tides include polypeptides (vith conservative substitutions of
     In one approach, tlm bi speci bc antibodies are composed of    amino acid reaiducs. one or morc delctions or ndditions of
a hybrid immunoglobulin heavy chain with a tirst binding 1 amino acids which do not signilicantly deleteriouslv chmige
specificity in one ann, and a hybrid imnnmoglobulin heavy           the fiuictioim I activity. or wlfich mature (enhance) thc affinity
chain-light chain pair (providing a second binding. sp(wilic-       of thc polypcptidc for im ligiuid. or u(c of chemical aimlogs.
Ity) In the otlier arm. Tlus asymmetnc structure, with an               Alllillo IIcld scqucncc lllscltloIIs lllcludc alii(no- i(lid/ol
inuuunoglobulin light chain in only one half of the bispecific      carboxyl-mnninal fusions ranging in length from one rc<U+00BB>idue
molecule. facilitates the separation of th(. desired bispecilic mi to polypcptides contnining a hundred or more r(si(hics. Sws
compound from unwanted immunoglobulin chain combina-                well as intrasequence insertions of single or multiple amino
tions. 'Iliis approach is described in P&'T Publ. No. WO            acid residues. I:xamplcs of tenninnl insertions include mi
94/04690                                                            amibody with an N-terminal metluonyl residue or the anti-
     Heteroconjugate antibodies. comprising two covalently          body fused to an epitope tag. Other Insertional variants of the
joined antibodies, are also within the scope of thc invention       antibody molecule include the fusion to the N- or &'-terminus
Such antibodies have been used to target utunune system cells       of the antibody of un enzyme or a polypepude wluch
to unwanted cells (U.S. Pat. No. 4,676.980). and for treatment      increases the half life of the antibody in the blood circulation.
                                                                   US 8,080,243 B2
                                       33                                                                        34
      Substitution      varim&LS  lmvc at   1m&st  one amino acid residue      acid substitutions are n&ade within a CDR domain In still
in tlm m&tibody molecule removed and a different residue                       other embodiments. the C DR domain s CDR 1 13 and/or CDIL
                                                                                                                          &
inserted in &ts place. 11&e sites of greatest &nterest for substi-             L3.
tutio&u&l mutagencsis include the hypervariable regions, but                      Modificstions also inch&de glycosylated and nonglycosy-
FR alterations are also contcmplatcd C:onservative substitu- I lated polypeptides. as well as polypeptides with other post-
tions are shown in Table 2 under the heading of" conservative                  trnnslational modifications, such as. for example, glycosyla-
substitutions" If such substitunons result in a chan e &n              bio-    tion v ith different sugars, acetyla(ion, m&d phosphorylation.
lo ical activity, then more substantial chm&ges, denonunated                   Antibodies are glycosylated at conserved positions &n their
*'exemplary substitutions" in Table 2, or as further described                 constant regions (Iefli:ris dnd I und. 1997. (.hcm. Immunol.
                                                                            lo 65,H1-128, Wught and Morrison. 1997, T&bTFCH 15:26-
helot& In reference to amino acid classes. mny be introduced
                                                                               32). The oligosacclmride side chains of the inununoglobulins
and the products screened.
                                                                               affect thc protcm*s tinct<U+00AB>m (Boyd et al, 1996. Mol Inunu-
                                                                               nol 32:1311-1318: Wittwe and Howard. 1990, B&ochem.
                                   1ABLF 2                                     29 4175-4180) Slid the intrmnoleculnr interaction between
                             Amu)o Acid So<U+00AB>su&nouns                            portions of the glycoprotein. &vliich min sfli:ct Ihe conli)rma-
                                                                               tion and presented three-di mens i one I surface of the glycopro-
0<U+00AB>uuud               Co)uer,un e     Esca)plan                                 toin (.Ietferis and I.&md, supra Wyss mid Wagner, 1996. C:ur-
lies&due              Suhs<U+00AB>&uuons    Sub&&du<U+00AB>on)
                                                                               rent Opia. Biotech 7.409-416). Ohgosaccharides may also
 A&a (A)             Val             Va& Ia)L u*                               serve to target a given glycoprotein to certmn molecules based
       i<U+00AB>)           L s             L)s. Oln Asn                            n i&pun spccilic recognition structures Cslycosylation of ai&ti-
Asn (8)              Oh)             Oln. H)s. Asp Lss. A&S
                                                                               bod&es lms also been reported to affect antibody-dependent
Asp (0(              Ohl             Glu. Asn
Cvs (C)               Scl            Se&. Al,&
                                                                               cellular cytotoxicity (AI&CC). In particular, C'HO cells with
(  It& (
         Q  I        Asn              &so. G&u                                 tetracycline-regulated expression ol (3(1.4) N-scetylglu-
mu! T)               Asp             A)P: r h)                                 cosaminyltransferase Hl (C/nTIH), a glycosyltransferase
Gl (GI                Ma
                                                                               catalyzing founation of bisecting CilcNAc, was reported to
H)s IH)              A&              Asn. r'o. I 1: As,
ne (Il               Leu             Ieu.xal. VI A(K Ph .Hcnennne
                                                    &
                                                                               have &mproved ADCC activity (Umana et al.. 1999, Nature
I.eu L I   I         He              <U+00AB>odeucwe. He.t)l, Me& Ala Phe             Biotech. 17:176-180).
Lrs(K)               A&s             A&    & h),Asn                               Glycosylation of antibodies &s typimilly either N-linked or
Met (Ml              Leu             Ieu. Phc, nc                              0-linked. N-linked refers to the attaclm&ent of the carbohy-
The&pl               T)s             Leu. Val. I&e Ala. Tir
                                                                            sn dmte moiety <U+00AB>) tlm side chain of an aspmdoi&m rcsi&hm Thc
Pro \P)              Ala             Ala
Se&(S)                Thr            Th&                                       tupeptide sequences asparagme-X-senna. msparaguie-X-
 Iau (I'1            S<U+00BB>l             se&                                       tlu eonine, and nsparaooine-X-cyste&ne, where X &s nny amino
Tsp iu')             Ts              T n Phe                                   acid Lxccpt p<U+00AB>1bi&L) dr'L thc ccogn&t&on scquc&iccs RII'u/s'"
                        I'h<U+00BB>                                                                                   I
Tv) (Y)                              T)p Phe, Ths. See
Vat (V)              I eu            ne. Leu. Me&, Phe. &&s. Xodenca)e         metic attachment ol'he carbohydrate moiety to the aspar-
                                                                            "<U+00BB> agine side chain. Thus, the presmicc of citlmr of these tripep-
                                                                               t&de SL<U+00AB>Inc<U+00AB>con in a polypeptide crmdcs a potential
      Substantial modifications in the biological properties of the            glycosylauon site. 0-linked glycosylation refers to the
antibody ue accon&phshed by sefectuig subsututions tlmt                        attaclnncnt of one of the sugnrs N-acctylgalactosamine,
differ significantly u& their efl'ect on mmntauiing (a) the struc-             galactose, or xy lose to a hydro xyainu&o acid, most conunonly
ture of tlm polypeptide backbone in the area ol'lm substitu- nn serine or tlueonine, although 5-hydroxyproline or 5-hydroxy-
tion, for example, as a sheet or helical conformation, (b) the                 lysiim may also be used
char e or hydrophobicity of the molecule at the target site, or                   Addition of glycosylation sites to the antibody &s conve-
(c) tlm bulk of the side clmui Naturally occurring residues are                niently accomplished by altering the amino acid sequence
divided into groups based on common side-chain pmperties:                      such that it conmins one or more of the above-described
      (11 Non-polar: Norleucine, Met, Ala, Val, Leu. He;                       tripeptide sequences (f&ir N-linked glycosylation sites). The
      (2) Polar without char e: Cys. Ser, Tlu<U+201E>Asn. Gin:                        altemti on may also be made by the addition of, or substitution
      (3) Acidic (ncgati&mly charged) Asp. Cilu,                               by, one or more senne or tlu eon&ac residues to the sequence of
      (4)     Basic (positively  charged)      I.ys,  Arg,                     the onginal antibody (for 0-linked gfycosylation sites).
                                                                                  Thc glycosylation pattern of antibodies may also be altered
      (5) Residues that influence clmin orientation: Crly) Pro; and
                                                                             u without alteung the underlying nucleotide sequence. Glyco-
      (6) Aromauc Trp. Tyr, Phe, His.
                                                                               sylation largely depends on tlie host cell used to express the
      Non-Lonscrvativc substitutions are made by exchan ing a
                                                                               antibody Since the cell type used lor expression of recombi-
member of one of these classes for another class.
                                                                               nunt glycoproteins. e.g., antibodies, as potential therapeutics
      Any cysteine residue not involved In mau&taining the                     is rarely the native ccfl. variations in the glycosylat ion pattern
proper conformauon of the sin&body also may be substituted, I of the antibodies can be expected
                                                                                                                      (s&m, e.g.. I lee et al.. 1997,
gcnernlly with scrinc, to impro<U+00AB>'. thc oxidnti&m stability of thc              I. Biol. Che&u. 272:9062-9070).
molecule and prevent aberrant cross-linking. Conversely.                          In addition to tlm choice of host cells, I)nctors that aft'Lmt
cyste&ne bond(s) may be added to the antibody to impmve its                    glycosylauon dunng recomb<U+00AB>rant producuon of nut&bodies
stability, particularlv where the antibody Ls u& antibody lrag-                include growth mode, media fom&ulation, culture density,
ment sucli as an Fv fcdgmenL                                                ai oxygenation, pH. purilicati&m schcmcs and tlm like Various
      Amino acid modifications can mnge from changing or                       methods have been proposed to alter the glyco aylati on pattern
n&odif& In one or more amino acids to complete redesign of a                   achieved in a particular host organism including introducing
region, such as the variable region. Changes &n the venable                    or overexpressin cer(aui enzymes uivolved &n ofi osaccha-
rey'on can alter binding aflinity and/or specificit. In some                   ride production (U.S. Pat. Nos. 5,047,335; 5,510,2C)l and
cn&bodimcnts. no n&orc than one to live conwrvative amino s 5,278,299) Cilycosylation. or certain types of glycosylation,
acid substitutions nre made ssithin a CDR domain. In other                     can be enzymnticully removed fmm the glycoprotein, for
embodiments, no more than one to three conservative amino                      example. using endoglycosidase H (Fndo H). N-glycosidase
                                                               US 8,080,243 B2
                                    35                                                                             36
    F, endoglycosidase F I, endoglycosidase F2, endoglycosidase                     pmcedures known in tlm art (Marks et al, 1992, Bio/Tech-
    F3.1n addit&on, the recomb&nant host cell can be enetically                     nology. 10 779-783, Barbas ct al.. 1994, Proc Nau Acad. Sci,
    m&gineered to be defect&ve in process&ng certain types of                       USA 91:38(8-3813; Scluer et al., 1995, Gene. 169;147-155;
    polysaccharidcs. I'hcsc and similar techniques arc well                         Yeiton e& al, 1995..1. hnmunol., 155 1994-2004, Jackson et
    known in the art.                                                       I       al, 1995,.1 Immunol . 154(7):3310-9: Hawkins et al.. 1992,
       Other methods of moditication include using coupling                         J. Mol. Biol., 226&88&9-896; and PCT Publ. No. WO2004/
    techn&ques known in the arh including, but not h&uhed to.                       058184).
    enzymat&c means. oxidative substin&tion and chelation.                             The fo1 low u&g n&ethods may be used br ad) using the aflin-
                                                                                                                              1
          ol'abels
    Modilications can be used. Iior cxmnplc. for attachment
                                                                                    ity of an antibody and for characterizing a ('DR. One v,ay of
             Ii&r immunoassay. Modified polypept&des are made               u&
                                                                                    charactenz&ng a CDR of an annbody anChor altering (such as
    using established procedures in the an and can be screened
                                                                                    unproving) the binding aflinity of a polypeptide, such as m&
    using standard asm&ys kn&&wn ui the an, some ol uhich are
                                                                                    antibody. tanned *'libr ay scanmng mutagenesis" Cienerafly,
    descnbed below and &n the Examples.
                                                                                    library scanninv nn&tagenesis works as foflosvs. One or more
os
        In some en&bodinmnts of the invention, the antibody com-
                           act &vste region. such ns a &xmstm&t region
    prises a modified constant                                              i.
                                                                                    amino acid positions in the Cllk are replaced v;ith tuo or
    that &s inununoloy'cally inert or partially inert. e.g., does not               more (such as 3, 4, s, 6, 7. 8, 9, 10. 11, 12, 13. 14, 15. 16. 17,
    trigger complenmnt mcdiatcd lysis, docs not stimulate                            18. 19. or 20) amino ncids using art recognized nwthods. '11&is
    ADCC, or does not                nucrogl i a: or have reduced activ&-           generates smail libraries ol'lones (in some embodiments,
    ties (compared to the unmoditied antibody) in any one or                        one for every mnino acid pos&tion that is analyzed) each with
    more of the following triggering complacent n&cdiatcd lysis,            ".o     a complex&ty el'wo or more members (&f tu o or more amino
    stuuulating ADCC. or acuvaung micmglia. Different mod&-                         acids are subst&tuted at e&'e&y pos&t&on). GeneIallv. &he hbla&1
    fications of the constant region may be used to achiswe opti-                   also includes a clone comprising the native (unsubstituted)
    mal level and/or comb&nat&on of effector functions. See, for                    amu&o ac&d A small number of cfones. e.g, about 20-80
    example, Morgan et al.. 199S. htununology 86:319-324;                           clones (depending on the complex&ty of the libmry), fmm
    I.und et al., 1996, J. Imnninology 157'4963-9 IS7:4963-                         each library arc screened for binding aftinity to tlm target
    4969: Idusog&e et al.. 2000..1. Inuuunolo s 164:4178-4184;                      polypeptide (or other bind&ng tar et), and c mdidates w&th
     fao et al.. 1989, J. Immunology 143: 2595-2(&01; and Jefferis                  increased, the same, decreased, or no binding are identified.
    et al, 1998, Imnn&nological R&wicsvs 163.59-76. In some                         Methods for determining b&nding nflin&ty are u all-knoss n ui
yl at &on
    embodiments, the constant reg&on is modified as descnbed in
    Fur I Immumil., 1999. 29 2613-2624. PC'T Publ No
    WO99!58572, and/ or I JK Paten& Application No 9809951 8.
    In other embodunents. the antibody compnses a luunan
                                                                            so
                                                                                    the art. 1)u&ding alhmty may be deternuned us&n B&score
                                                                                    surfncc pk&sirlo&'I rcsoflancc &i&'lalysis. which dc&oem difli.r-
                                                                                    ecess u& binding aflinity ol'about 2-fold or greater. B&score is
                                                                                    part&culnrly useful when the stoning ant&body already bu&ds
                                                                                    v ith a relatively high alTinity, li&r cxamplc a K<U+201E>ol'about 10
    hmivy chain IgG2 constm<U+00BB> region comprising the li&flowing
    nnitations: A330P331 to S330S331 ( unino ac&d munbenng                          nM or loss er. Screen&ng us&ng B&score surface plasmon reso-
    wnhrcterencetothew&ldtypelg()2sequm&ce) Eur.J.lnumi-                    "<U+00BB>      nance is described in tlm Examples, lmrein
    nol. 1999, 29 2C&13-2624 In still other cinbodimm&ts, thc                          Binding aflimty may bc Ccterminnl using Kinexa Biocen-
    constant reg&on &s aglycosylated for N-l&nked glycosylation.                    sor, scinnllation prox&muy essays. ELISA. ORIGEN &nunu-
    In some embodiments, thc constant region is avlycosylatcd                                    I'),
                                                                                    noa ssay (I Ci     tluo re scen ca quenching, fluorescence trm&s-
    I'or N-linked lycosyla&ion by mutating the glycosylatcd                         fer, and/or yeast display. Bindmg nlfinity may also bc
    anuno acid residue or flanking residues that are part of the            so      screened using a suitable bioassay.
    N-glycosylation recognition sequence in the constant region                        In son&e em bc din&ants, every amino acid position in a ('DR
    For example, N-glyc                 site N297 may be mutated to A,              is replaced (in some emboC&ments. one at a time) anth all 20
    Q. K. or H. See. lao et al., 1989. J. Inummolony 143: 2595-                     natural amino acids using art recognized mutagenesis meth-
    2&&01. m&d.leff& ris ct al, 1998, Inununological kcvicsvs 163                   ods (some of which are described herein) This generates
    59-76. In some embodunents. the constant reg&on &s aglyco-              s.      small lib mries of cl ones (in some embodunents. one for every
    sylatixI for N-linked glycosylation. fhe constant region may                    amino acid position that is analyzed), each with a complexity
    be aglycosylated lor N-hnked glycosylat&on enzymatically                        of 20 members (&f all 20 amino acids are subsututed at every
    (such as removing carbohydmte by enzyme I'NC&ase), or by                        pos&&&on).
    expression in a glycosyla&ion delicient host cefl                                 In some embodmicn(s. the library tobe screened composes
       Other antibody mod&iicntions include ant&bodies tlmt have                o subst&tuuons &n two or more posit&ons, wluch may be &n the
    been modified as described in PCT I'ubl. No. WO 99/SSS72,                     same ('Dk or in two or more CDks. 11&us. the library may
    These nnt&bodies comprise. u& addition to a binding domnin                    compose substitut&ons in &uo or more posit&m&s u& one CDR.
    d&rected at the target molecule. an elfector domo&n Imvu&g an                 'I he library may compose substitut&on &n tv,o or more posi-
    amino acid sequence substantiafly homologous to all or part                   tions in tuo or morc ( DRs. The librnry n&ay comprise sub-
    of a constant domain of a humnn uumunoglobuhn heavy                         I stitution in 3. 4, 5, or more pos&lions, smd posiuons f&&und in
    chain These antibodies are capable of binding the target                      nvo. three, four, five or six (.'DRs. I'he substitution may be
                                                                                          ol'afiut
    molecule without triggering signilicant complcmcnt dcpmi-                       prcpnrcd using low redundancy codons. Swx c.g, Table 2
    dent lys&s, or cell-med&ated destruct&on of fite target In soine                       et al . 1993. Ciene 137(l).109-18).
    embodinmnts, the effector domain is capable of speciticafly                        The CDR may be ('IJRH3 and/or C'1)RI.3. The <U+00AB>)JR may
    buiding FcRn nnd/or Fc) Rllb. These arc typically ix&scd on             a&      bc onc or morc of C'DRI,I, C'DRI.2, ( DRIuk C'DRHI,
    chimeric domains derived from nvo or more lnuuan mmui-                          CDki12. and/or <U+00AB>DR113. 11&e CDR may be a Kabat ('Dk. a
    noglobuli n hcavy c1m in ('n2 domains. Antibodies n&odi tied in                 <U+00AB>hotl&ia ('DR, or m& extended ( DR.
    this mmu&er are particularly suitable for use ui cluo&uc ann-                      Cand&dates w&th improved bind&ng may be sequenced,
    body therapy, to avoid intlammatory and other adverse reac-                     thereby Identify&ng a CDR substinuion mutant which results
    tions to conventional nntibody therapy.                                 6       in in&provixI aflinity (also termed an "improved" substitu-
       The Invent&on u&eludes affinity matiued emboduuents. I'or                    t&on). Catxhdates tlmt b&ud may also be sequenced, thereby
    exmuple, aflinity n&aturisI antibodies can be produced by                       ident&fying a CDR substitution which retains binding.
                                                            US 8,080,243 B2
                                  37                                                                       38
    Multiple munds of screening may be conducted. For                    or more antibodies and another amino acid sequence to which
exmuple. candidates (each composing an anuno acid substi-                it is not attached in the native molecule. for example. a het-
tution at one or more position of one or more CDR) with                  erologous sequence or a homologous sequence from another
improved binding are also usefiil for thc design of a second             region. Iixemplary hcterologous sequences include, but nre
library containing at least the onginal and subsntuted anuno          s not limited to a "tag'* such as a FLACi tag or a 611 is tag. Tags
acid at each improved (.'DR position (i.e.. amino acid position          are vvell known in the art
ui the CDR at wluch a substitution mut mt ahois ed nuproved                  A liision polypeptide can be created by methods knoivn ui
bindm ). Preparation, screenuig, and selection of this library           the art. for example. synthetically or recombinantly. Typi-
is discussed I'artier bekiw                                              cally, thc fusion proteins ol'his invention are made by pre-
    Library sc uuung mutagenesis also provides a memis for           t(1 paring an expressing a polymicleotide encoding them usin
cltamcterizing a CDR, in so far as the frequency of clones               recombinant methods described herein. altlxiiigh they may
with improvexI binding. tfie same binding, decreased binding             also be prepared by other means knov, n in the nn, nicluiling,
or no binding also provide information relating to the impor-            for example, chemical synthesis.
tance of each amino acid position for the stability of the                   This invention also provides compositions comprising
antibody-antigen complex For example, if a positioii of the              antibodies or polypeptides con)ugated (fiir example, linked)
C DR retains binding vvhen changed to all 20 nmino acids, that           to an agent tliat facilitate coupling to a solid support (such as
position is identified as a position that is unlikely to bc              biotin or avidin). I'or simplicity. refcrmice will bc made gen-
requirediiirantigenbinding Conversely,ifapositionofCDR                   erally to mtibodies with the understanding that these methods
retains binding in only a small percentage of substitutions.             apply to any of the P(.: SK 9 binding mid/or antagonist embodi-
tliat position is identified xs a positimi tliat is important ui o mmits described herein Conjugation gcni:rally rcli;rs to link-
CDR fiuiction. '11tus. the library scanning mute enesis meth-            ing these components as described hereui. Tire linking (winch
ods generate information regarding positions in tlie CDRs                is generally fixing these components in proximate association
that can be changed to many different amuio acids (includin              at least for administration) cmi be achieved ui any number of
all 20 amino acids), and positions in the CDRs which cannot              ways. For example, a direct reaction between an agent and an
be changcxl or which cmi only be changcdl to n fiw mnino                 antibody is possible whmi each possesses a substinient
acids.                                                                   capable of reactin<U+00BB>vith the other. For example. a nucleo-
    I'andidates ivith improved affinity may be combined in a             philic youp, such as an amino or sulihydryl group. on one
second library, which mcludes the improvixI amino amd. the               may be mipable of reacting is ith a carbonyl-conuunm griiup,
oriynal mmno acid, and may further include additional sub-               such as an anhydnde or an acid halide, or auth an alkyl youp
stitutiolis at that positiiln. depending oil the complexity ill tlic io containing a good leaving group (c.g, a halide) on tlie otlmr.
library that is desired. or penm t ted usia<U+201E> the desired screen-             An antibody or pohpep tide of tlus invention may be luiked
iilg iir selection method. In addition, if desired, and adjacent         to a labeling agent such as a ihiorescent molecule, a radioac-
mnuui acid position can be mndomized to at li ast two or nuirc           tive lliolccillc or'liv tithers labels knovvn in the art I,abcls arc
amuio acids. Randon<U+00BB>zation of ad)scent amuio acids may                   known in the art wluch generally provide (either directly or
permit additional conformational tlexibility in the nuitant "<U+00BB> indirectly) a signal.
CDR. which inay. in turn, permit or Iiacilitatc the intr&iduciion            Thc invmiiain also provides compositions (including phar-
of a larger number of uuproving mutations. The library may               maceutical compositioas) and kits compnsing. as this disclo-
nlso comprise substitution at positions that did not show                sure makes clear, any or all of the antibodies and/or polypep-
unproved alfinity in thc iirst round o I'screening                       tides dcscnbcd herein
    'lite second I ibrary is screened or selected for library mem- 4o        The invention also provides isolated polynucfeotides
bers with inipmvcd nnd/or altered binding affinity using miy             micoding the mitibodies mid peptides of tlm invention, and
method knov;n ui the art. including screening using 1)iacore             vectors and host cells comprising the polynucleotide.
surface plasmon resonance analysis, and selection using any                  Accordingly, the invention provides polynucleotides (or
method known in the art for scloction. including phage dis-              compositions, including pharmaceutical compositions),
play. yeast display, and nbosome display.                                compnsuig polynucleotides encoduig any of the following;
    Tiie invention also encompasses fiision proteins compris-            the antibodies 4A5, 5A10, 6FEi, 7D4. 1.11 3, or any fragment
uig one or more fragments or regions from the antibodies or              or part thereof havuig the ability to antagonize PCSK9.
polypeptides of this invention. In one embodinient, a fiision                In another aspect. the invention provides polynucfeotides
polypeptide is provided that mmiprises at lmist 10 contiguous            encoding any ol'he mitibodies (including mitibody I'rag-
anuno acids of a venable light cliain reyon shown ui SEQ ID a ments) and polypeptides descnbed herein, such as antibodies
NOs: 53. 16, 17. I g, or 19 and/or at least 10 amino acids of a          and polypeptides lusving impaired eifector function. Poly-
variable heavy chaui region shoivn in SFQ ID NOs 54. 20.                 nucleotides can be madeand expressed by procedures Drown
21. 22. or 23. In other embodiments, a fiision polypeptide is            ui the art.
provided that comprises at least about 10, at least about 15, at             In another aspect, tlm invention provides compositions
least about 20, at least about 25, or at least about 30 contigu- 5 (such as phamiaceutical compositions) composing any of the
ous amino acids of the variable light chain region and/or at             polynucleotides of thc invention. In some embodiments. the
least about 10, at least about 15, at least about 20, at least           composition euniprises an expression vector comprising a
about 25, or at least nbout 30 ctintiguous amuio acids of the            polynucleotide encoding the anubody as described hereui ln
variable hcavy cltain region In another embodiment. the                  other embodiment, the composition comprises an expression
I'usmn polypeptide comprises a light chain vnriable region ro imcuir comprising a polvnuclcotide encoding any of thi: miti-
and/or a heavy chaui variable region, as shov;n in any of the            bodies or polypeptides described herein. In still other
sequence pairs selected from among SFQ ID NOs: 53 mid 54,                mnbodi ments, tlm composition comprises citlmr or both of the
16 and 20, 17 and 21. I g and 22, and 19 and 23. In another              polynucleotides shown in SRQ ID NO.25 and SFQ ID
embodiment, tlie fusion polypeptide comprises one or more                NO:26. Expression vectors. and administration of polynucle-
('DR(s) In still other embodimmitg tlic fusion polypeptide               otidc compositions are furtlmr described herein.
comprises CDI& 113 (VI I CDR3) and/or CDR L3 (VL CDI&3).                     In another aspect, the invention provides a method of mak-
For purposes of tlus invention, a fusion protein contains one            ing any of the polynucleotides described herein.
                                                         US 8,080,243 B2
                                39                                                                    40
    Polynucluotides complenmntary to any such sequences me            demrmining the number of positions at v,hich the identicnl
also encompassed by the present invent&on. Polynucleotides            nucle&c ac&d bases or anuno ac&d res&due occurs &n both
may be single-stranded (coding or antisense) or double-               sequences to yield the number of matched posit&ons. divi du&g
s&tended, and may bc DNA (genomic, cDNA or synthetic) or              tlm number of n&atchcd positions by tlm total nun&ber of
RNA molecules. RNA molecules uiclude I lnRNA molecules,            s positions in the reference sequence     (&.e. the wuidow size) and
which contain introns and correspond to a DNA molecule in             nniltiplying the results by 100 to yield the percentage of
a one-to-one manner, md mRNA molecules, wluch do not                  sequence ident&ty
contmn introns. Add&tional coding or non-codin sequences                 Vanants may also. or alternatively, be substantially
may, but ixmd mib bc present within a polynuclc&itide of the          lximologous to a nat&ve gcnc. or a portion or complmnm&t
present u&vention, mui a polynucleotide may, but need not, be      u& thereol. Such polynucleot&de vanants are capable of hybnd-
linked to other molecules und/or support matenals.                    izing under modemtely stnngent conditions to a naturally
    Polynucleotides nuit'o&lip&lse a &&attic scxiuencc (& e . a&1     occurring DNA &cqumicc encoding a native antibody (or a
endogenous sequence that encodes an ant&body or a port&on             complementary sequence).
tlmreofl or may comprise a variant of such n sequence. Poly-             Suitable "&miderately stringent conditions" include pre-
nuclcioitide vanants contain one or more substitutions, add&-         &&saltu& u<U+00BB>I soh&&ion of &xSSC, 0 5% SDS. 1.0 mM I:DTA
tions. deletions an&1'or insertions such that the inununoreac-        (pH 8.0); hybridizing at 50" ( .-(i5" (.'., 5xSS('. overnight;
tivi&y of the encoded polyp&7tidc is not diminished. relative to      fiilkiwed by washing twice ai 65" C for 20 minutes with each
a native immunoreact&ve molecule. The elTect on the &mmu-             of 2x. 0.5x and 0.2xSSC conuiining 0.1% SDS.
noreactivity of the encoded polypeptide may generally be                 As used herein, "hivgly stringent conditions'r "hikes
assessed ns describe&I herein Variants prefemblv cxlribit at        o stringency conditions'* aro those lira& (I) employ low ionic
least about 70% ident&ty. more preferably. at least about 80%         strength and hi h temperature for wa slung. for example 0 01 &
identity, yet more preferably, at least about 90"/a identity, and     M sodium chloride/0.0015 M sodium citmte!0 I "/a sodium
most preferably. at least about 95% &dent&ty to a polynucle-          dodecyl sulfate at    50's    (2) employ dune hybndization a
otide sequence that encodes a nat&ve antibody or a portion            denaturing agent. such as formam&de, for example. 50/8 (v/v)
thereof                                                               formamidc with 0.1% bovine serum albumin/0.1" k Ficoll/
    Tivo polynucleot&de or polypepude sequences are sa&d to           0.1% polyvinylpyrrol&dot&e/50 mM sodium phosphate buffer
be "identical" if the sequence of aucleoti des or emu&o acids in      at pH 6&.5 with 750 mM sodium chloride, 75 mM sodium
the tivo scx)ounces is the same when aligned for maxinnuu             citrate at  42':   or (3) employ 50'/& formamide. 5xSSC (0.75
correspondence as descnbed beloiv. Compansons between                 M NaCI. 0.075 M sod&um citmte), 50 mM sod&um phosplmte
two sequences arc typically pcrfonn&.d by cianparinv thc &o (pH 6 8), 0 1% sodium pyroplxisphatc, 5xDenhardt*s sulu-
sequences over a companson windoiv to identify wid com-               &&&1&1. son&cared saki&on spe<U+00BB>'11 DNA (50 iighnl). 0.1% SDS,
pare local reg&ons of sequence sundanty. A "comparison                and 105!a dextran sulfate at    42'.,   iv&th washes at 42'.    &n
w indov, *'& used herein, rcfi rs to a &ugnmnt oi'at least about      0.2xSS('sod&um chloride/sodium ci&rate) and 50'/&& lonna-
20 conuguous posiuons, usually 30 to about 7 &, or 40 to about        n<U+00BB>de a& 55'., followed by a high-stnngency wash cons&stu&g
&0, in ivhich a sex)uence may be con&par&xi to a reference "<U+00BB> of O.lxSSC containing RDIA at 55''. Thc skilled n&tissu
&mqucnce &ii'hc seine number ol'ontiguous posit&ons aficr             &vill recognize how to adiust thc tempcniturc. ionic strength<U+201E>
the two sequences are opt&mally al&gned.                              etc. as necessary to ace onuno date factors such as probe length
    Optimal alignment of sequences for comparison mny be              and thc like.
conducted using the Megaligo progrmn in the l,asergenc suite             It i&ill be appreciated by &hose ol'ordinary skill in the art
of bioinformatics software (DNAS'IAR. Inc., Madison.                  that. as a result of the degeneracy of the genetic code, there are
Wis ), using default parwneters This progran& mnbodies scv-           nmny nucleotide sequences that encode a polypeptide as
eml al&gnment schemes described in the follow&ng refer-               described herein. Some of these polym&cleotides bear mim-
ences: Dayhoff. M. O.. 1978, A model of evolutionary change           ma1 homology to the nucleotide sequence of any native gene.
in proteins Mntrices fiir detecting distant relationships. In         Nonothcless. polynucleotidcs that vary due to differcnccs in
Dayhoff. M. O. (ed.) Atlas of Pmte&n Sequence and Structure           codon usage are spec&ficaily contemplated by the present
(National Biomedical Research Foundation. Washington                  invention. Further, ageles of the genes comprising the poly-
D C.). Mol. 5. Suppl 3, pp. 345-358: Heu& J.. 1990. Un&tied           nucleot&de sequences prov&ded herein are w&thin the scope of
Approach to Alig&ut&ent and Phylogenes pp. 626-645 Meth-              the present invention. Alleles are endogenous genes that are
ods u& Furymology vol 183, (Academic Press. Inc, Sun                  altered m& a result o I'one or more mutnti oui. such as deleuo ns.
D&ego. Calif.): H&gg&ns. D. Ci. w&d Sharp, P M., 1989, u add&t&ons and/or subst&tut&ons of nuclco&tides. The result&ng
CABIOS 5:151-153: Myers. L'. W. and Muller W., 1988,                  mRNA and prote&n may, but need not, l&ave nn altered stnic-
CABIOS 4:11-17. Rob&nson. Pk D.. 1971, ('on&b. Theor                  ture or function. Alfcles may bc identilied using stmidard
 11 10&: Santou, N., Nes. M.. 1987, Mol. Biol. Lvol. 4:406-           techniques (such as hybri&h&mt&on. &unpl&iieet&on and/or data-
425: Sneath. P. H. A and Sokal. R R.. 1973, Numerical                 base sequcncc comparison).
Taxonomy the Princ&plea and Practice of Numencal Tax- s                  The polynucleotides of this invention can be obtauled
onomy (Freeman Press, San Francisco. I'nlif.): Wilbur. W J.           using chemical synthesis, recombinant methods, or P('R.
mid I ipmm&. D..i . 198'3. Proc Natl. Aced. Sci. USA 80 726-          Methods of chemical polynuclwitide &yntlmsis arc well
730.                                                                  knoivn in the art wid need not be described in detad herem.
    Preferably. the "percentage of sequence identity's deter-         Onc of skill in the art can use the sequences provided herein
mined by comparing two opt&mally aligncdi sequences over a ro and a commercial DNA synthesizer to produce a desired
w&ndow of comparison of at least 20 positions, wherein the            DNA sequence.
portion of the polynuclmtide or polypeptide sequence in the              For preparing polym&clcotides using recombinant meth-
comparison window may compose add&t&ons or deletions                  ods. a polynucleot&de compnsuig a des&red sequence can be
(i e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10    inserted into a suitable vector, and the vector in turn can be
to 12 percent, as compnrcd to thc refcrcnce sequences (w hich         introduced into a suitable host cell fiir replication and ampli-
does not compose addiuons or deletions) for optimal ahgn-             ficauon. as further discussed here&n. Polym&cleot&des muy be
ment of the two s&xpiences. 'I'he percentage is calculated by         inserted into host cells by any means known in the a&t ('ella
                                                           US 8,080,243 B2
                                41                                                                       42
are transformed by introducing an exogenous polynucleotide              87/04462. Suitable non-n&anunalim& host cells include
by direct uptake. endocitosis, tmnsfection, Ixmaung or elec-            pmkaryotes (such as E co /i or R sub/i i/is) and yeast (such as
troporat&on. Once u&troduced, the exogenous polynucleotide              5'. Cerevisve, R pv&abc: or K. lvc/is). Preferably the host cells
can bc maintained witldn the cell ms a non-intcgratcd v&xtor            express the cDNAs at a level of about 5 fold higher, more
(such as a plasm&d) or &a&earn&ed into the host cell genome. 1 preferably, 10 fold lugher. even more preferably, 20 fold
 fhe pclynu ciao tide so amplified can be isolated from the host        higlier tin n that of tile corresponding endogenous antibody or
cell by methods well knov,n w&thui the art. See. e.g, Sam-              pmte&n of interest, if present, m the host cells. Screen&ng the
brook et al., 1989, supra.                                              host cells for a specific binduig to PCS K9 or a lxC SK9 dome&n
     Allcmativelv, PC'R allows reprixlnclion of DNA                     is cl'll:ctcd by an immunoassay or FACS. A cell overcxpress-
sequences. PCR teclmology &s well into&vn ui the art and ls lo uig the antibody or proteui of interest can be &denuiied.
described in U.S. Pat. Nos. 4,683,195. 4,800.159, 4.754,065             C. Ciimpositions
'i&id 4,683.202. Cs well cs PC'R The Polymcrase C'hain Reac-                The composiiions used m the methods of tlm invention
tion, Mullis et al., 1994, eds. (Birkauswer Press. Boston,              compnse an effective amount of a PCSK9 ant&1 onist ant&-
Mass ).                                                                 body. a PCSK9 antagonist m&tibody dcrivcd polypeptide. or
     RNA cau bc obta<U+00BB>ied by using lhe isolated DNA in an                other PC'SK9 mitagon&sts describexI herein, Iixamples of such
appropriate vector and inserting it into a suitable host cell.          compositions, as well as how to formulate them, are also
When the cell replica&as and the DNA is transcribed into                described in mi oarlier sccction and below. In one embodiment,
RNA. &he RNA m&n that& be isolaled using nielhods well                  the compos&t&on lhrther compnses a PCSK9 antagonist In
known to those of skill in the art, as set forth in Sambrook et         another embodiment, the composition comprises one or more
al, 1989, supm, I'or cxaluplc.                                       "v PC'SK9 antagonist m&libodics In other embodimen(S lhc
     Suitable cion&ng vectors may be constructed according to           PCSK9 antagon&st antibody recoy&izes lnunan PCSK9. In
standard teclmiques, or may be selected from a large number             still other embodiments, the P(.'SK9 antagonist antibody is
of clonuig vectors evadable in the art. Wlule the clo&un                human&zed. In yet other embodiments, the PCSK9 antagonist
vector selected nmy vary according to the host cell intended to         antibody compnses a constant region that does not trigger an
be used, useful cloning vectors will generally have the ability " unwanted or undesirable imnumc response, such as antibody-
to self-replicate. may possess a s&ngle tar et for a part&euler         med&ated lysis or ADCC. In other emboduuents, the PCSK9
restriction endo nuc lease. and/or may carry genes fora marker          antagoiust antibody compnses one or more ('DR(s) of the
that can be used &n selecting clones contamin the vector.               a&uibody (such as one. u&o. three. I'our, live, or. m some
Su&table examples uiclude plasnuds and bactenal v&ruses,                embod&ments. all s&x CDRs), ln some emboduuents. the
c g. pUC'l8, pU('19, Blucscript (c g.. pBS SK+) and its &v P('SK9 m&tagonist nntibody is bim&an
derivatives, inp lb, mp 19. pBR322. pMB9, Coll',I. pCR),                    Il &s understood that lhe composit&ous mui comprise more
RP4. phage DNAs, and shuttle vectors such as pSA3 and                   than one PCSK9 antagonist antibody (e.g.. a mixnire of
pAT28 Tlmse nnd many othir clmung vectors are avnilablc                 PC'SK9 antagonist antibodies that recognize dilfcrm&l
from conunerc&al vendors such as B&oRad. Strategene, and                ep&topes of PCSK9) Other exemplary compos&uons com-
I llv& t fr& get'1                                                      prise more than one P('SK9 antagonist antibodies tlmt recog-
     Expression vectors generally are replicablc polynucleotidc         nize lhc same CT&itope(s). Cr dilfcrenl spec&es ol'C'SK9
constructs that contain a polymicleot&de according to tile              amagoiust antibod&es that bind to different ep&topes of
invm&tion. It is implied that an expression vector must be              P()SK9
replicable in the Ix&st cells e&ther as CT&iso&ucs or cs an integral        The composit&on used in lhe pres&ait invention can lurther
part of the chron&oson&al DNA. Suitable expression vectors sv comprise phannaceut&cally acceptable carriers, excipients, or
include but arc not limimd to plasmids, viral vectorz includ-           stabilizers (Rcmington: The Science and Practice of Phar-
ing adenov&ruses. adeno-associated v&ruses, retrov&ruses,               macy 20th Ed., 2000, Lippincott W&lliams and W&lkins. Ed.
cosmids, and expression vector(s) disclosed in P('T Publ. No.           K. E. Hoover), in the form of lyophilized formulations or
WO 87/04462. bc&or components may generally include.
                    &
                                                                        aqueous solutions Acceptable carriers. excipienis. or stabi-
but are not limited to, one or more of the follow ing: a signal 4. 1&zers are nontox&c to recip&ents at the dosages and concen-
sequence: m& origin of replication; one or more marker genes;           uations, and may comprise buffers such as phosphate, citrate,
su&table transcnpt&onal contml l&ng elements (such as promot-           and other organic ac&ds: ant&ox&dents &nclud&ng ascorb&c ac&d
ers, enhancers and termu&ator). I&or expression (&.e., transla-         and metluon&ne: preseivatives (such as octadecyldunethyl-
tion), one or nmre translatu&nal controlluig elemcnm are also           bm&zyl mnim&niun& chlonde, hexmnellmminn chloride, ben-
usually required. such as nbosome b&nduig sites. translation c zalkoiuum cldonde. benzethoiumn cldonde; phenol. butyl or
initiation sites. and stop codons.                                      benzyl alcohol, allyl parabens such as methyl or propyl para-
     The vectors containing the polynuclex&t&des of u&terest can        ben. catechol, resorcinol, cyclohexano1<U+201E>3-pentanol, nnd
be uitroduced into the host ceil by any of a number of appro-           m-cresolk low molecular we& ht (less than about 10 res&dues)
priate nmanw including clectroporation, transfection employ-            polypeptides, proteinz such ns senun albun&in. gelntin, or
ing calmum chloride, nibid&um chloride, cele&um phosphate, s &mn&uuogobulins: hydrophil&c polymers such as polyvi-
DL'AE-dextran. or other substances; microprojectile bom-                nylpyrrolidone; amino acids such as glycine, glutamine,
bmdment, lipofixtion, mxl in 1'ection (c g, v'lmre the vector is        aspalagi<U+00BB>c, lustidinc. Cn ininc, or lysinm monosaccharidcs,
an infect&ous agent such as vaccin&a &in&s). The choice of              d&saccharides. aud other carbohydrates u&clud&ng glucose,
introducing vectors or polynucleotides will often depm&d on             mannosc, or dextrm&s; chelating agents such as Vl) I'A: sugars
I'eatures of limbos'ell                                              sa such ns sucrose. mannitol, trclmlosm or sorbilol, salt-fonnmg
     'lite invention also prov&des host cells comprising any of         counter-iona such as sodium; metal complexes (e.g., Zn-pro-
the polynuclcotides described herein Any la&st cells capable            tein complexes); and/or non-ionic surfnctm&ts such as
of over-express&n hetemlogous DNAs cmi be used for tile                 TWEENPC, PLURONICS<U+2122> or polyethylene glycol (PECi).
purpose of isolating the genes encoding the antibody,                   Plmnuaceutically acceptable excipients are further descnbed
polypeptide or protein of interest. Non-limiting exmnples of ( herein.
manuualian host cells uiclude but are not l&mited to COS.                   In one embodiment. the antibody &s achnimstered ui a for-
HeL1. NSO. and CHO cells. See also PCT Ih&bl. No. WO                    nui lation as a sterile aqueous solution Imv ing a pH t1&at ranges
                                                                        (js 8,080,243 B2
                                       43                                                                               44
from about 5.0 to about 6 5 and comprising from about I                                 limitation, alaninc or serine. For exanlplc, there can be a
m /ml to about 200 mg/ml of antibody. from about I milli-                               substitution of a non-canonical cysteine. The substitution cmi
molar to about 100 mtllimolar of histidine buffer, from about                           be made in U CDR or fmmew ork region of a variable domaui
0 01 mg&ml to about 10 mg/ml of polysorbatc80, from nbout                               or in the constmlt domain ol'n antibody. In some embodi-
 100millimolarto about400millimolaroftrehalose,and from                              1  nlents, the cvsteinc is canonical
about 0.01 millimolar to about 1.0 millimolar of disodium                                  The antibodies may also be modified, e.g., in the variable
I,DTA dihydrate.                                                                        domauis of the heavy and/or light chains. e... to alter a
    The PCSK9 antagonist antibody Und compositions thereof                              binding property of the anubody I or ex unple, a mutation
can olso be used ui ConjunCuon with other agents tlmt serve tO
                                                                                        nlay bc maCk in onc or morc of tlm C'DR regions to increase
enhance and'or complement the efiectiveness of the &gents.                          Ui
                                                                                        or decrense the K<U+00BB> of thc mitibody I'or PCSK9. to increase or
D. Kits
                                                                                        decrease k,C or to alter tile binding specificity of the antibody.
    Thc invention also provides kits liir use in the instant meth-                      Techniques~in site-direcmd mutageiwsis nre v;cll-known in
ods. Kits of the invention include one or more contauiers                               the art. See. e.g., Sambrook et al, and Ausubel et al., supra.
comprising a P( SK9 antagonist antibody (such as n human-                                  A modification or mutation may also be made in a frame-
Ired mitibody) or peptide descnbed hereul alai ulstructimis                             work region or constmlt domaul to increase the half-fife of a
for use in accordance w ith any of the methods of the invention                         I'C SK9 antibody. See, e.g., PCT Pub l. No. WO 00/09560. A
dcscribcd hcrcin Cicncrally, thcsc instnictions comprise a
                                                                                        nnimtion in a framewnrk region or constant domain can also
descnptmn of administratmn of the PC'SK9 ant ig&mist uiti-                              be made to alter the unnulnogemcity of the antibody, to
body. peptide, or aptamer for tlm above described therapeutic                           provide a site for covalent or ixm-covalent binding to another
lrcauucllni                                                                         "o
                                                                                        molecule. or to alter such properties as cmnplement lixntion,
    In some embodiments, the anubody is a humamzed anti-
                                                                                        PCR bmdin and anubody-dependent cell-mediated cytotox-
body In some embodiments, the antibody is lnunan In other
                                                                                        icity. According to the uivention. a single antibody may have
embodiments. the antibody Is a monoclonal antibody. The
                                                                                        mutations in any one or more of the CDRs or frammvork
instructions relating to the use of a I'CSK9 antagonist anti-
                                                                                        regions of the venable domain or in the constant domain.
body generally include inf&imiation as to dosage, dosing                            "
                                                                                           In a process kno&vn as "germ lining", certain mnino acids in
schedule, Und route of adnuiustration for the intended treat-
                                                                                        the VII and Vi scqUPllccs cUll be mutated to match those iinuxl
ment. The containers may be unit doses. bulk packages (e.g..                            naturally in germline V,& and Vs sequences. In particular, the
nndti-dose packages) or sub-&uut doses Instructions supplied
                                                                                        amino acid sopmnces o I'tlm I'rmnew ork rcgmns in the V<U+00BB> and
ill tile kIts of thc 1llvcitt1 oil Bl'c typic all'&' ll (tell l its tinct lolls oil
                                                                                        V, sequences can be nnitated to niatch Ihe germline
a label or package insert (c g.. a paper sheet includ&.d in Ihc                     so
                                                                                        sequences tn reduce the risk of inmumogenicity when the
kit), but machine-readable instructions (e... uistructious cer-                         antibody is adnnnistered Ciennline DNA Sequences Ior
ned on a magnetic or optical s tom ge disk) are also acceptable.                        human V<U+00BB> and Vc genes are known in the art (see e.g.. the
    The kits of this invent<U+00AB>m arc in suitabl&. packaging Suit-                          'Vbase'* human gernlline sequence database, siv. also Kabat,
able packaging ulcludes. but is not linuted to, vials. bottles,                         lk A., et al. (1991) Sequences of Proteins of Immunolo Ical
jars. flexiblc packaging (e g., sealed Mylar or plastic bags),                      "<U+00BB>
                                                                                        interest, Fifth Hdition, H S. Deportment of Health and Hummi
Bud Ihc like Also coIUPJupl&11&xl itrc pack&&gas liir usc in com-
                                                                                        Services, NIH Publ No 91-3242, Tomlinson ct al.. 1992, .1.
buiation v'ith a specific device. such as an inhaler. nasal                             Mol. Biol. 227:776-798: Und Cox et al., 1994. Bur, J. Inunu-
ndministrafiondks ice(P g,anatomixer)ormlinfusiondevice
                                                                                        nol 24:827-83ti.
such ms a niinipump A kit may have a stenle access port (I'o r                             Another type of amino acid substinluon tlrat may be made
example the container may be an intravenous solution bag or                         So
                                                                                        is to remove potential proteolytic sites In the antibody. Such
a vial having a stopper picrccnblc by a hypodermic injection                            sites may occur in a ('DR or franwwork region of n vtmiablc
needle). The container may also have a stenle access port (for                          domaui or In the constanl dom Un of an antibody. Subslitution
exmnple the contniner may be an intravmious solution bag or                             of cysteine residues and removal of proteolytic sites may
a vial having a stopper picrccablc by a hypodermic injection                            divroase thc risk of heterogeneity in the antibody product and
needle). At least one actne agent in the composition is a                           ss  tluls increase its homogeneity. Another type of amulo acid
P('SK9 antagonist antibody. The container (e.g., pri-tilled                             substitution eliminates a~sparaginc-giycinc pairs, which form
syniige or autointector) may further compose a second phar-                             potential deanudation sites. by altering one or both of the
maceutically active agent.                                                              residues. In miother example. thc (utenninal lysins of the
    Kits may optionally provide additnmal componenms such                               hcavy chain of a P( SK9 antibody of tlm invention call bc
                                                                                        clem ed. In vanous embodiments of the ulvention. the hea&0
as buffers and interpretive information. Normally, the kit                            U
                                                                                        and light clu&ins of the I&CSK9 antibodies nlay optionally
comprises a contmner and a label or package insert(s) on or                             ulclude a signal sequence.
Bssocuucd with the contmner.                                                               Once DNA fragtuents encoding the V<U+00BB> and Vc segtuents of
Mutations and Modificauons                                                              th&. prcsmlt in&mntion are obtainixi, these<U+00BB>DNA fragnwnts cnn
    To express tlm P( SK9 antibodies of tlm present invention,                          be further manipulated by standard recombinant DNA tech-
DNA fragments encoding V<U+00BB> and V, regions can first be                                 1 niques, for example to mmvert the variable region genes ro
obtained using any of the methods described abnvc Various                               Ihll-length mlt&body chain gcncs, to Fnb fra ment genes. or to
modifications, c g . nuitat iona, dclctions, tind/or additions can                      a scfv gene. In these manipulations. a Vc- or Vr<U+00BB>encodutg
also be intr&xluced into the DNA sequences using standard                               DNA fragment is opemtivcly linked to arixitber DNA fnsg-
methods known to those of skill in die art. For example,                                ment encoding another protein, such as an antibody constant
&UUtagcllcs&s call bc cart'lcd UUI uslllg staudal'0 lac(linda. such                 ui  region or a flexible linker. The tenn "operatively linked*', as
                                                                                        used in Ibis contexk is illtelldcd Io &nevi&i tfmt the tv 0 DNA
as I'CR-mediated mutagenesis, in wluch the mutated nucle-
                                                                                        fbagments are )oined such that the mnino acid sequences
otidcs nre incorporated into tlm P('R primem such tluit the                             mlcodcd by tlm t&vo DNA I'ragnmnts rcnlain in-I'rmnc
PCR product contmns the desired mutations or site-directed                                 Tile isolatcd DNA encoding the V<U+00BB> regimi cnn be c&mvcrted
mutagenesis.                                                                            to a full-length heavy chmn gene by operatively linking the
    One type of substitution, fiir example. tlmt may bc made is                     /   VI/ encoding DNA to another DNA nmlecule encodmg
to change one or more cysteines in the antibody, which may                              heavy chain constant regions (CIII, CH2 and CI13). The
be cliemically reactive, to another residue. such as, without                           sequences of human heavy chain constant region genes are
                                                           (js 8,080,243 B2
                               45                                                                       46
known in the art (scca ge Kabat, I..A., et al . 1991, Sequences        I'ng, 10:949-57)."Minibodies" (Mnrtinctel..1994, FMBO I.
of Proteins of Inununological Interest, I'ifth I.dition, U S.           13 5303-9), "Diabodies'Holliger et al, 1993, Proc. Natl.
Deparunent of I lealth and Human Services, Nil I I'ubl. No.            Ac ad. Sc&. (ISA 90: 6444-6448), or "Janu sins" (Trm&necker et
91-3242) and DNA frag&cents encompassing these regions                 al., 1991. L'MBO J. 10:3655-3659 and 'Iraunecker et al.,
can be obtained by standard PC R an&plifhcatiim The hcavy              1992. Int Ji. Cancer (Suppl.) 7 51-52) nuiy be prepared usu&g
chain constant region can be an IgCi l. Igf)2, IgCi3, Igti4. IgA,      standard molecular biolog&cal techn&ques follow&ng the
Igp.. IgM or I D constant re &on, but most preferably is an            teachings ol'he speciiimitmn.
igCII or 180i2 constant region. The Ig(i const&lnt leg&on                 B&spec&iic antibod&es or ant&gen-b&nding fragments can be
sequence can be any of the various all el as or a I 1otypes known
                                                                       produced by a vanety of methods including fus&on of hybri-
to occur among differm&t individual a such as Cim(1). h im(2)
                                                                       dumas or linking of Fab'ragments. See, e.g, Songsivilai k
Cim(3). and Gn&(17) These allotypes represent naturally
                                                                       Laclm&mu&. 1990, C1&n. Bxp. Inununol. 79: 315-321<U+201E>Kostelny
occurring amino acid substitution in the igtil constant
regions. Fora I'ab fragment heaiy chau& ene. the VI I-encod-           ct al, 992. J. hnnnmol. 148 1547-1553. In addition, bispc-
                                                                               1
&n DNA cm& be opemt&vely linked to another DNA molecule
                                                                       cilic anubodies may be formed as "d&ab&&dice" or '*Jmiusins '*
encoding only the hcavy clmin I HI constant region. The I H I          In some embodiments. the bispieciiic antibody binds to two
heavy chain const u&t reg&on may be denved from any of the             diffi:rent epitopes of PC.SK&J In some mnbodiments. the
heavy chain genes.                                                     modified ant&bodies duse&&bed above are prepared using one
    The isola&cd DNA encoding thc Vr region inn bc converted           or more of the variable domains or C'DR regions from a
to a full-lenegth light chain gene (us well as a 1&ab light cha&n      inunan PC'SK9 antibodv provided herein.
gene) by operatively linking the Vr-encoding DNA to m&other            Cienerauon of Antigen-Specific Annbodies
DNA molecule encodu&g the l&ght ch nn constant region, Cr .".n            More than 500 polyclonal and monoclonal antibodies
 I'he sequences ofluunun fight cl&mn constant region scenes are        cused against recomb&nant full-length human PCSK9,
knoivu in the art (aei e g . KabaL F.. A . ct al . 1991, Sequences     recombinm&t full length mouse PCSK9, and various synthet&c
of Prote&ns of Immunolo ical InteresL I'ifth Bdit&on, U S.             pi7 tides w ere evaluated for their ability to down regulate tots I
Department of Health and Ilunmn Serv&ces, NIH Publ. No.                LDLR protein u& cultured Huh7 human liver cells. Amon
91-3242) and DNA frag&name encompassing these regions "                these antibodies were a set of antibodies raised to and reactive
can be obtained by standard PCR unpliiicat&on. The 1&ght               with a set of 12-20 mnim& amd rcs&due polypc7uides that,
chain consmnt region can be a kappa or lambda cimstant                 based on the structure of PCSK9, were predicted to cover
region. The kappa constant region mav bc any ol'the vari&ms            &up&ority of the protein simfacc At thc highest conccntmtion,
alleles known to occur among different individuals, such as            the best antibodies exhib&ted only about 60% block&ng activ-
Inv(l). Inv(2), and inn(3). The lmnbda constant rcgim& nmy bc Tn       ity.
derived from any of the tinea lambda ence.                                Thus, an alternntive aml hercu&fi&re unexplored approach
    To create a scl'v gene, the V~ and Vr-encoding DNA                 was employed, nmnely. the geneuu&on of monoclonal u&t&-
I'ragmcnts are operatively linked i(& dnothc&'&ugn&cnt cncoll-         bodies by inununizing PC'SK9 null mice with riccombinant
&ng a fiexible 1&nker, e.g.. encoding the mnino acid sequence          fuII-long&h PC'SK9 protein This mannir of antibody pri7a-
(Cily4-Ser),, such that the Vu and Vi seqtmnces cm& be "<U+00BB>              muon y&aided antagorust anubodies that show complete
expressed as a cont& uous su&gle-chau& prote&n, with the Ve            blocking of PC'SK9 binding to I.DI,R, mhmpletc blocking of
and Vav regions joined by the flexible linker (See e g., Bird et       PCSK90&ixfiatnxiloweringol1 DI R levelsinlluh7cells,and
al, 1988, Science 242.423-42t&, Huston et al, 1988, Proc               loitering of LDLc in vivo including in mice to levels compa-
Natl. Acad. Sci. USA 85; 5879-5883: McCafferty et al., 1990,           mble to tlmt seen in PCSK9-/- mice, as shown in Fxample 7.
Namre 348:552-554. The single chain antibody may be nn                    Representative ant&bodies (hybridomas) of the present
monovalenL if only a single Vu and Vn are used. b&valent, &f           invention were deposited in the American fype I'ulture Col-
tw 0 V<U+00BB> and V, are used, or polyvalent, &f more than nvo V<U+201E>            lection (ATC'C') on Feb 28, 200K and were assigned tlm
m&d Vn are used. BisP&x:itic or Polyvalent anfibodics &nay bc          access&on numbers u& Table 3. Hybridomas were depos&ted
generated that bu&d specdically to PCSK9 and to another                for antibodies 4AS, 5A10. 61'Ci and 7D4.
molecule.                                                          4.
    In m&otlmr einbodimint, a fusion antibody or immunoad-                                           TABLL'
hesin may be made tluit compmses all or a portion oi a PCSK9
m&tibody of the invention linkcxl to another polypeptide In                      i,n& bnd Re&&&ence          ATCC *iccesunn inn
another embodimenL only the vmiable domains ol'he                                4A                          P&'Admns
PCSK9 antibody are linked to the polypeptide. In another u                         A&(&                      &n&A4066
cmbodinmnt,theVTudon&ainofaPC'SK9antibody islinkedto                             6&6                         PTA-SS64
                                                                                 &un                         PTA Scent
afirstpolypeptidi.whilethcV, dmnainofaPCSK9antibody
is linked to a second polypeptide that associates with the first
polypeptide in a mannersuch that the VuandVr domains can
interact ivith one another to form an ant&gen bind&ng s&te. In       6                              LXAMPI.DS
another preferred embodiment, the VH domain is separated
I'rom the Vr domain by a linker such that tlm VH mul VI,                                             Fxmuplc  I
domains can interact with one another. The V<U+201E>-hnker-'e',
antibody is then linked to the polypeptide of interest. In                       Cicnerating and Screening PC'SK9 Antagonist
add&t&on, fiis&on anubodkes can be created in wh&ch tivo (or       m&                                Antibodies
more) single-chain antibodies are linked to one another. 'IKis
&s useihl il'one wanLs u& create a divalent or polyvalent ant&-        Cieneral Procedures for Immunization of Animals fihr Ciener-
body on a su&gle polypeptide cha&n. or if one wants to create          atu&g  Monoclonal Antibodies:
a bispecific antibody.                                                    Balb/c or 12971&16 pcsk9-/- mice were injected 5 times on
    In other ambi&dimenta other umd&lied m&tibodies may be         6   a 13 day schedule with 100 pg antigen PC:SK9-/- (tlmt is,
prepared us&ng PCSK9 anubody encoding nucleic ac&d mol-                nul I or lu&ock out au ca) can be obtained fmm. or as des cubed
cculcs For instance, "Kappa bodies" (ill ct ale 1997, Pmtcin           by, Rashid et al.. 2005. I'mc Natl Acad Sci USA 102: 5374.
                                                        US 8,080,243 B2
                              47                                                                         48
See also H.S Pat. No. 7.300,754. For the tirst 4 injections,        of hi(itin(i P('Ski) than mouse P('SK9 I'he several nntibodies
an<U+00AB>gen was prepared by nuxing the recombinant proteins              haivgenerally similoroffinities forhumanP('SK9but vary in
with adjuvant. Inununogen was given via injection to the            their affiiuty for munne PCS K 9.
scruff of thc nnvk. the fiiot pads and intraperitoncafly,
approximately every 3 days over the course of 11 (hnys. Ivith 5                                      Fxample 2
the last boost administered i.v., without adjuvmit. On Day 13.
ihc roice uci'c cufliiliiizcd Iiiil ilmir splccus werc I'cI(iovcil.                Determining Antibody Binding Athnity
Lymphocytes were inunortalized by fusion with an estab-
lished cell liim <U+00AB>I make hybridoma clonimx using siimdard                I'he affinities of V(.:SK9 antibodies to VCSKI9 were mea-
hybridoma technology. distnbuted uito 96 well plates. Clones '" sured on a surface plasmon resonmice Biacore 3000 biosen-
were allowed to gross. then selected by ELISA screenuig             sor cquippcd with a research-ornde sensor chip using HBS-
using the immimixing mitigen. as behuv.                             FP runnuig buller (BuicorcAB, Uppsala, Siveden nou GF.
ELISA Screemng ot Antibodies:                                       Healthcare). Rabbit polyclonal anti-Ms Ig(is vvere amine-
   Supernatant medin from growing hybrid(mia cloncs were            couplod at saturating levels onto dm chip using a stmidard
screwnnxt separately for their ability to bind the recombuinnt " N-lndroxysuccininude/etlnldimethylmninopropyl carbodi-
luunan P('SK9 or recombinant mouse VCSK9. The assays                imide (NHS/1113(') chemistry. I'he buffer was sv;itched to
werc performed with i)6-well plates coated overnight with           IIBS-EP+I mg,'mL BSA+I mg/mL CM-dextmn Full-length
100 pl of a I Vg/ml solution of ime of the an<U+00AB>gens Fxcess           PCS K 9 IgCis were diluted to about 15 Vno/niL and capnired for
reagents were washed from the wells be<U+00AB>veen each step with          I min at 5 ttt /min to give levels of about 500RII per flou cell,
PBS containing 0 05% Twnmn-20. Pintos werc then blocked "-" leavuig one bl udi io serve as a reference chmuiel, 3.73-302
with PBS containing 0.5% BSA. Supernatant was added to              nM hl'C'SK9 or 2.54-206 nM ml'CSK9 mere injected as a
the plates and incubated at room temperature for 2 hours.           5-membcrnxt 3-fold series for I min at 100 VI /niin.
Horse radish peroxidase (IIRP) conlugnted goat-anti mouse               Dissociation was monitored for 5 min. The chip was re en-
Fc wos added to bind to the mouse antibodies bound to the           emted afler the last injection of each titmtion tvith tu o 30 sec
antigen. Tetrmncthyl beozidine was then ndded as substrate -"'ulses ol'100 mM phosphoric amd Buffi:r cycles provided
for HRP to detect the unount of mouse antibody present in the       blanks for double-referencuig the data. v, luch Ivere then tit
supeniatant. The reaction uas stopped and the relative              globnlly to a simple binding nmdcl using Biacvaluation sofi-
amount of uiu body was quonti lied by reading the absorbance        u are v 4.1. Atiimties were de<U+00AB>laced from the quotieoi of the
at 450 nm. I lybndoma clones that secreted antibodies that are      kinetic rate constants (Ko=k<U+201E>Fkox). The results of Example 2
capable of binding to ciihcr mouse or lnmian PCSK9 werc '" arishowninTablc4. Tficscdatashou tluitihemiubodies have
selected for furflier onnlysis.                                     excellent athmty for nninne PCSK9 or human PCSK9. as
PCSK9-Mediated LDLR Down-Reg(<U+00AB>lotion in 1luh7 Cells:                indicated
   Hybridoma cloncs secreting human or mouse PC'SK9
binduig antibodies were expmided and supematants were                                                  TABLL'
harvcstcd 'Iotai IgCis were purihed from approximately 10
ml of ihc supernatant using protein A bead~. diolyzedt uito                               inh(bi<U+00AB>on(t       K,<U+201E>ror    Kiiini    Knrni
PBS buffer, and the tinal voliune reduced to yield solutions                               DI K Pi SK9
                                                                                             7              PPSK9     Pr'SK9    PC~SK9
                                                                    mib          gnni    bmrbng(K'v)        ii Mi)     (3 Sl     (nMI
with 0 7-1 mg/mt of antibodies. I'uri tied antibodies u crc then               I
used to test their ability to mhibit the ability ol'CSK9 to         445                                   6.66 io   (.89 in
                                                                                        ',4
                                                                               SUUIUU             IIM                              '.. 8
mediate LDLR dovin-regulation in Huh7 cells. Huh7 cells nn 3(0 7111(I(i(l
                                                                    67'6       h(n non
                                                                                             0,4 UM
                                                                                             (.5 Mi
                                                                                                          8.47 in
                                                                                                          9 Isx in
                                                                                                                     '55
                                                                                                                     .84 in
                                                                                                                           io
                                                                                                                                   6.4
were plated and aflou cd to grow to SO'Ao coirflu( (Icy in RPMI                                      n
                                                                    7D4        hnn(UU        I    (UMI    (2 x(0 7 94 x I 0 "      64
media contauiing 10% IIBS. 4 mM glutomine, and penicdlin                                        3 UM      I 4( x io  7 x in        I I
and streptavidin in 96 well plates. 1he mediiun vvos chanoed        5.4(n
                                                                              Ulnas('(OUUO
                                                                                                 1UM      I 7 x ino 4 S9 x 10
                                                                                                                              '
to onc containing 10%v dc-1 ipidatnxt F BS fiir 3-16 hra to induce  6I16       n(OUU           i<U+00AB> UM      I ii x IO   77 x io     177
                                                                    7D4        n(UUU            I nvt     3 97 x IU        in
LDLR expression. Cells were then incubated for g-16 hours                                                                          I 3
with 40 pl/well of 293 expression media supplementixt with C(
pg/ml of Inunan (preferably) or mouse PCSK9. u 3th or with-
out 70-100 ug/nil of test antibodies. The PCS K9 and antibody                                        L'xample 3
contmning midin were removed at ihe cnd of incubntion, and
cells were lysed with 17 gl lysis buffer by shakuig at 4 C for 0             Ai<U+00AB>slys(s of the Effect of PCSK9 Antibodies on
an hour. 11ie lysis buffer consisted of 50 mM glycerol phos-                             PCSK9-LDLR interaction
phate. 10 mM HFPES pH 7.4. 1% Tn<U+00AB>m X-IOO, 20 mM
NaCI, mid a cocktail of protease intubitors (Roche). Cell               PCSK9 hos been shou n to bind LDLR with un aflinity of
lysates were cottcctnxt and analvzcd fiir I,DI R protein levels     130 nM under neutral pH ((.unningham ct al. 2007, Nat
via staining o I'Western blots folloii ing SDS pclyacryl anode 5 Struct Mol Biol. 14(57413-9). Recombinant mouse orhuman
gel electrophoresis Hybridoma clones producing antibodies           VCSK9 protein was biotinylated using the Pierce reagents
that can partially or Iiully rose<U+00AB>c I,DI R level wcn. selected fiir following tfm manul'UC<U+00AB>ire'S inatructiOns. F/EISA platea
further mudysis By '*I,DLR down regt(lotion assay" is memit         (Corning Mixisorb) were coated u ith a solution of I t(g'mt
the above assay using Huh7 cells.                                   recombinant LDI,R extracellular domain (Rdrt) Systems) in
   FICi I iflustratcs thc CITcct ol'nti-PC'SK9 antagonistic 60 each v cll at 4 C oveniighi. blocked with 2% BSA+PBS liir2
monoclonal antibodies 7D4.4, 4AS.C73. 6F6.(i10.3 mid                hrs at room tempemture, and then iva shed 5 times with wash-
5AI 0.BS on the ability of In(mon and mouse V( SK9 to down          ing buffer (I xVBS+0.05%v Tween-20). Wells were incubated
regulate LDLR ui cultured I iuh7 cells. 100 CM of n<U+00AB>Ouse or         u 3th 50 pl of indicated concentrations of bionny lated PC SK9
luunon recombinant I'CSK9, and a serial dilution of 25-300          protein for I hr Kf. LDLR-PCSKD) binding can be stabilized
nM of antibodies werc used. A) mouse P('SK9 B) lniman               by adding 50 td of 4% FDH+4% sucrose+PBS solution and
PCSK9. 11ie figures are Western blots shomng that the anti-         incubate for 5 min. Wells were wushed 5 tunes with wosiung
bodies are in general more effective in blocking the function       butTer. incubated with I:2000 dilution of HRV conjugated
 bi
                                                           US 8,080,243 B2
                                  49                                                                         50
  Strepavidin (Invitrogen) I'or I hr at RT. wasJ&i&J 5 tinm& v ith       injecting human-P( SK9 at 50 nM for I min at 10 pl /min (ro
  washing buffer TMB substrate &has added to the v,ella. the             tether it via tlm Ig(i on the clup) and then binding an army of
  solut&on v;ls incubated 20 to 30 min at RT, and the reaction           I C&s (final 500 nM each) for 2 mine each. The &mmobil&zed
  was tern&inated using I M phosphoric acid. Signals were read           lg(is were regenerated with 0 mild acid (Pierce gentle elution
  at 450 mu.                                                             bufl'sr+I M NaCJ) Antibodies dirovted to known dilfercnt
Rorno
     FIO. 2 illustmtes the dose-response
                                  lixed     of ant&-PCSK9 antago-        epitopes were used as controls for positive sandhvich forma-
  nist monoclonal m&tibodies 6F6Ci103. 7D4.4. 4A5(i3,                    tion in th&s assay
  5A I 0 Bg, negat&ve control antibody 42117. and PB S on block-            c. Siructure-guided muta enesis to map antibody b&nd&n
  ing the b&nding of recombinant biotinylated lnunan PCSK9               cpitopes. Ha&cd on the crystal stn&cture of P(.SK9 m&d thc
  mxl mouse P( SK9 Hi                   rceeombi&umt I DI R extra-    &0
                                                                         1&kely u&volvement of D374 in LDLR binding (Cunningham
  cellular dom un u& v&tro. Part A) shov;s humm& PCSK9 bu&d-             et 01., 2007. Nat Struct Mol Biol. 14(5): 413-419), nu&eteen
  ing, to human I.DI R extracellular domain and that 7D4, 4A5.
                                                                         PCSK9 siaface-r&widue mutunts (F379A. 1369A, R194A,
  5A10. m&d 6F/1 are cll'ective in blocking binding, ulmreas
                                                                         l&374Y, D238R. T377R, K222A. R199A, F216A, R218A,
  42H7 and I'BS are not. Part B) shov, s mouse PCSK9 binding
                                                                         R237A Dl 92R l&367R R165 k R167 4 A443T A53V
  to human I.DI,R exrracellular domain
                                                                         I 474&r, 11449A) near or far from the posiuon of D374 were
     The interaci&on cm& also be evalun&ed ul free soluuon at
  neutral pH. FJO. 3 illustrates the dose-response of anti-              chosen fbr nnitation to map the antibody binding epitopes.
  P( SK9 monoclonal antagonist antibodies 6F6.(i 10 3, 7D4 4,               d Mutant and antibody production The 19 single point
  4A5.63 and 5AI0.B8 on blocking binding of recombinant                  mutants &here generated I'rom the prev&ously describe&I hh ikl-
  biotinylated human P('SK9 (30 nM) to liuropium labeled                 type DNA construct ((loaning&L7&n et al., 2007, supra) using
  recombinant LDLR extracellular dom un (10 i&I) u& soluuon              standard DNA techniques. Thc mutant proteins werc
  at neutml pH in vitro. 'Ilus assay measures b&nding &n free            expressed usus transient tronsfowt&on &n HIJK293T coils and
  solution at neutml pH.                                                 secreted into the cell media. 'I he mutant proteins were puri-
                                                                         licd v ith thc high-throughput AKTA Xprcss system ((iF,
                              I')&ample 4                             <U+201E>- llealthcare) by        Ni'nd    size-exclusion chromatography
                                                                         steps, using conditions similar to those described earlier Pro-
        J.'p&tope Mapping/Binding of Ant&bodies using the                teu& concentrations were detenmned usu&g the LabClup
         Crystal Structure of the LI I,3   P('SK9   Complex,             instrument (Bio-Rad). The PCSK9-blocking murine antibod-
                       Biacore, and Mutagenes&s                          ies 4A5, 7D4. 5A10 and fiF6 uvre expressed with transient
                                                                      10 transfect&on &n IIL&K2931 cells and purilied &Pith 0 pn&te&n (1
     a Crystal structure ol the 1.11,3.P('SK9 complex. The res&-         column eluted w&th 0.1 M (ilycine buffer at pH 2.8 and
  dues were &dent&fied by calculatu&g the difference &n acces-           neutralized into 1.0 M Tns at pl I 9.0.
  sible surl'ace arcs bctwccn tlm1,113:P('SK9 crystal stnicturc             e. The reg&ons of PCSK9 that are contacted by monoclonal
  and PCSK9 structure alone. PCSK9 res&dues that shov. buned             antibodies 5 A 10 and 7D4 (preparation describe&I later herein)
  surface area upon complex fonuation v,ith I,IL3 antibody ;; were determined by proteus tomography (Sidec A B, Stock-
  Wore u&Cluded as apart GI'thi: Lpilopc Thc solvent accessible          holm. Sweden). The loops at positions 186-200, 371-379,
  surface of a proteu& he as de lined as the locus ol the centre of a     176-181, 278-283. 449-45'3. 402-406. and 236-245 of P('SK9
  probe sphere (representing a solvmu molecule of I 4 A                  were   prox&mal to uuino ac&d residues of the ant&body. The
  radius) as it rolls over the%ender W<U+00BB>RJS surlhccof the protein         sequm&ces corresponding to tlm loops arc shown in Table 5,
  fhe solvent accessible surface area was calculated by gener-           and in a prcferrcd embodi men&<U+201E> the antagonis(h ol'he inven-
  ating surface poif&ts on an cxtcndc&J sphcrc about each R&onl          txul bind to one or more of these sequences in PS('K9.
  (at a distance from the atom centre equal to the s&uu of the
  atom and probe radii), and eliminating those that lie witlfin                                      TABLE 5
  cquivalcnt sphorcs associand with neighboring atoms as
                                                                               PCSK9 Loop"       Sequence                SEQ ID <U+00BB>0
  unplemented &n proc+'an& ARBAIMOL (Bnggs, P..i., 2000,
  C(.:P4 Newsletter No. 38, C('I.R('. Daresbury).                                186-200         DTSIQSDHREIEGRV
     The result of the crystal structure analys&s are shown &n
                                                                                 236-245         GPDAGVAKGA
  FICi. 23. I'JO. 23A shou s the crystal structure of the PCSK9
  (light gray surface ILT&reseutafion) bound io the 111,3 mlti-                  371-379         rssDcsTcp
  body (black cartoon representat&on). The epitope for L 1L3 0
  binding to PCSK9 involves residues 1 &3-155, 194, 197, 237-                    176-181         GGSLVE
  239. 367, 369, 374e&79 and 381 of thc P('SK9 amino acid                            278-283        QPVGPL
  sequence (SLQ ID NO:53). By companson, the epitope for
  the I DI.R HOF domain binding to P('SK9 involves residues                          449-453        HGAGI&
   15:)-1<U+00AB>, 194, 238, 367, 369, 372, 374-375, and 377-381
                                                                                     402-406        REPEL
  (Khvon et al.. 2008, PNAS 10&: 1820-1825).
     b (iroup antib&alice and epitopcs based mi competition in
  P('SK9 buuling. I'ull-length Jg(is were unine-coupled to a                     f. Biacore bu&du&g of the nu&tents to &mmobihzed I,DI R.
  CM5 sensorchip(three per chip at about 7000RU final), using                 Recombinant LDLR extracellular domain protein was immo-
  a standard FDC/NHS-mcd&etc&I aminc-coupling chemistry                  R&   bili/cd onto 0 Biacore SA chip Fach nnitant protein uas
  One flow cell uas left umnodified to pmvide a reference                     inlected to the Biacore-3000 M) in duplicates at 25 mM to
  channel Htunm&-P(.'SK9 (J00 nM) &has premixed with an                       0.012 mM at five concontmtions (from I' . v, ith a running
  array of IgGs (final 500 RM) and these complexes were                       bufl'er of 50 mM Tns pil 7.5, 2 mM CaCls. 200 mM NaCJ,
  injected over the clup using I min injections at 10 PL/min.                 0 02A01 20 and I tng/ml BS 3 All the results fit nicel)'o 0 I: I
  Antibodies that bind to competing cpitope& will block the                   binding kinetics model As expected, nuitation at residues in
  b&nding of PCSK9 to the antibody inunob&lized on the chip.                  direct contact with the L&(ilAA domau& (I'379A. R194A,
  Alternatively. a c la as icn I sandhv ich approach was used by tirst        1369M 'I'377R. 0238R) significantly weakens (by 10-100
                                                                  US 8,080,243 B2
                                    51
fold) 1.171 R binding Moreover, tinea nnirants not in contact                                               Fxaf<U+00AB>'pic 7
with E(IF-A fR199A, R218A, K222A) showed weaker bind-
in 85-15 fold). Tins new finding suggests that they are                                 PCSK9-Specific Antibodies as PCSK9 A<U+00BB>taco<U+00BB>tats
involved in hindu&8 other donuiins ol' DI,R Overall, Iheae
experiments vahdatc thc mtcgrity and activity ol'thc mutants                    I      Identification of P('SK9-Specific Antagonist Antibodies
for subsequent epitope mapping experiments.                                     a. Identification of PCSK9-Blocking Antibodies
   g. Buiding oi the mutants to immobilized 4A5, 7D4<U+201E>5A10                          Murine antibodies to human and/or mouse PCSK9 were
and 6F6 uiubodies Biotuiylated uit&-PCSK9 antibodies                            generated by uumumzing mice with 1<U+00BB>uuan-PCSK9 and
were immobilized on SA chips using standard methods                             niousc-PCSK9 synthetic pcptidcs as prepared in I'xaniple 6
                                                                           1<U+00BB>
Mutant buiding experiments &vere perfonued using Biacore                        or recombinant proteins. and screening antibodies by ELISA
3000 at 25'.    with a running buffer of 50 mM Tn s-I ICI pl I                  assay usinug human and'or mouse PCSK9 recombinant pro-
7 5, 1&0 mM Na('I and 0.02'A P20 Mutm<U+00BB>s were tested at                          tein us Ilm untigens as de&cubed in Fxmnple I mid other
333 nlVI or 111 nM concentmtions in duplicates, with the ones                   standard hybridoma procedures. Over 500 positive clones
giving weakened hindi<U+00BB>su compared to the wild-type as the                       '&9&fe oh&ainu&I and allowed to gros& to confiuency in 6 well
residues uivolved ui nugb binding /listed belov,).                              plates with 10 ml media. Media supernatant were collected
                                                                                and ton&1 IgG& in tlm conditioned media were purified using
                                                                                n&Ab Selccct (Pierce) The ability ofpurifmd and concentrated
                                                                                mouse ig(is to inhibit nuiuse and human PCSK93 function was
mwd         <U+00BB>u&dw   Res&duce   u&   Dcs eudu&e 0&dc&   I Mu&.ua I:ircc&s
                                                                            6   tested in lluh7 cells using the methods descubed in Iixample
4e<U+00AB>,        RZ17 F379;6&7 R&94 RI99        D 364                                1. Hybridoma clones expressing Ig(is that she&cad some
6.3&u       R&94, <U+00BB>337, 1369 D'9&, RI 99
                                                                                degrees of blocking v ere expanded and retested. 60 promis-
696         IL&37, a&94, F379 D336. 1369. I" 77. x&99
 134        IL'I.R&94, F379 1369. R&99                                          uig clones were subcloned. expanded, and injected into either
                                                                                Balb/c or nude nuce to produce sac&tea. Antibodies puniied
                                                                                thorn dsmtes fiuid werc rctestcd for their ability to inhibit thc
                                                                                do&un rcuulation of I DI,R by human or mouso PCSK9 in
                           Example         &
                                                                                Huh7 cells. I&our hybridoma clones. 4A5, &A10. 6F6, and
                                                                                7D4. were identified as being able to completely inlub&t
           Cloning and Sequencing of Antibodies
                                                                                lnunan PCSK9 I'unction, and at least partially udiibit mouse
                                                                           "o
                                                                                PCSK9 function. To determiiw IC39 of each of tlmse b loci ing
   One million hybridoma cells were hmnogcnircd usia tbu
                                                                                untibodies, a senal dilution of lg(is i&ere used in the assay.
QIAshrcddcr spin columns uml total RNA was cxtractcd
                                                                                stamng from 100 ugml to 3.125 ug/ml, with human and
according to RNAeasy Micro kit from QIA(JL'N. cDNA was
                                                                                mouse P('SK9 c&mc&.ntration being comstant at 6 pg&ml
synthesized using SuperScript III RT lot from Invitrogen.
                                                                                b. Effect of PCSK9 Antagonists on P('SK9-LDLR Binding
Mauable ruegions from the PCSK9 antibodies were cloned
                                                                                   PCSK9 has been sluiwn to be co-localized with LDLR in
using the mouse Ig(i-Primer Sets froni Novagen. which con-
                                                                                cellular compartments fl agdce et al.. 2006, .I ('lui lnv, 116
sist of degenerate pruners for clonin mouse igC& heavy chain
                                                                                (11):2995-3005 Recombinant P(.SK9 protein also binds ro
genes and the mouse kappa or lambda hght chains. PCR
       ('or
                                                                                I.DI R extrnccllular domain in vitm (Fislmr ct el., 2007, JBC,
cycluig conditions werc the liilkrwuigs I cycle ai 92 ('ior 2
                        ('or                                                    282/28):20502-12. To determine the relationslup betv,een
min: two cycles at 94           30 sec. 44 (.'or 30 sec mid 72             46
                                                                                inlubiiimi of P('SK9 mcuirdted do&un-regulation of I,DI.R nnd
     2 min: two cycles at 94 C for 30 sec. 46 C for 30 sec and
                                                                                inlubiti&m of P('SK9-I,DI R bindmg by mitibodies, we tested
72 C for 2 min: two cycles at 94 C lor 30 sec, 48 C for 30 sec
                                                                                the P(.'SK9 antibodies tliat partially or completely blocked
and 72 (. for 2 ni in, tw o cycles ai 94 (.'or 30 scc. 50 C fir 30
                                                                                PCSK9 function on I,I)I R and representative& of antibodies
secand72( for2min;twocyclcsat94C for30scc,52( for
                                                                                that do not block. All partial antagonistic antibodies also
30 sec and 72 C for 2 min; follo&ved by 35 cycles at 9)4 C fbr
                                                                                partially inhibited LDI,R extmcellular domain binding to
30 sec. 54 C for 30 sec uid 72 C for 45 scc. The resulung PCR                   PCSK9. except one. Antagonisuc antibodies that can com-
producw& were cloned into Topo-TA clem ng veck&r I'rom lnvit-
                                                                                pletely block PCSK9 function, namely 4A5, 5A10, 6i&6 and
rogen and sequenced. Jhe clo&&cxl antibody sequences were                       7D4 also completely inhibited LDLR cxtmcellular domam
coniimied by <U+00B9>ennuial sequencin of the tirst 10 anuno                       u   buidin to PCSK9 /fable 5). 1050 values of these four wit&-
acids of the onginal antibodies pmduced from ascites.                           bodies correlates with their binding affinity ui PCSK9.
                                                                                c. Fpitope Dctenuination of the Blockuig Antibodies
                           I',xample 6                                             FI(i. 4 illustrates the epitope bi<U+00BB>ning of anti-PCSK9 anti-
                                                                                bodies. Part A) shows cpitopc infornmtion ol'nti-P('SK9
          C&cneration   of Aniigcns       Iior   Immunization               3   mAbs, deternuned by binduig to synthetic 13-18-mer pep-
                                                                                tides or epitopc binding via Biacore Part B) shows the ability
   Recombinant human I'CSK9 protein was pmduced as                              of immobilized antibodies 6F6, 5A10 and 4A5 to bind to
reported (.unningham ei al., 2007. Net Struct Mo I Biol, 14(5).                 human PCSK9 premixed with the mAbs mdicated on the y
413-9. To produce recombinant mouse PCSK9 protein, the                          axis by Biacore assay
cDNA of mouse P('SK9 was clone&I into mammalian expres-                    Mi      Another monoclmufi miti-P('SK9 mitibody, tcrnwd 6Ci7,
sion vector PRK& with the addition of a 6-His tag at the                        binds to recombinant nuiuse I'CSK9 but not human PCSK9.
( -temiinus by methods knov;n in the art. transiently trans-                    Scuo Table t&. 6(i7, 4A5. &A10, 61'Ii, and 7D4 mutually exclude
fected and expressed in IIBK293 cells. Recombinant pmtein                       each other's buiding to mouse PCSK9. Chimem analysis
was purified from conditioned media using a Ni colunm.                          benveen mouse and human PCSK9 reveals that 6(17 binding
   Surface peptides of human and mouse P( SK9 were                              to P('SK9 require& the catalytic domain. Scc Table 6. Thus the
selected based on PCSK9 protein structure, and synthesized                      binding sites of 4A5, 5A10, 6F6, und 7D4 overlup the cata-
by Elim Biopharmaceuticals.                                                     lytic site and/or the epitope bound by 6(17.
                                                                           US 8,080,243 B2
                                          53
                                     TABLLI 6                                              Anti-P('SK 91g(is 4A5, 5 A 10 and 6 F6 were am inc coupled
                                                                                       to the Biacore chip. hl'(.'SK9 f100 nM) was mixed with 500
     Recoiilbmslii pi'oieili                                     607 t iimiix          nM of 4A5, 5A10, 6F6 or 7D4 in vanous ratios and ut)ected
     Hunt:ui Pt:5K9                                              ho                    Iior I min at 10 pl'min The fmu anubodimv nuitually blocked
     Hunmn pm 4 ffufffm estab ti 4 inousc C-temi                 ho                    one another irrespective of the Rvmiy oriemation tested. sug-
     liurncn um 4 mouse catalvtic 4 mouse C-term                 1'cs
     Is(oint pro + )fllfnm t ilill ifii + liiiiiiilii I ft'i'iii
                                                                                       gesting that they all bind to competing epitopes. In contrast,
                                                                 So
     Ivlouse Pro+ inonse estab trc + hutnsn C tenn               Yes                   they are able to form sandwich complexes tvith other non-
     tv(mise PCSK9                                                'es                  fully-bloclung antibodies that were mapped to specific
                                                                                       regions using syntlmtic pcptides.
                                                                                    )0
d. Deternuning Sequences Species Specificity of Anti-                                  2. Effect of PCSK9 Specific Antibodies as PCSK9 Antagonist
P('SK9 Antibodies                                                                      lll Mlvo
   To determine the species sperilicity of the anti-PCSK9                              a. PCSK9AE(agonis(Antibodiesl owcrSemmC'holevterolin
antibodies. antibodies were incubated with plasnta from dif-                           Mice
I'crcnt species and the result mt complexes were purified and                              To determine if PCSKQ) antagonist monoclonal antibodies
probed by an independent anti PCSK9 anubody on Western                                 can all act cholesterol levels ut vivo by inhibit utg the l unction
blots. The mltibodies 4 tt5, 5A10, 6F(i, mtd 7D4 recognized                            of extmcellular P('SK9, the effect of 7D4 tvas tested against
hummt. cynmnolgus monkey. ntouse. Snd rat PCSK9. See                                   mouse PCSK9 ut vitro. on serum cholesterol tvhen inlcc(ed
FI( L 5. Antibody 6(17 recogiu zed only murine PCS K9 and an                           ulto mice. 6 to 7 week old male C57/bl6 nuce were kept on a
unrelated control antibody 42H7 did not recognize any tostcd                            12 hr light/dnrk cycle, blcdl to colltmt approximately 70 pl
P('SK9. Id.                                                                            serum ou day -7 Antagonist PCSK9 anubody 7D4, nnd 0
e. Determining Stxfttences of Antagonist P(.'SK9 Antibodies                            control isotype matching monoclonal antibody were injected
   Tfm mnino acid stx)ucnccs of the variable douuiins of                               into mule 7 wcck old ('57/bl6 mice via i p injections on days
P('SK9 antibodies 4A5. 5A10, 61'6. and 7D4 were deter-                                 0, l. 2, and 5 Mice v,ere saculiced on day 4 without fasting,
mined using the method described in I',xample 5. The <U+201E>, and senun samples were collected. All frozen sentm samples
scqucncca indicate that the mtt if udice are related but different                     werc vun( to IDFXX laboratoues for totnl cholesterol, Irig-
from each other. Table I shows the amino acid sequences of                             lyceride, HDL clxllesterol and LDL cholesterol measure-
the variable regions of each antibody Table 7 shows thc CI&K                           ments. FI(i. 6 shou s Chat 7194 lowered serum cholf Sterol by
sequences of the 11 ht chains und heavy chuuts of Table I as                           4S%r v.bile the contml antibody did not have any sigmlicant
identified by the Kabat and Dhotis methods.                                            affect. Both the amount and percentage of reduction are simi-
                                                     TABLE 7
      SlocXtng      PCSK9      Antlbodlen and Anttgen-binding                   CDR  Sequence:
             according        t.o    rabat iundetlfnedl and chotia (bold)
        VL CDRZ                                VL CDR2                            VL CDR3
4A5     RASQNVGTNVA                            SASYRYS                            QQFYSYFYT
         (SEQ ID NQ. 27)                        (SEQ ID NQ       28l              (SEQ ID NO      29l
5AIQ    K~AS  DVSTAVA                          SASYRYT                            QQRYSTPRT
         (SEQ ID No         30)                 (SEQ ID No        12)             (SEQ ID No      31)
6P6     SASizGISNYLN                           YTSSLHS                            ~YSKLPPT
         (SEQ ID No         32i                 (SEQ ZD No. 33)                   (SEQ ID IIO     55)
7D4     K~AS  DVSNALA                          aASYRYT                            QQRYSTFWT
         (SEQ ID    110     34l                 ISEQ ID Nor 12)                   !SEQ ID No      35)
LZL3 RASQGISSALA                               SASYRYT                            QQRYSLWRT
         (SEQ ID No         ill                 (SEQ ID No        12)             (SEQ ID NO      13)
        VH CDRZ                                VH CDR2                            VH CDR3
4A5     GYTFTDYYNN                                                                WLLPAY
         (SEQ ID Non                            (SEQ ZD No          38  and 39)   iSEQ   ZD  No   40)
        56(vhole),       36 and 37i
5AIQ GYTPTSYWNH                                 E IMP SNGRT NINE KF KS            ERPLYANDY
         (SEQ ID Nos                            (SEQ ID NQ. 43         and 44)    (SEQ ID NQ      45)
        57(Whole), 41 and 42l
6F6     GYTPTDYPHtl                                                               GGIYYRYDRNYPDY
         (SEQ ID Nos                            (SEQ ZD No        38 and 4        (SEQ ID IIO     47)
        56(vholet,       36 and 37)
7D4     GFTPSOYYI'IA                           IIINYDGSNTSYLDSLKS                 SKFAIiNOY
         (SEQ ID    uos                         (SEQ ID NO          50 and 51)    (SEQ ID No      52)
        50(vholel,       48 and 49l
LIL3 GYTPTSYYIIH                                E I SP PGGRTNYNE KF KS            ERPLYASDL
        SEQ ZD No                               (SEQ ZD NO. 9         ard  61)    iSEQ   ZD  Iio  10)
        59(whole), 60, and               8
                                                           US 8,080,243 B2
                                 55
lnr to what was reported for P( SK9-!- mice (PC'SK9) knock-                FI(i. 11 illustrates tlmt anti-PC'SK9) mitagonist antibodies
out mice). suggesting that one can actueve complete or near             4A5 and 61'ti lower cholesterol levels in mice in a dose-
complete inhibition of I'C'SK9 fiuiction tluough blocking               dependent fashion. Eight week old C57'b16 mice(n 8/group)
extracellular PCS K 9 only. and that intrace it u lar PCS K 9 p lays    were administered &bc indicated doses ol';m&ibodies or saline
little or no role ui down-regulating LDLR under normal s on uay 0 by i.p bolus injcciion Scnmi samples &vere col-
physiological conditions. As expected. liver LDLR levels                lected and tested for cholesterol le~ala on day 7. In FIC). I I A,
were uiduced ui mimals treated uith 7D4 compared to tlxise              the mttibody 4A5 showed a raduated decrease in total serum
treated with a control antibody (FIG. 6).                               cholesterol withincreasingdoseol'antibody In I'ICi. IIB, the
b A P utially Blocking Antibody lied No FITiut on Blood
                                                                        antibody 6F6 shinned decrcasc in toml serum cholesterol at 10
Cholesterol Levels                                                   &a
                                                                        mg/kg/day.
    FI(i. 7 illustrates tlmt a partial antagonist polyclonal anti-
                                                                           Anti-PCSK9 antagonist antibodies 4A5. 5A10, 6116 and
PC'SK9 mAb C'RN6 docs not alTect cholesterol Icvcls in mice
                                                                        7D4 increase liver I.DI,R levels in mice as I'ound by Western
Tuo groups of S week old C57/b16 mice (n 10 ance/youp)
were blixl mid tcstixi for cholesterol levels on day -7, dosed          blot analysis. See FICi. 12. For 4A5, 5A10 and 6F6. 8 week
with 15 nty&kg/day ol'CRN6 or a comtrol antibody by &.v.                old C57&b16 mice were administercxt with 10 ms+8 of anti-
acbninistration on days 0, l. 2 and 3: and then bled and tested         bodies or saline on day 0 by i.v, bolus us)ection. animals were
for cholesterol levels 24 Iux after the tinal dose. FIG 7A              sacrihccd on day 7, and whole liver lysate of 3 individual
shows that CRN6 an1ibody partially blocks PCS K9 inc din&cd             aninud s uvre analyzcxt fit r I DI.R and (IAPDH pm tain levels
dovvn regulation of LI&LR in Huh7 cells in vitro. I'l(r 7B              by Western. I!or 7D4. 8 week old B16/c57 nuce were admin-
shoes that administration of C'RNti antibody does not alTi.ct         o istered u 1&h 10 m !kg of antibodies on days 0. I, 2, and 3 vu&
serum cholesterol levels in mice.                                       i p bolus injection, animals were sncrificed on day 4. and
c. Prolonged I.ffect on Senun ('holesterol by Antagonist                whole liver lysate of 3 individual mr&mals were mialyzcxl tiir
PCSK9 mAb ui Mice.                                                      LDLR and CiAPDI I proteui levels by Westeni blot. All miti-
    A time course study was performed to determine the time             body-treated nuce showed lu h levels of LDLR as compared
of onset and duration of thc cholesterol lovmring effect of          " to tile I BS c&1&ltl'ol alice.
PCSK9 ants omst antibodies in mice. IvLAb 7D4 or salute                    FICi. 13 illustrates that miti-PCSK9 antagonist antibody
control &vere each injected i.v. at 10 ms&kg or 3 mV1 g iu 48           has no effect in the LDLR-!- mouse, L'1 ht week old
6-week-old C57/bl6 mice Eight mice froiu each treatment                 [,DI.R-/- mice (I,DI R KO mice) were administered 10
  roup were sacrificed on days I, 2, 4. 7. 14 und 21 after              mg/kg 4A5 or sahne on day 0 by &.p. bolus in) ecuon. Serum
injection. A single injection of 704 producod a fast and pro-        so smnples (from n 9-10 nuce) were collected mid tested for
lmi ed lov cong etTect on senun cholesterol. A 25% reduc-               cholesterol le&mls mi day 7. Administration ol'he antibody
tion in senuu cholesterol vias seen at 24 lus after injection.          did not appreciably alter the levels of total serum cholesterol<U+201E>
Scc FICi. 8 Maximum drop of serum cholesterol uas                       HI&L, or LI&I ..
observed at the 7 day tune point. At 21 days. the reduction in             FICi. 14 illustrates that multiple treaunen(s of anti-PC'SK9
cholesterol is no longer statistically significant. Pau B) shows     "<U+00BB>
                                                                        antagoiust aimbodies ui nues can substantially decrease total
HDI choh:sterol I.DI, cholesterol levels were very low                  serum cholesteml. I',ight u eek old ('57/blfi mice were admin-
    FIG. 9 illusimtes that the anti-PCSK9 ants omst mAb 7D4             is&eredt the indicated doses ol'antibodies or PBS on days 0, 7.
dose dcpcndcntly reduces scn&m total cholesterol, HDI.. and             14 and 21 by i.v. bolus injection. Serum samples (n<U+2014> 5-11
LDI. in mice Six groups ol'8 week old C'57!bl6 mice (n 8/               niicc) uvre collected and tcstcd for cholesterol levels on dny
group) werebledandtestedforbatmlcholesteroHevelsonday                so 28.
-7 and administered with the indicat cat doses of antibodies or
saline on days 0, l. 2, and 3 by i. p. bolus in)ection. Senun                                         L'xampfe S
samples were collected and tested for cho les tern l levels 24 lus
atlcr tlm Inst dose FICi. 9A shows total cholesterol levels.                PCSK9Antagonist Antibodies lower Serum I,DI. in
wluch decreased to less tlmn 60'!!o of control after administra-     s.                        Non-luunan Primates
tion of 3 to 30 m Jokg/chsy. The maximal effect on total cho-
lesteml was seen at 10 mg'kg, and statist&cally signdicant                 To test the in vivo eIIect of antibodies to PCSK9. annbody
reduction at I nioo/kg. Iihi. 9B shows HDL levels, uluch                7D4 was tested in cynomolgus monkeys. I'our 3-4 year old
dix:reused &o less &lain 70'fio al'ter &dian&latm&ion el' ui 30         cynomo l gus ni on key is ere injected u it h vehicle (PB8 s0 01%o
mg!kg/day. FIG. 9C shows LDL levels, wluch decreased to               u Tu een 20) on day 0, and 10 my kg 7D4 on day 7. Plasma lipid
nearly zero at all tested doses of 0.3 my&'kg/day and above.            profiles were analyzed on days 0. 2, 7, 9, 11, 14. 21 and 28
d Dose Response of Antagonist Antibodies Spccilic to                    folkming overnight fastin . A single injection of 10 mg/kg
PCSK9 ut Mice                                                           7D4 Produced a drmnatic reduction in Plasma LDL (60'!!o)
    FRi 10 illustrates that anti-PCSK9 mitagonist antibody              (FI(i 15A) and I,DI paiticle numbers (FI(i. 15D) in all 4
5A10 dose dependently lowers cholesterol levels in nues               1 aiumals, wlufe having muiimal sfl'ect on their HDI levels
FIC). 10A shows six groups of 8 vveek old ('57/bl(i mice                (FIG. 15B) and HDI, particle numbers (Fl(i. 15E). Iiital
   <U+2014>
(n 8/group) to which werc administimcd the indicated doses              cholcstcrol (FICi 15C:) &vas also rcdiucmd following 7D4 treat-
of antibodies or salute daily ou days 0. I, 2, and 3 by 1 v. bolus      ment. wlule tngfyceride level (PIC& 151') was uot signifi-
injection. Senim samples were collected and tested for cho-             cantly affected. Total 7D4 ((I), and total PCSK9) levels (H)
lesterol levels 24 hrs after the last dose and shov,ed a gradu-      ai were also measured.
ated decrease with increasing dose of antibody. PIC&. 10B                  PIC&. 16 illustrates the dose-response of miti-PCSK9 anti-
shovvs five groups of 8 week old ( 57/b16 mice (n=g!y&mp) to            body 7D4 on serum cholesterol levels in the cynomolous
wluch were administered the uidicated doses of antibodies or            monkey. Two male and two female cynomolgus monkeys 3-5
saline on day 0 by i. p. bolus injection. Senun samples were            yearn of age in each group st ere given the indicated dose of
collected mid tcstcd fiir cholesmrol levels on day 7 and also        ( 7D4 on day 7 and an equal volume of saline on oay 0 by i v.
showed a graduated decrease with increasing doses of anti-              bolus uiiecuon. Plasma samples were taken at indicated tune
body                                                                    points and plasma LDL levels v;ere measured.
                                                          US 8,080,243 B2
                                 57
    I'if) 17 illustrates a con&parison of anti-PCSK9 nntibodies        week old 057/b16 &nice w ere do seal with 10 n&g/kg I. I I 3 or m&
4A<U+00AB>, A10. 6F6 and 7D4 (&n scnun clx)lc&terol levels in thc             equal volume of aalu&e by i. p, iniect&on on day 0, Serum
cynomolgu& monkey Tvvo male and two female cynomolgus
                                                                       smnples werc 00&llcctcd and nssayed for cholesterol levels on
monkeys 3-6 years of age in each gn&up werc gii cn I mg/kg
of the indicated antibody on day 0 by i.v bolus i<U+00BB>)ection              days 2. 4 and 7. LIL3 decreased total serum cholesterol by
                                                                   6
Plasnui 6 unplcs narc taken at indicated tnne points, plasma           about 40% at days 2 and 4 In another study, when 10 mg/kg
IiDI. levels wcm measured and noi&haling to tlmt on day -2             of1,113 was affininistered as a single intrapcritonenl (IP) dose
    FICi 18 illustmtes thc eifect ol'nti-PC'SK9 nntngonist             to I 57BI /6 mice feed a normal dict (n=10), scn&m cholesterol
antibody 7D4 nn plasma cholesrerol levels of cynomolgus                levels v ere reduced by 47%0 compared to safu&e treated con-
monkeys fed a 33 4% kcnl Iat dict suppicn&en&vedi w&th 0.1%
                                                                   n&  trois. 4 days post treatment. When LIL3 was a(hnuustered as
cholesterol. Six 3-5 yenr old cynonu&lgus monkeys (vere put
on high-Iht dict I'or 16 wacke Three monkeys werc tres)cd              a s&ogle IP dose at 0<U+201E>0.1, 1<U+201E>10 and 80 mg('kg (n 6/youp) u&
with 10 mg/kg 7D4 and three with saline on thc indicated               a dose-response experiment in male Spra gue-Daw ley rats fed
date I.DI levels of individunl moid(eys were measured and              a normal diet, serum cholesterol levels were dose-depen-
nonnahzed to tlmt of the treatment day.                                dently reduccxI. n ith nmximum effect of 50% seen at 10 and
                              Fxan&pie 9                               80 mg/kg. 48 hours post dosinc. The dumtion of the choles-
                                                                       terol repression vms also dose dependent, rm&gu&g fron& I tn
                 Humanized Anti-PC'SK9 Antibody                        21 days
                                                                          The un&no acid sequence of 1,11.3 fully hu&dani red hea(y
    11&e  murine monoclonal antibody 5A10 was humanized                chain (SL'Q ID NO'15) is shown in Table 8. 'H&e sequence of
'itld affinity matured to provide the I 113 antibody LI I 3 has        the variable region is underlined (SFQ ID NO. 54).
                                                                                       TABLE     B
                                                ~v&v s ae    ~vkk   asv&v   scka~cf(tft   ~sheer       a ~&evm     e ~&s f   rtn       60
                                                nekfksrvtv,  trdtststvy melsslrsed        (tea&a(carer ~1 asdlv      gttvtvssas      120
                                                 tkgps(fpla pcsrstsest aalgclvkdy         fpep  (tvsvn sgaltsgvht fpavlqasgl 100
                                                y 1 svvtvp      nfgtqtyt cnvdhkp nt kvdktverkc cvecppcpap pvagpsvflf                 260
                                                pp)pkdtlmi srtpevtcvv vdvshedpev qfn(yvdgve vhnakt)pre eqfn tfrvv 30o
                                                 svltvvhqdv lngkeykckv snkglpss&e kt&.sktkgqp repq(yt&pp sreemtknqv 360
                                                 a&tel(kgfy psd&aveses ngqpennykt. tppmldsdgs fflyskltvd ksrwqqgn(f 620
                                                 rcsvmhealh nhytqksl     1  spgk
an affi&uty for munne PCSK9 of 200 pM and an affin&ty for                 The am&no ac&d sequence of LIL3 fi&lly humanized light
hummi PCSK9 ol'100 pM when mmisured by Biacorc 1.113                   chain (SFQ ID N(yl4) is six)wn in Table 9 Thc variable
completely u&h&b&ts the PCSK9-med&ated down reyilat&on of              reyon &s underl&ned (SBQ ID NO: 53).
                                                                                       TABLE 9
                                                ~di   t s    I asvcidtvt ~xtcza-       i- ~ala&.    i:   ~ka  alii . ~a. r t      .    60
                                                ~rfs  0 s td ~ftft&ssl      ~edict   c    ~rs&vrtf       gtkle&krtv aapsvf&fpp       120
                                                 sdeqlksgta svvcllnnfy preakvqvkv dnalq gnsq esvteqdskd              styslsstlt lsc
                                                 1  kadyekhk (yacevthqg     lsspvtksfn rgec                                          216
LDLR &n cultured Huh7 cells when incubated w&th 100 nM                    11O. ZZ shows the effect of mtravenous admimstmtion of
luunan or murine PCSK9 ant&body. See FIO. 19.                          an effect&ve dose (3 n&cc/kg) of antibody 5A10 (solid circles)
    I'ICi. 20 illustrates the dose-response of I I L3, mouse pre-      or m&tibody L I IB (solid sqimres) to each ol'our cynonuil us
musor 5A10. and ncSative control mti body 42117 to block the        6  monkeys at day zero. 'I he change in senm& HDI (FICI. 22A)
bindins of recnmbinant biotinylated human P(.'SK9 and                  and senun LDI. (VI(i. ZZB) was n&easurcxI from -2 to +28
mouse PCSK9 to inm&ob&iized recombinant LDLR extracel-                 days Both antibodies resulted in greater than about 70%0
lular domain in v&tro. I'ICI. 20A shows ln&man PCSK9 b&nd&ng           decrease in sen&m I,DL levels by about seven days, an effect
                                                                       that substantially persistcxI for about six more days in the
to human I,DI.R extracellular domain at pH 7 5 FICI 20B
                                                                  u&   animals admmistcred I,H 3 All thc animal& slmwed nom&nl
shows human PCSK9 binding to Imnmn LDLR extmcellular
                                                                       1&ver and kidney function and near-normal hematocrits.
domain at pl I 53. 1&ICi. ZU('hou s mouse P(:SK9 binding to
                                                                          I,H 3 dose dependently rcduccd I DI.-CL with a max innun
hum m I,DI,R extracellular domau& at pH 7.5. I'ICL 20D                 effiect observed &othe mg/k group. wh&ch mau&tained a 70%0
shows uu&use PC SK9 lund&ng to hiuntu& I,DI,R extracellular            reduction u& LDL-I'evels uun I day 21 post-dosing. and fully
dona&in at pH 5 3.                                                     recovered by day 31. HDIc('evels werc not affcected by
    I'IO. 21 shows the effect on serum cholesterol of treatment        L I L3 treaunent in all dose groups. The aiumals u& the 3 mg'kg
with 10 mg/kg LIL3 in mice. Two groups (n <U+2014> 8/group) of 8              dose youp (n <U+2014> 4) were also given nvo add&tional IM doses nf
                                                         US 8,080,243 B2
                                 59                                                                    60
3 mg/ko I 11 3   on study days 42 mid 56 (2 wucks npart). These     post treatment, and gradually recovered in 2.5 to 3 wrecks
nvo additional doses again lowered LDL-C mid maintauied             while not afi'ectmg IIDL-C levels. Upon switclun the ani-
LDL-('evels belovi 50% for 4 weeks. LDL-('evels remnied             mals to daily administration of 50 mg/kg Zocotot (simvasta-
to normnl two weeks later Senmi HDI.-C lcvcls remained              tin), their I DI,-(. Icvcls reach' maximal reduction of 43%
unchanged tlmiupout the study.                                   I at day 5, and stabilized thereafter. After 3 weeks of 50 mg/kgi
   'lite efficacy of LI L3 in non-human primates with hyper-        day! ocor(tt administration, these miima Is were treated with a
clxilesterolemia and pluimiacodynanuc interactions between          suigle dose ol 3 mg~kg I,11.3 ii bile still receiving 50 mg/kg/
L I L3 and I IMO-CoA reductase inhibituioo s tati ns were inves-    day Zocorg, Administration of LIL3 resulted in another
tigated Priortothcinitiationofihcstudy,thcl,DI.-C'Iuvclsol'         additional 65% rahictimi m I DIe(., ui addition ui the 43%
  cohort of cynomolgus monkeys (n 12) were elevated to an i(i reduction by Zocorg. by day 5. and returned to pre-dosin
average of 120 nig/dL. compared to the normal average levels        levels within 2 ii eeks.
ol 50 mg/dl<U+201E>by fcehng with a dict contaiimi 35%o I'at                  Other CDR amino acid substitutions welf.''iilr'. 113 5A10 in
(wtiwt) and 600 ppm cholesterol lor over I g months. Surpris-       thr coUise iif lliiillailiEtititlil tiild afiinity maturation and to
ingly, no effect was observed on senun total cholesterol or         achieve particulnr properties. The sequences of tlm moditied
I.DI -C'levels afier the daily admutist ration ol'a medium-dose     CDRs and the PCSKQ buiding abiliucs ol'he nntibodies
(10 myo'animal) of Crestorag (msuvastatin calcium) for 6            containing these modifiixt ('DRs are listed in Fq(IS. 24 A-Ci.
weeks, and after a subsequent dnily administcition ofhigh-          Tlm numbers following each sequence in FICIS. 24 A-(i rep-
dose (20 mg,'k ) for 2 weeks A single administration of 3           resent the SRQ ID NO for that sequence.
mgil 0 I,I L3 with Crestorii'r vehicle treatment for 2 weeks.          fhe disclosures of ail references cited herein are hereby
olfivtivcly lowered scntm [,DI.-C 1st'i.ls by 56i'o bv dny 5        incotporatuxf by rcfi:rcncc herein
                                            SEQUEtiCE LISTING
      160   NUNBER OP SEQ ID NOS        167
      210   SEQ ID No I
      211   LENGTH     15
      212   TYPE PRT
    a213    ORGPNISH Homo        aPren
      400   SEQUENCE      I
   asp Thr Ser     Ile    Gln Ser asp His Erg Glu     Ile Glu Gly Rrg Val
    I                     5                       10                    15
      210   SEQ ID No 2
      211   LENGTH     10
      212   TYPE PRT
      213   ORGIUIISii Homo     sapiens
      400   SEQUEIICE     2
   Gly arg asp     ala    Gly Val Rla Lys Gly    ala
                          5                       10
      210   SEQ ID No
      211   IENGTH 0
      212   TYPE PRT
      213   ORGmiISN      Homo  saprens
      400   SEQUENCE      3
   ala Ser Ser ifsp       Cys  Ser Thr Cys Phe
    I                     5
      210   SEQ ID NO
      211   LENGTH 6
      212   TYPE PRT
      213   ORGSIIISii    Homo   apreno
      400   SEQUENCE      4
   Gly Gly Ser Leu Val Glu
    I
      210   SEQ ID No
      211   LEIIGTH 6
      212   TYPE PRT
      213   ORGBNISH Homo        apren
                                                  US 8,080,243 B2
                             61                                    62
                                                   -continued
  400   SEQUENCE    5
Gln Pro Val Gly Pro Leu
I                   5
s210    SEQ ID NO 4
  211   LEI'GTH 5
  212   TYPE PRT
  213   ORGANISE Homo    sapzens
  400   SEQUENCE
Hzs Gly Ala Gly Trp
I                   5
  210   SEQ ID NO 7
  211   LENGTH 5
  212s  T'ZPE PRT
  213   ORGANISE Homo    sapzens
  400   SEQUENCE    7
Ala Glu Pzo Glu Leu
I                   5
  210   SEQ ID NO 8
  211   LENGTH 5
  212   TYPE PRT
  213   ORMEISH     Artzfzc zal
  220   FEATURE
  223   OTHER INFORFLATION    VARIABLE HEPNY CHAIN CDR
s400    SEQUENCE    8
Ser Tyr Tyr Net Hrs
I                   5
  210   SEQ ID NO 9
  211   LENGTH 17
  212   TYPE PRT
  213   ORGAEISH Artzfzc    lal
  220   FEATURE.
  223   OTHER INFORHATION     VARIABLE HEAVY CHAIN CDP.
  400.  SEQUENCE    9
Glu   Ile Ser  Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
                    5                    10                15
Ser
  210   SEQ ID EO 10
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzfrc zal
  220   FEATURE.
  223   OTHER INFORHATION VARIABLE HEAVY CHAIN CDR
  400   SEQUENCE    10
Glu Arg Pro Leu Tyr Ala Ser Asp Leu
I                   5
  210   SEQ ID I'10 11
  211   LENGTH 11
  212   TYPE PRT
  213   ORGANISE Artzftc zal
  220   FEZTURE
  223   OTHER INFORSZATION VARIABLE LIGHT CHAIN CDR
  400   SEQUENCE    11
Arg Ala Ser Gln Gly     Ile Ser Ser  Ala Leu Ala
I                   5                    10
                                                       US 8,080,243 B2
                              63                                             64
                                                         -continued
  210    SEQ ID NO 12
  211    LENGTH    7
  212    TYPE PRT
c213     ORG.SHSN    AZtzfzC ral
c220     FEATURE:
  223    OTHER 11'IFORNATION    V..RIABLE LIGHT CHAIN CDR
  400    SEQUENCE    12
Ser Ala Ser Tyr Arg Tyr Thr
I
  210    SEQ ID NO 13
  211    LENGTH 9
  212    TYPE PRT
  213    ORGWIISN Artzfzc    lal
  220.   FEATURE.
  223    OTHER INFORN'ZION      VARIABLE LIGHT CHAIN CDR
  400    SEQUENCE    13
Gln Gln Azg Tyr Ser Leu Trp Azg Thr
I                    5
  210    SEQ ID NO 14
  211    LENGTH 214
  212    TYPE PRT
  213    ORG621ISH Artzfzc zal
  220    FEATURE
  223    OTHER INFORFZATION HUHZUZIEED LZL3 LIGHT CHTIN
c400     SEQUENCE    14
Asp   Ile  Gln Het Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
I                    5                       10                    15
Asp Arg Val Thr      Ile Thr Cys Arg Ala Ser Gln Gly       Ile Ser Ser Ala
                20                       25                    30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly L.           Ala Pro Lys Leu Leu     Ile
           35                       40                     45
Tyr Ser Ala 6'er Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
      50                      55                      60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65                       70                      ". 5                    80
Glu Asp    Ile  Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg
                     85                      90                    95
Thr Phe Gly Gln Gly Thr Ly. Leu Glu          Ile Lys Arg Thr Val Ala Ala
                100                      105                   110
Pro Ser Val Phe      Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
           115                      12 0                   125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
      130                     135                     140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                      150                     155                     160
Glu Ser Val Thr Glu Gln       A  p Ser Ly    asp Ser Thr Tyr Ser   'u Ser
                     165                     170                   1. 75
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys Hzs Lys Val Tyr
                180                      185                   190
Ala Cys Glu Val Thr Hzs Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
           195                      200                    205
Phe Asn Azg Gly Glu Cy-
      210
                                                    US 8,080,243 B2
                              65                                         66
                                                      -continued
  210    SEQ ID NO 15
  211    LENGTH    444
  212    TYPE PRT
  213    ORGANISE Artzftc    tal
  220    FEATURE
a223     OTHER INFORHATION     HUI131IZED LIL3 HEAVY CHAIN
  400    SEQUENCE    15
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
I                    5                     10                   15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                20                     25                   30
Tyr Het Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Het
           35                     40                    45
Gly Glu    Ile Ser   Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Ly- Phe
      50                      55                    0
Lys Ser    Irg Val   Thr Het Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
                         70                    75                    80
Het Glu Leu Ser Ser Leu Arg Ser Glu Asp Tht Ala Val Tyr Tyz Cys
                     85                    90                   95
Ala Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr
                100                    105                  110
Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
           115                    12 0                  125
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly
      13 0                    135                  140
Cys Leu Val Ly       Arp Tyr Phe Pzo Glu Pro Val Thr Val Ser Trp Asn
145                      150                   155                   160
Ser Gly Ala Leu Thr Ser Gly Val Hzs Thr Phe Pro Ala Val Leu Gln
                     165                   170                  I  5
Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser
                180                    185                  190
Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp Hzs Lys Pro Ser
           195                    200                   205
4 n Thr Lys     Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys
      210                     215                  220
Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe
225                      230                   235                   240
Pro Pro Lys Pro Lys Asp Thr Leu Het        Ile Ser Arg Thr Pro Glu Val
                     245                   250                  255
Thr Cy. Val Val Val Asp Val Ser Mzs Glu Asp Pro Glu Val Gln Phe
                260                    265                  270
Asn Trp Tyr Val Asp Gly Val Glu Val Hts Asn Ala Lys Thr Lys Pro
           275                    280                   285
Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr
      290                     295                  300
Val Val Hr ~ Gln Aap Trp Leu Ann Gly Ly- Glu Tyr lys Cy. Lya Val
305                      310                   315                   320
Ser Asn Ly- Gly Leu Pro Ser Ser        Ile Glu Ly  Thr  Ile Ser Ly- Thr
                     325                   330                  335
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg
                340                    345                  350
Glu Glu Het Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
           355                    360                   365
Phe Tyr Pro Ser Asp      Ile  Ala Val Glu Trp Glu Ser Asn Gly Gln Pzo
      370                     375                  380
                                                     US 8,080,243 B2
                              67
                                                       -continued
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser
385                      390                   395                   400
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln
                     405                   410                   415
Gly Asn Val Phe Ser Cys Ser Val Met Mrs Glu Ala Leu Hrs Asn His
                420                    425                   430
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
            435                    440
  210    SEQ ID NO 16
  211    LEIIGTH 108
  212    TYPE PRT
  213    ORGANISM Mu     mu  culus
  400.   SEQUENCE    16
Asp   Ile   Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
                     5                     10                    15
Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thz Asn
                20                     25                    30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Ala Leu          Ile
            35                     40                    45
Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly
      50                      55                    60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr        Ile Ser   Asn Val Leu Ser
65                       70                    75                    80
Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Phe Tyr Ser Tyr Pro Tyz
                     85                    90                    95
Thr Phe Gly Gly Gly Thr Lys Leu Glu        Ile Lys Arg
                100                    105
  210    SEQ ID NO 17
  211    LEIIGTH 108
  212    TYPE PRT
  213    ORGANIS'N Mus   mus<U+00AB>ulu
  400.   SEQUENCE    17
Asp   Ile   Val liat Thr Gln Ser His Lys Phe   Met. Ser Thr Ser Val Gly
                     5                     10                    15
Asp Arg Val Ser      Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala
                20                     25                    30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Set Pro Ly. Leu Leu          Ile
            35                     40                    45
Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
      50                      55                    60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr        Ile Ser Ser   Val Gln Ala
65                       70                    75                    80
Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln Arg Tyr Ser Thr Pro Arg
                     85                    90                    95
Thr Phe Gly Gly Gly Thr Lys Leu Glu        Ile Lys Arg
                100                    105
  210    SEQ ID NO 18
  211    LENGTH 107
  212    TYPE PRT
  213    ORGANIS'N Mus   musculu
  400    6'EQUENCE   18
!\sp  Ile   Gln Met Thr Gln Thr Thr Ser Ser Leu Ser .Ala Ser Leu Gly
                                                     US 8,080,243 B2
                              69                                         70
                                                       -continued
                                            10                   15
Asp Arg Val Thr      Ile Ser  Cys  Ser Ala Ser Gln Gly   Ile Ser Asn Tyr
                20                      25                   30
Leu   A  n Tzp Tyr Gln Gln Lys Pzo .'. p Gly Thr Val Ly- Leu Leu     Ile
           35                      60                    65
Tyr Tyr Thr Ser Ser Leu Hts Ser Gly Val Pro Ser Arg Phe Ser Gly
      50                      55                    60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr         Ile Ser  Asn Leu Glu Pro
65                       70                     75                   80
Glu Acp    Ile  Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Phe
                     85                     90                   95
Thr Phe Gly Ser Gly Thr Ly- Leu Glu         Ile Ly
                100                     105
  210    SEQ ID NO 19
  211    LENGTH    108
  212    TYPE PRT
  213    ORGANISN    Nu- tsusculus
  600    SEQUENCE    19
Asp   Ile  Val Met Thr Gln Ser His Lys Phe Net Ser Thr Ser Pits Gly
1                    5                      10                   15
Asp Arg Val Ser      Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Asn Ala
                20                      25                   30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Hzs Ser Pro Lys Leu Leu          Ile
           35                      60                    65
Phe Ser Ala Ser Tyr Azg Tyr Thr Gly Val Pro Asp Azg Phe Thr Gly
      50                      55                    60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr         Ile Ser Ser  Val Gln Ala
65                       70                     75                   80
Glu Acp Leu Ala Val Tyr Tyr Cys Gln Gln         Hz  Tyr Ser Thr Pro Trp
                     85                     90                   95
Thr Phe Gly Gly Gly Thr Lys Leu Glu         Ile Ly  Arg
                100                     105
  210    SEQ ID 110 20
  211    LENGTH    115
  212    TYPE PRT
  213    ORGANISE    Nus musculus
  600    SEQUENCE    20
Glu Val Gln Leu Gln Gln Sez Gly Pro Glu Leu Val Ly- Pro Gly Ala
1                    5                      10                   15
Ser Val Lys     Ile Ser  Cys Lys   I\la Ser Gly Tyr Thr Phe Thr I\sp Tyr
                20                      25                   30
Tyr Net Asn Trp Val Lys Gln Ser Hzs Gly Lys Ser Leu Glu Trp          Ile
           35                      40                    65
Gly Asp    Ile  Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe
      50                      55                    60
Ly. Gly Ly      Ala Thr Leu Thr Val Asp Ly- Ser Tyr Ser Thr Ala Tyr
65                       70                     75                   80
Net Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                     85                     9Q                   95
Ala Arg Trp Leu Leu Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr
                100                     105                  110
Val Ser Ala
           115
                                                    US 8,080,243 B2
                             71                                        72
                                                      -continued
  210    SEQ ID NO 21
  211    LENGTH    118
  212    TYPE PRT
a213     ORGANIISN Nu-   musculus
  400    SEQUENCE    21
Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
I                    5                     10                  15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                20                     25                  30
Trp Net Hzs Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp        Ils
           35                     40                    45
Gly Glu    Ile  Asn Pro Ser Asn Gly Arg Thr Aan Tyr Asn Glu Ly- Phe
      50                     55                     0
Lys Ser Lys     Tla Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
                         70                    75                  80
Net Gln Leu Ser Ser Leu Thz Ser Glu Asp Set Ala Val Tyr Tyz Cys
                     85                    90                  95
Ala Arg Glu Arg Pro Leu Tyr Ala Net Asp Tyt Trp Gly Gln Gly Thr
                100                    105                 110
Ser Val Thr Val Ser Ser
           115
  210    SEQ ID NO 22
a211     LENGTH 123
  212    TYPE PRT
  213    ORGANIISN   Nu  mu culus
  400    SEQUENCE    22
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
I                    5                     10                  15
Ser Val Lys     Ile Ser  Cys Lys Ala   Ser Gly Tyr Thr Phe Thr Arp Tyr
                20                     25                  30
Tyr Net Asn Trp Val Lys Gln Ser Hza Gly Lys Ser Leu Glu Trp        Ile
           35                     40                    45
Gly Asp    Ile  Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe
      50                     55                    60
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ssr Ser Ser Thr Ala Tyr
65                       70                    75                  80
tact Glu Leu Arg Ser Leu Thr Ser Glu Asp Set Ala Val Tyr Tyr Cys
                     85                    90                  95
Ala Gly Gly Gly      Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr
                100                    105                 110
Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
           115                    12 0
  210    SEQ ID NO 23
  211    LENGTH 117
  212    TYPE PRT
  213    ORGANISE Mu     mu culus
  400    SEQUENCE    23
Glu Val Lys Leu Val Glu Ser Glu Gly Gly Leu Val Gln Pro Gly Ser
I                    5                     10                  15
Ser Net Lys Leu Ser Cy- Thz Ala Ser Gly Phe Thr Phe Ser Asp Tyr
                20                     25                  30
Tyr Het Ala Trp Val Arg Gln Val Pro Glu Lys Gly Leu Glu Trp Val
                                                          US 8,080,243 B2
                               73                                                      74
                                                            -continued
            35                     40
Ala Asn     Ile Asn Tyr Asp Gly Ser Asn Tfsr Ser Tyr Leu Asp Ser Leu
      50                       55                        60
Ly. Ser Arg Pfse     Ile Ile   Ser Arg  .'.  p A  n Ala Ly- Asn  Ile  Leu Tyr
65                        70                         75                      80
Leu Gln Het Ser Ser Leu Lys Ser Glu Asp Tnr Ala Tnr Tyr Tyr Cys
                     85                        90                      95
Ala Arg Glu Lys Pfre Ala Ala Net Asp Tyr Trp Gly Gln Gly Tnr Ser
                100                     105                      110
Val Thr Val Ser Ser
            115
  210    SEQ ID NO 24
  211s   LENGTH 15
  212    TYPE PRT
  213    ORGANISE Artrf    rcral
  220    FEPTUPE
  223    OTHER INFORNTTI ON     LINKING PEPTIDE
  400    6'EQUENCE   24
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
I                    5                         10                      15
  210    SEQ ID NO 25
  211    LENGTH    642
  212    TYPE DNA
  213    ORGAEISN    Artrf rcral
s220     FEATURE:
  223    OTHER 11'IFORHATI ON   HUILANIZED LIGHT CH..II'1 NUCLEOTIDE SEQUENCE
  400    SEQUENCE    25
gatatacaaa tgacacaatc tccatcctct ctttccgcat cagtcggcga ccgcgtaacc                   60
at.cacatgta gagcttctca aggcatctcc tccgccctcg catggtacca acaaaaacca                 120
ggtaaagccc caaaactcct catatactca gcttcataca gatacaccgg cgtaccctca                  180
agattctcag gttcaggctc tggaacagac tttactttca ccatttcatc actccaaccc                  240
gaagacatag ctacatatta ctgccaacaa agatacagcc t.ctggagaac att.tggccaa                300
ggaacaaaac tcgagatcaa acgtacggtg gctgcaccat.             ctgtcttcat ctt.cccgcca    3 0
tctgatgagc agttgaaatc tggaactgcc tctgttgtgt gcctgctgaa taacttctat                  420
cccagagagg ccaaagtaca gtggaaggtg gataacgccc tccaatcggg taactcccag                  480
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacg                  540
ctgagca g        g   t  g    g              gt t   g  ct gcgaagtcac  c.cat.c.agggc 600
ctgagctcnc ccgtcacaaa gagcttcaac aggggagagt gt
  210    SEQ ID NO 26
  211    LENGTH 1332
  212    TYPE DNA
  213    ORGANHSH    Artrf rcral
  220    FEATURE.
  223    OTHER INFORf4ATI ON    HUSUUIIZED HEAV'I CHAIN NUCLEOTIDE SEQUENCE
  400    SEQUENCE    26
caagttcaac tcgttcaatc tggagcagaa gtaaaaaaac ctggcgcctc tgttaaagta                   60
agttgtaaag catccggtta cacattcaca tcatattaca tgcattgggt aagacaagcc                  120
cctcgacaag cactcgaatg gatgggtgaa atctctcctt ttggcggccg aacaaactat                  180
aatgaaaaat ttaaatcccg cgtaactatg acccgagaca catccacatc tactgtttat                  240
                                               US 8,080,243 B2
                           75                                            76
                                                -continued
atggaacttt cctcactgcg ttctgaagac actgctgttt attactgtgc acgcgaaaga    300
cctctctacg cttccgatct ctggggccaa ggaacaacgg tcaccgtctc ctcagcctcc    360
accaagggcc   catctgtctt cccactggcc ccatgctccc gcagcacctc cgagagcaca  420
gccgccctgg gctgcctggt caaggactac ttcccagaac ctgtgaccgt. gtcctggaac   480
tctggcgctc tgaccagcgg cgtgcacacc ttcccagctg tcctgcagtc ctc.aggtctc   540
tactccctca gcagcgtggt gaccgtgcca tccagcaact tcggcaccca gacctacacc    600
tgcaacgtag atcacaagcc aagcaacacc aaggtagata agaccgtgga gagaaagtgt    660
tgtgtggagt gtccaccttg tccagcccct ccagtggccg gaccatccgt gttcctgttc    720
cctccaaagc caaaggacac cctgatgatc tccagaaccc cagaggtgac ctgtgtggtg    780
gtggacgtgt cccacgagga cccagaggtg cagttcaact. ggtatgtgga cggagtggag   840
gtgcacaacg ccaagaccaa gccaagagag gagcagttca actccacctt cagagtggtg    900
agcgtgctua ccgtggtgca ccaggactgg ctgaacggaa aggagtataa gtgtaaggtg    960
tccaacaagg cactcccatc cagcatcgag aacaccatct ccaagaccaa gggacagcca   1020
agagaqccac agctgtatac cctgccccca tccaqagacg acatgaccaa gaaccaggtg   1080
tccctgacct gtctggtgaa gggattctat ccatccgaca t.cgccgtgga gtgggagtcc  1140
aacggacagc cagagaacaa ctataagacc acccctccaa tgctggactc cgacggatcc   1200
ttcttcctgt attccaagct   gaccgtggac aagtccagat ggcagcaggg aaacgtgttc 1260
tcttgttccg tgatgcacga ggccctgcac aaccactata cccagaagag cctgtccctg   1320
tctccaggaa ag                                                       1332
  210  SEQ ID NO 27
  211  LENGTH 11
  212  TYPE PRT
  213  ORGANISE Hus    musculus
  400  SEQUENCE    27
Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala
1                  5                  10
  210  SEQ ID NO 28
  211  LENGTH    7
  212  TYPE PRT
  213  ORGANISE    Nus musculus
  400  SEQUENCE    28
Ser Ala Ser Tyr Arg Tyr Ser
I                  5
  210  SEQ ID NO 29
  211  LENGTH 9
  212  TYPE PRT
  213  ORGAEISN Nus    musculus
  400  SEQUENCE    29
Gln Gln Phe Tyr Ser Tyr Prc Tyr Thr
1                  5
  210  SEQ ID NO 30
  211  LENGTH 11
  212  TYPE PRT
  213  ORGANIB'N Mus   musculu
  400  6'EQUENCE   30
Lys Ala Ser Gln Asp Val Ser Thr Ala Val Ala
                                                   US 8,080,243 B2
                             77                                   78
                                                   -continued
                                          10
  210   SEQ ID NO 31
  211   LENGTH    9
s212    TYPE PRT
s213    ORG.NIS14   Nu tAll culu
  400   SEQUENCE    31
Gln Gln Erg Tyr Ser Thr Pro Rrg Thr
I                   5
  210   SEQ ID NO 32
  211   LEIIGTH 11
  212   TYPE PRT
  213   ORGRNISII Mu   mu   culus
  400.  SEQUENCE    32
Ser Rla Ser Gln Gly     Ile Ser   Rsn Tyr Leu Isn
                    5                     10
  210   5'EQ ID NO 33
  211   LENGTH 7
  212   TYPE PRT
  213   ORGRNISM Mus   musculus
  400   SEQUENCE    33
Tyr Thr Ser Ser Leu Hrs Ser
I                   5
  210   SEQ ID I'10 34
  211   LENGTH 11
  212   TYPE PRT
  213   ORGRNISM Mus   musculus
  400   SEQUENCE    34
Ly    Rla Ser Gln Rsp Val Ser     R n Rla Leu Rla
I                   5                     10
  210m  SEQ ID NO 35
  211m  LENGTH 9
  212   TYPE PRT
  213   ORGRNISbt Mus  mttscullts
  400   SEQUENCE    35
Gln Gln Hrs Tyr Ser Thr Pro Trp Thr
I                   5
  210   SEQ ID NO 36
  211   LENGTH 7
  212   TYPE PRT
  213   ORGRNISN Mus   musculus
  400   SEQUENCE    36
Gly Tyr Thr Phe Thr Rsp Tyr
I                   5
  210   SEQ ID I'10 37
  211   LENGTH 5
  212   TYPE PRT
  213   ORGRNISM Mus   musculus
  400   SEQUENCE    37
Rsp Tyr Tvr Met Rsn
I                   5
                                               US 8,080,243 B2
                          79                                      80
                                                -continued
  210   SEQ ID NO 39
  211   LENGTH
  212   TYPE PRT
  213   ORGANISN  Mus musculus
c400    SEQUENCE  39
Aan Pro Asn Aan Gly Gly
I                 5
  210   SEQ ID NO 39
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Mus  musculu
  400   SEQUENCE  39
4 p   Ile Aan Pro Aan Aan Gly Gly Thr Thr Tyr Aan Gln Lya Phe Ly-
I                 5                   10                  15
Gly
  210   SEQ ID NO 40
  211   LENGTH
  212   TYPE PRT
  213   ORGPAHSN Mu   musculu
  400   SEQUENCE  40
Trp Leu Leu Phe Als Tyr
I                 5
c210    SEQ ID NO
  211   LEI'GTH 7
  212   TYPE PRT
  213   ORGPIIISM Mu  mu culua
  400   SEQUENCE  41
Gly Tyr Thr Phe Thr Ser Tyr
I                 5
  210   SEQ ID NO 42
  211m LENGTH 5
  212m T'IPE PRT
  213 ORGANISM Mus    musculus
  400   SEQUENCE  42
Ser Tyr Trp Met Hts
                  5
  210   SEQ ID NO 43
  211   LENGTH 6
  212   TYPE PRT
  213   ORGANISM Mus  musculus
  400   SEQUENCE  43
A  n Pro Ser Asn Gly Arg
                  5
  210   SEO ID NO 44
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISM Mus  musculus
  400   SEQUENCE  44
Glu   Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Glu Lya Phe Lys
I                 5                   10                  15
Ser
                                                US 8,080,243 B2
                           81                                      82
                                                 -continued
  210   SEQ ID No 45
  211   LEItGTH 9
  212   TYPE PRT
  213   ORGANISN Mus   musculus
ssoo    SEQUENCE    45
Glu Arg Pro Leu Tyr Ala tset Asp Tyr
I                   5
  210   SEQ ID No 46
  211   LENGTH 17
  212   TYPE PRT
  213   ORGAEISM Mus   musculus
  soo   sEQUENCE    46
4 p   Ile  Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys
I                   5                  10                  15
Gly
  210   6'EQ ID No 47
  211   LENGTH 14
  212   TYPE PRT
  213   ORGANISM Mus   musculus
  400   SEQUENCE    47
Gly Gly    Ile Tyr Tyr Arg Tyr Asp Arg Asn Tyr Phe Asp Tyr
I                   5                  10
  210   SEQ ID I'io 48
  211   LENGTH 7
  212   TYPE PRT
  213   ORGANISM Mus   musculus
  400   SEQUENCE    48
Gly Phe Thr Phe Ser Asp Tyr
I                   5
  210m  SEQ ID No 49
  211m  LENGTH 5
  212   TYPE PRT
  213   ORGANISbi Mus  musculus
  400   SEQUENCE    49
Asp Tyr Tyr Met Ala
I                   5
  210   SEQ ID No 50
  211   LENGTH 6
  212   TYPE PRT
  213   ORGANISN Mus   musculus
  400   SEQUENCE    50
Asn Tyr Asp Gly Ser Asn
I                   5
  210   SEQ ID I'io 51
  211   LENGTH 16
  212   TYPE PRT
  213   ORGANISM Mus   musculus
  400   SEQUENCE    51
Asn   Ile  Asn Tyr Asp Gly Ser Asn Thr Ser Tyt Leu Asp Ser Leu Lys
I                   5                  10                  15
                                                   US 8,080,243 B2
                             83                                       84
                                                     -continued
  210    SEQ ID NO 52
  211    LENGTH    8
  212    TYPE PRT
  213    ORGAEISN    Mus musculua
s400     SEQUENCE    52
Glu Ly. Phe Ala Ala Net      A  p Tyz
I                    5
  210    SEQ ID NO 53
  211    LENGTH 107
  212    TYPE PRT
  213    ORGANISN homo    aapzen
  400    SEQUENCE    53
4 p   Ile  Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1                    5                    10                  15
Asp Arg Val Thr Zle Thr Cys Arg Ala Ser Gln Gly Zle Ser Ser Ala
                20                    25                  30
Leu Ala Tzp Tyr Gln Gln Lya Pzo Gly Lys Ala Pro Ly- Leu Leu       Ile
           35                     40                   45
Tyr Ser Ala Ser Tyr Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly
      50                     55                   60
Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr       Ile Ser Ser Leu Gln Pro
65                       70                   75                  80
Glu Asp    Ile  Ala Thr Tyr Tyr Cys Gln Gln Arg Tyr Ser Leu Trp Arg
                     85                   90                  95
Thr Phe Gly Gln Gly Thr Lye Leu Glu       Ile Ly
                100                   105
  210    SEQ ID NO 54
  211    LENGTH 118
  212    TYPE PRT
  213    ORGANISN homo    sapzen
  400    SEQUENCE    54
Gln Val Gln Leu Val Gln      ser Gly Ala Glu Val  Lys Lys Pro Gly Ala
1                    5                    10                  15
Ser Val Ly" Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
                20                    25                  30
Tyr Net Hzs Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Net
           35                     40                   45
Gly Glu    Ile Ser   Pro Phe Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe
      50                     55                   60
Lys Ser Arg Val Thr Net Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr
65                       70                   75                  80
Net Glu Leu Ser Ser Leu Arg Ser Glu Psp Thr Ala Val Tyr Tyr Cys
                     85                   90                  95
Ala Arg Glu Arg Pro Leu Tyr Ala Ser Asp Leu Trp Gly Gln Gly Thr
                100                   105                 110
Thr Val Thr Val Ser Ser
           115
  210    SEQ ID NO 55
  211    LENGTH 9
  212    TYPE PRT
  213    ORGANIS'N Artzfzczal Sequence
  220    FEATURE:
  223    OTHER INPORNATIOE Synthetzc
  400    SEQUENCE    55
                                             US 8,080,243 B2
                             85                             86
                                             -continued
Gln Gln Tyr Ser Lys Leu Pro Phe Thr
                    5
c210   SEQ ID NO 56
c211   LENGTH 10
  212  TYPE PRT
  213  ORGANISE     Artific ial Sequence
  220  FEATURE
  223  OTHER INFORHATION      Synthetic
  400  SEQUENCE     56
Gly Tyr Thr Phe Thr Asp Tyr Tyr Net F.cn
1                   5                    10
  210  SEQ ID NO 57
  211s LENGTH 10
  212  TYPE PRT
  213  ORGANISE     Artific ial Sequence
  220  FEATUPE
  223  OTHER INFORNITION      Synthetic
  400  6'EQUENCE    57
Gly Tyr Thr Phe Thr Ser Tyr Trp Net Mi
I                   5                    10
  210  SEQ ID NO 58
  211  LENGTH    10
  212  TYPE PRT
  213  ORGAEISN     Artific ial Sequence
c220   FEATURE:
  223  OTHER Il'IFORNATION    Synthetic
  400  SEQUENCE     58
Gly Phe Thr Phe Ser Asp Tyr Tyr Net Ala
I                   5                    10
  210  SEQ ID NO 59
  211  LENGTH 10
  212  TYPE PRT
  213s ORGWIISN ArtifiC     ial Sequence
  220. FEATURE.
  223  OTHER INFORNATION      Syntlietic
  400  SEQUENCE     59
Gly Tyr Thr Phe Thr Ser Tyr Tyr Net His
                    5                    10
  210  SEQ ID NO 60
  211  LENGTH 7
  212  TYPE PRT
  213  ORGANISE     Artific ial Sequence
  220  FEATURE
  223  OTHER INPORKATION      Synthetic
  400  SEQUENCE     60
Gly Tyr Thr Phe Thr Ser Tyr
1                   5
  210  SEQ ID NO 61
  211  LENGTH 6
  212  TYPE PRT
  213  ORGANISE     Artific ial Sequence
  220  FEATURE.
  223  OTHER INFORHATION      Synthetic
  400  6'EQUENCE    61
Ser Pro Phe Gly Gly Arg
                                               US 8,080,243 B2
                             87                                   88
                                                -continued
  210   SEQ ID NO 62
  211   LENGTH    0
.212    TYPE PRT
.213    ORGANIS14   Artrfrc ral Sequence
  220   FEATURE:
  223   OTHER INFORHATION     Synthetrc
  400   SEQUENCE    62
Gln Asp Val Ser Thr Ala Val Ala
                    5
  210   SEQ ID NO 63
  211   LENGTH 11
  212   TYPE PRT
  213 s ORGMIISN ArtrftC    ral Sequence
  220   FEATURE
  223   OTHER INPORKATION     Synthetrc
  400   SEQUENCE      3
Gly Gly Thr Arg Val Val Ser Thr Ala Val Ala
1                   5                    10
  210   SEQ ID NO 4
  211   LENGTH 10
  212   TYPE PRT
  213   ORGANISN Artrfrc    ral Sequence
  220   FEATURE
  223   OTHER INPORKATION     Synthetrc
  400   SEQUENCE    64
Arg Gly Asp Phe Val Ser Thr Ala Val Ala
1                   5                    10
  210   SEQ ID NO 65
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Artrfrc    ral Sequence
  220   FEATURE:
  223.  OTHER INPOPNATION     Synthetrc
  400   SEQUENCE      5
Glu   Ile Asn Pro Ser Gly Gly Arq Thr Asn Tyr Asn Glu Lys Phe Lys
1                   5                    10               15
Ser
  210   SEQ ID NO 66
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISE Artrfrc    tal Sequence
  220   FEATURE
  223   OTHER INPORKATION     Synthetrc
  400   SEQUENCE    66
Glu   Ile Aen Pro Ser Ser Gly Arg Thr Aen Tyr Aen Glu Ly. Phe Lya
1                   5                    10               15
Ser
  210   SEQ ID NO 7
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANIS'N Artrfrc   ral Sequence
  220   FEATURE:
  223   OTHER INPORHATION     Synthetrc
  400   SEQUENCE    67
                                                  US 8,080,243 B2
                             89                                      90
                                                   -continued
Glu   Ile Asn Pro Ser Thr Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
                    5                    10
Ser
  210   SEQ ID I'10 68
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISM Artzfzc zal Sequence
  220   FEATURE
  223   OTHER INFORMATION Synthetzc
  400   SEQUENCE    68
Glu   Ile Asn Pro Ser   Ile  Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                   5                    10                  15
Sez
  210   SEQ ID NO 69
  211   LENGTH 17
  212   TYPE PRT
  213   ORnaNISM Aztzfrc zal Sequence
  220   FEATURE:
  223   OTHER IEFORMATION Synthetrc
  400   SEQUENCE      9
Glu   Ile Asn Pzo Ser Asp Ser Azg Thr Asn Tyr Asn Glu Lys Phe Lys
I                   5                    10                  15
Ser
  210   SEQ ID NO 70
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Artzftc zal Sequence
  220   FEATURE
  223   OTHER INFORMATION Synthetzc
  400   SEQUENCE    70
Glu   Ile Asn Pzo Ser Gly Asn Azg Thz Asn Tyr Asn Glu Lys Phe Lys
I                   5                    10                  15
Sez
  210   SEQ ID NO I
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Aztzfrc    ral Sequence
  220   FEATURE:
  223   OTHER INFORNATION     Synthetzc
  400   SEQUENCE    71
Glu   Ile Asn Pro Ser Ser Ser Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                   5                    10                  15
Ser
  210   SEQ ID NO 72
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISN Artrfrc    tal Sequence
  220   FEATURE
  223   OTHER INFORMATION     Synthetzc
  400   SEQUENCE    72
Glu Arg Pzo Leu Tyr Ala Met Asp Tyz
I                   5
                                          US 8,080,243 B2
                            91                           92
                                          -continued
  210   SEQ ID NO 73
  211   LENGTH   9
  212   TYPE PRT
  213   ORGAEISN Artzfrc   tal  Sequence
  220   FEATURE
r223    OTHER INFORHATION    Synthetzc
  400   SEQUENCE   73
Glu Arg Pro Leu Tyr Ala Ala Asp Tyr
I                  5
  210   SEQ ID NO 74
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE   Artrftc ral sequence
  220   PEATURE:
  223   OTHER INPORI6ATION   synthetrc
  400   SEQUENCE   74
Glu Arg Pro Leu Tyr Ala     Ile  Asp Tyr
I                  5
  210   SEQ ID NO 75
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE   Arttftc tal  Sequence
  220   FEATURE.
  223   OTHER INFORH'TION    Synthetzc
  400   SEQUENCE     5
Glu   'rg Pro Leu Tyr Ala Azg    A p Tyr
I                  5
  210   SEQ ID NO 76
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE .Artrftc  tal  Sequence
  220   FEATURE.
  223   OTHER INFORHATION    Synthetzc
  400   SEQUENCE   76
Glu Arg Pro Leu Tyr Ala Gly Asp Tyr
I                  5
  210   SEQ ID NO 7
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISN Artzfrc   ral Sequence
  220   FEATURE:
  223   OTHER INFORNATION    Synthetzc
  400   SEQUENCE   77
Glu Arg Pro Leu Tyr Ala Lys Asp Tyr
I                  5
  210   SEQ ID NO 78
  211   LEI'GTH 9
  212   TYPE PRT
  213   ORGANISE   Artrftc ral sequence
  220   PEATURE:
  223   OTHER INFORHATIOE    Synthetrc
  400   SEQUENCE   78
Glu Arg Pro Leu Tyr Ala Pro Asp Tyr
I                  5
  210   SEQ ID NO 79
  211   LENGTH 9
                                       US 8,080,243 B2
                          93                          94
                                       -continued
  212 TYPE PRT
  213 ORGANISM    Artificial Sequence
  220 FEATURE
  223 OTHER INFORHPTION    Synthetic
s400  SEQUENCE    79
Glu Arg Pro Leu Tyr Ala Ser 8 p Tyr
I                 5
  210 SEQ ID NO 80
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISN    Artificial Sequence
  220 FEATURE.
  223 OTHER INFORMATION    Synthetic
  400 SEQUENCE    80
Glu Arg Pro Leu Tyr Ala Leu Asp Tyr
                  5
  210 SEQ ID NO 81
  211 LENGTH 9
  212 TYPE PRT
  213 ORGPSHSN    Artificial Sequence
  220 FEATURE.
  223 OTHER INPORHATION    Synthetic
  400 SEQUENCE    81
Glu Arg Pro Leu Tyr Ala Val Asp Tyr
1                 5
  210 SEQ ID NO 82
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISN    Artificial Sequence
  220 FEATURE
  223 OTHER INFORMATION    Synthetic
  400 SEQUENCE    82
Glu Arg Pro Leu Tyr Ala Trp Asp Tyr
1                 5
  210 SEQ ID NO 83
  211 LENGTH    9
  212 TYPE PRT
  213 ORGANISM    Artificial Sequence
  220 FEATURE
  223 OTHER INFORMATION    Synthetic
  400 SEQUENCE    83
Glu Arg Pro Leu Tyr Ala His Asp Tyr
I                 5
  210 SEQ ID NO 84
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANIISH   Artificial Sequence
  220 FEATURE.
  223 OTHER INFORMATION    Synthetic
  400 SEQUENCE    84
Glu Arg Pro Leu Tyr Ala Phe Asp Tyr
                  5
  210 SEQ ID NO 85
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISM    Artificial Sequence
                                        US 8,080,243 B2
                           95                          96
                                        -continued
  220  PEATURR.
  223  OTHER INFORN"ZION    Synthetzc
  400  SEQUENCE   85
Glu Arg Pro Leu Tyr Ala Thr .. p Tyr
1                 5
  210  SEQ ID NO 86
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN Artzfzc zal Sequence
  220  FEATURE
  223  OTHER INPORFLATZON Synthetzc
  400  SEQUENCE   86
Gln Gln Arg Phe Ser Thr Pro Arg Thr
1                 5
  210  SEQ ID NO 87
  211  LENGTH 9
  212  TYPE PRT
  213  DRONISH    Aztzfzc zal Sequence
  220  FEATURE:
  223  OTHER IEFORHATION    Synthetzc
  400  SEQUENCE   87
Gln Gln Prg Tyr Ser Aep Trp Azg Thr
I                 5
e210   SEQ ID NO 88
  211  LEZ'GTH  9
  212  TYPE PRT
  213  ORGAIIISH Artzftc  tal Sequence
  220  FEATURE.
  223  OTHER INFORKATION    Synthetzc
  400  SEQUENCE   88
Gln Gln Arg Tyr Ser Ser Trp Arg Thr
1                 5
  210a SEQ ID NO 89
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN Artzftc   tal Sequence
  220  FEATURE
  223  OTHER INFORH'TION    Synthetzc
  400  SEQUENCE   89
Gln Gln Arg Tyr Ser Thr Ala Azg Thr
I                 5
  210  SEQ ID NO 90
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN Artzfzc zal Sequence
  220  FEATURE
  223  OTHER INPORHATION synt.hetzc
  400  SEOUENCE   90
Gln Gln Arg Tyr Ser Leu Tyr Arg Thr
I                 5
  210  SEQ ID NO 91
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE Aztzfzc zal Sequence
  220  FEATURE.
  223  OTHER INFORMATION Synthetzc
                                          US 8,080,243 B2
                            97                           98
                                          -continued
  400  SEQUENCE    91
Gln Gln Arg Tyr Ser Phe Trp Arg Thr
I                  5
  210  SEQ ID I'10 92
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE    Arttftc tal Sequence
  220  FEATURE
  223  OTHER INFORIAATION    Synthettc
  400  SEQUENCE    92
Gln Gln Arg Tyr Ser Prc Trp Arg Thr
I                  5
  210  SEQ ID NO 93
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN    Arttftc tal Sequence
  220  FEATURE:
  223  OTHER INPORINATION    Synthettc
  400  SEQUENCE    93
Gln Gln Arg Tyr Ser Gly Trp Arg Thr
I                  5
  210  SEQ ID NO 94
  211  LENGTH    9
c212   TYPE PRT
  213  ORGANIISN   Arttfrc tal Sequence
  220  FEATURE:
  223  OTHER INFORNATZON     Synt hat rc
  400  SEQUENCE    94
Gln Gln Arg Tyr Ser    Ile  Trp Arg Thr
I                  5
  210  SEQ ID NO 95
  211e LENGTH 9
  212a T'IPE PRT
  213  ORGANISE    Arttftc tal sequence
  220  FEATURE:
  223  OTHER INFORNATION     Synthettc
  400  SEQUENCE    95
Gln Gln   rrg Tyr Ser Ala Trp Arg Thr
I                  5
  210  SEQ ID NO 96
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN Artrfrc    tal Sequence
  220  FEATURE
  223  OTHER INFORNATION     Synthettc
  400  SEQUENCE    96
Gln Gln Arg Tyr Ser Leu Phe Arg Thr
I                  5
  210  SEQ ID NO 97
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANIS'N Artrfrc   tal Sequence
  220  FEATURE:
  223  OTHER INPORNATION     Synthettc
  400  SEQUENCE    97
                                         US 8,080,243 B2
                            99                          100
                                         -continued
Gln Gln Arg Tyr Ser Thr Arg Arg Thr
                   5
r210   SEQ ID NO 98
r211   LENGTH 9
  212  TYPE PRT
  213  ORGANISE    Artific ial Sequence
  220  FEATURE
  223  OTHER INFORHATION     Synthetic
  400  SEQUENCE    98
Gln Gln Arg Tyr Ser Thr Leu Tyr Thr
1                  5
  210  SEQ ID NO 99
  211e LENGTH 9
  212  TYPE PRT
  213  ORGANISE    Artific ial Sequence
  220  FEATUPE
  223  OTHER INFORNITION     Synthetic
  400  5'EQUENCE   99
Gln Gln Arg Tyr Ser Thr Trp Arg Thr
I                  5
  210  SEQ ID NO 100
  211  LENGTH    9
  212  TYPE PRT
  213  ORGAEISN    Artific ial Sequence
r220   FEATURE:
  223  OTHER Il'IFORNATION   Synthetic
  400  SEQUENCE    100
Gln Gln Arg Tyr Ser Leu Ala Arg Thr
I                  5
  210  SEQ ID NO 101
  211  LENGTH 9
  212  TYPE PRT
  213a ORGWIISN ArtifiC    ial Sequence
  220. FEATURE.
  223  OTHER INFORNATION     Syntlietic
  400  SEQUENCE    101
Gln Gln Arg Tyr Ser Ser Glu Arg Thr
                   5
  210  SEQ ID NO 102
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE    Artific ial Sequence
  220  FEATURE
  223  OTHER INPORKATION     Synthetic
  400  SEQUENCE    102
Gln Gln Arg Tyr Gly Thr Ala Arg Thr
1                  5
  210  SEQ ID NO 103
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE    Artific ial Sequence
  220  FEATURE.
  223  OTHER INFORHATION     Synthetic
  400  5'EQUENCE   103
Gln Gln Arg Tyr Ser Gln !\la !\rg Thr
                                            US 8,080,243 B2
                             101                           102
                                            -continued
  210   SEQ ID NO 104
  211   LENGTH    9
.212    TYPE PRT
.213    ORGANIS14   Aztzfzc zal Sequence
  220   FEATURE:
  223   OTHER INFORHATION     Synthetzc
  400   SEQUENCE    104
Gln Gln Azg Tyr Ser Leu Hza Azg Thr
                    5
  210   SEQ ID NO 105
  211   LENGTH 9
  212   TYPE PRT
  213 a ORGM4ISN ArtzfzC zal Sequence
  220   FEATURE
  223   OTHER INPORKATION Synthetzc
  400   SEQUENCE    105
Gln Gln Azg Tyz Ser Gly Val Azg Thz
1                   5
  210   SEQ ID NO 106
  211   LENGTH 9
  212   TYPE PRT
  213   ORGAEISN Artzfzc zal Sequence
  220   FEATURE
  223   OTHER INPORKATION Synthetzc
  400   SEQUENCE    106
Gln Gln Arg Tyr Ser Gln Ser      .'. g Thr
1                   5
  210   SEQ ID NO 107
  211   LENGTH 9
  212   TYPE PRT
  213   ORGAEISN Aztzfzc zal Sequence
  220   FEATURE:
  223   OTHER INPOPNATION Synthetzc
  400   SEQUENCE    107
Gln Gln Prg Tyr Ser Ala Glu Arg Thr
1                   5
  210   SEQ ID NO 108
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzfzc zal Sequence
  220   FEATURE.
  223   OTHER INFORHATION Synthetzc
  400   SEQUENCE    108
Gln Gln Azg Tyr Ser Gln Phe Azg Thr
                    5
  210   SEO ID NO 109
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE .Artzfzc zal Sequence
  220   FEATURE
  223   OTHER INPORKATION Synthetzc
  400   SEQUENCE    109
Gln Gln Azg Tyz Ser Sez Azg Azg Thz
1                   5
                                       US 8,080,243 B2
                          103                         104
                                       -continued
  210  SEQ ID NO 110
  211  LElzGTH 9
  212  TYPE PRT
  213  ORGAMISN Artzfzc zal Sequence
a220   FEATURE;
a223   OTI'ER INPORIMATION Svnthetzc
  400  SEQUENCE    110
Gln Gln Arg Tyr Ser Cye Ser Arg Thr
I                  5
  210  SEQ ID NO 111
  211  LEIIGTH 9
  212  TYPE PRT
  213  ORGANISM Artzfzc zal sequence
  220  PEATURE:
  223. OTHER INFORMATION Synthetzc
  400  SEQUENCE    111
Gln Gln Arg Tyr Ser Thr Aen Arg Arg
I                  5
  210  SEQ ID EO 112
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISFI Artzfzc zal Sequence
  220  FEATURE
  223  OTHER INFORMITION Synthetzc
  400  SEQUENCE    112
Gln Gln Zzg Tyr Ser Arg Trp Azg Thz
I                  5
  210  SEQ ID NO 113
  211  LENGTH 9
  212  TYPE PRT
  213  ORGAMISN Artzfzc zal Sequence
  220  FEATURE.
  223  OTI'ER INFORFIATION Synthetzc
  400. SEQUENCE    113
Gln Gln Arg Tyr Ser Prc Tyz Arg Thr
I                  5
  210  SEQ ID NO 114
  211  LElzGTH 9
  212  TYPE PRT
  213  ORGPIIISH Artzfzc zal Sequence
  220  FEATURE;
  223  OTHER INPORHATION Synthetzc
  400  SEQUENCE    114
Gln Gln Arg Tyr Ser Tyr Trp Arg Thr
I                  5
  210  SEQ ID NO 115
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISM Artzfzc zal sequence
  220  FEATURE
  223  OTHER INFORMATION Synthetzc
  400  SEQUENCE    115
Gln Gln Arg Tyr Ser Gly Phe Arg Thr
I                  5
  210  SEQ ID NO 11
                                        US 8,080,243 B2
                           105                         106
                                        -continued
  211  LENGTH 9
  212  TYPE PPT
  213  ORG62IISN  Artrfrc ral Sequence
  220  FEATURE
  223  OTHER INFORFZATZON   Synthetrc
c400   SEQUENCE   116
Gln Gln Arg Tyr Ser Tyr Trp I\rg Thr
I                 5
  210  SEQ ID NO 117
  211  LENGTH 9
  212  TYPE PRT
  213  ORGAEISN Artrfrc   ral Sequence
  220  FEATURE:
  223  OTHER INPORHATION    Synthetrc
  400. SEQUENCE   117
Gln Gln   frg Tyr Ser Phe Lye Arg Thr
                  5
  210  6'EQ ID NO 115
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE   Artrfrc ral Sequence
  220  PEATURR.
  223  OTHER INFORFZATION   Synthetrc
  400  SEQUENCE   119
Gln Gln Arg Tyr Ser Ala Arg Arg Thr
1                 5
  210  SEQ ID NO 119
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN Artrfrc   ral Sequence
  220  FEATURE
  223  OTHER INPORFZATZON   Syntretrc
  400  SEQUENCE   119
Gln Gln Arg Tyr Ser Arg Tyr Arg Thr
1                 5
  210  SEQ ID NO 120
  211  LENGTH 9
  212  TYPE PPT
  213  ORGIUIISN Artrfrc  ral Sequence
  220  FEATURE:
  223  OTHER IEFORNATION    Synthetrc
  400  SEQUENCE   120
Gln Gln Arg Tyr Ser Leu Gln I\rg Thr
I                 5
  210  SEQ ID NO 121
  211  LENGTH 9
  212  TYPE PRT
  213  ORGPIIISN Artrfrc  ral Sequence
  220  FEATURE:
  223  OTHER INPORHATION    Synthetrc
  400  SEQUENCE   121
Gln Gln   frg Tyr Ser Thr Ser Arg Thr
1                 5
  210  6'EQ ID NO 122
  211  LENGTH 9
  212  TYPE PRT
                                         US 8,080,243 B2
                           107                          108
                                         -continued
  213 ORGANISM    Arttftc tal  Sequence
  220 FEATURE
  223 OTHER INFORM'TION     Synthetzc
  400 SEQUENCE    122
Gln Gln Arg Tyr Ser Hz     6;la Arg Thr
1                 5
  210 SEQ ID NO 123
  211 LENGTH 9
  212 TYPE PRT
  213 ORGAEISN Artzfzc    tal  Sequence
  220 FEATURE.
  223 OTHER INFORMATION     Synthetzc
  600 SEQUENCE    123
Gln Gln Arg Tyr   ser Lye Tyr Arg Thr
I                 5
  210 SEQ ID NO 124
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISN Artzfzc    ral Sequence
  220 FEATURE:
  223 OTHER IMFOPMATIOM     Synthettc
  400 SEQUENCE    124
Gln Gln Arg Tyr Ser Gln Ser Arg Thr
1                 5
  210 SEQ ID I'10 125
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISM    Artrftc ral Sequence
  220 FEATURE
  223 OTIIER INFORNFTIOM    Synthetzc
  400 SEQUENCE    125
Gln Gln Arg Tyr Ser Thr Ala Phe Thr
1                 5
  210 SEQ ID NO 126
  211 LENGTH 9
  212 TYPE PRT
  213 ORGANISN Artzfrc    tal  Sequence
  220 FEATURE
  223 OTHER INFORM'TION     Synthetzc
  400 SEQUENCE    126
Gln Gln Arg Tyr Ser Thr Cya Cya Thr
I                 5
  210 SEQ ID NO 127
  211 LENGTH 9
  212 TYPE PRT
  213 ORGAEISN Artzfzc    tal  Sequence
  220 PEATURE:
  223 OTHER INFORNATZON     aynt hat zc
  400 SEQUENCE    127
Gln Gln Arg Tyr Ser Thr !\ep !\rg Thr
I                 5
  210 SEQ ID NO 128
  211 LENGTH 9
  212 TYPE PRT
  213 ORGAMISN Artzfzcral      Sequence
  220 FEATURE
                                         US 8,080,243 B2
                            109
                                         -continued
  223  OTHER INPORNATION     Synthetic
  400  SEQUENCE    128
Gln Gln Arg Tyr Ser Glu Aep Azg Thr
1                  5
  210  SEQ ID NO 129
  211  LENGTH 8
  212  TYPE PRT
  213  ORGANISN    Artific ial Sequence
  220  FEATURE
  223  OTHER INFORHPTION     Synthetic
  400  SEQUENCE    129
Gln Gln Arg   Iiz  Val Gly Arg Thr
1                  5
  210  SEQ ID NO 130
  211  LENGTH    9
  212  TYPE PRT
  213  ORGANISN    Artific ial Sequence
  220  FEATURE:
  223  OTHER INPORNATION     Synthetic
  400  SEQUENCE    130
Gln Gln Arg Tyr Ser Leu Ser Arg Thr
                   5
  210  SEQ ID NO 131
e211   LENGTH 9
  212  TYPE PRT
  213  ORGANIISN   Artific ial sequence
  220  FEATURE.
  223  OTHER INFORNATION     Synthetic
  400  SEQUENCE    131
Gln Gln Arg Tyr Ser Leu Gly Azg Thr
1                  5
  210a SEQ ID NO 132
  211a LENGTH 9
  212  TYPE PRT
  213  ORGANISbl   Artific ial Sequence
  220  FEATUPE
  223  OTHER INPORNTTION     Synthetic
  400  SEQUENCE    132
Gln Gln Arg Tyr Ser Arg Ala Arg Thr
1                  5
  210  SEQ ID NO 133
  211  LENGTH 9
  212  TYPE PRT
  213  ORGAEISN    Artific ial Sequence
  220  FEATURE
  223  OTHER INFORNPTION     Synthetic
  400  SEQUENCE    133
Gln Gln Arg Tyz Ser Hi. Ala I.rg Thz
I                  5
  210  SEQ ID NO 134
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN    Artific ial Sequence
  220  FEATURE:
  223  OTHER INFORNATION     Synthetic
                                                US 8,080,243 B2
                            111
                                                 -continued
  400   SEQUENCE   134
Gln Gln Arg Tyr Ser Thr Pro Asp Thr
I                  5
s210    SEQ ID NO 135
  211   LEI'GTH 9
  212   TYPE PRT
  213   ORGANISE Artzfzc   tal Sequence
  220   FEATURE.
  223   OTHER INFORSIATION   Synthetrc
  400   SEQUENCE   135
Gln Gln Arg Tyr Gln Gln Pro Arg Thr
I                  5
  210s  SEQ ID NO 136
  211   LEHGTH 17
  212   TYPE PRT
  213   ORGANISN Artrfzc zal Sequence
  220   FEATURE
  223   OTHER INFORNATION Synthetic
  400   SEQUENCE   136
Glu   Ile Gln Val Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Plae Lys
I                  5                    10                 15
Ser
  210   SEQ ID NO 137
s211    LENGTH 17
  212   TYPE PRT
  213   ORGANIISN  Artzfzc Ial sequence
  220   FEATURE.
  223   OTHER INFORHATION    Synthetrc
  400   SEQUENCE   137
Glu   Ile Asn Pro Trp Gln Gly Arg Thr F.cn Tyr Asn Glu Lys Phe Lys
I                  5                    10                 15
Ser
  210   SEQ ID NO 138
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Artrfzc zal Sequence
  220   FEATURE
  223   OTHER INFORH'TION Synthetzc
  400   SEQUENCE   138
Glu   Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                  5                    10                 15
Ser
  210   SEQ ID NO 139
  211   LENGTH 17
  212   TYPE PRT
  213   ORGAIIISH Artzfzc zal Sequence
  220   FEATURE:
  223   OTHER INPORHATION Synthetzc
  400   SEQUENCE   139
Glu   Ile Ser  Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                  5                    10                 15
Ser
  210   SEQ ID NO 140
                                                     US 8,080,243 B2
                            113
                                                      -continued
  211   LENGTH 17
  212   TYPE PPT
  213   DEREISM    Artrfrc ral Sequence
  220   FEATURE
  223   OTHER INFORFLATION   Synthetrc
s400    SEQUENCE   140
Glu   Ile Gln Glu Ser Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                  5                       10                   15
Ser
  210   SEQ ID NO 141
  211   LEIIGTH 17
  212   TYPE PRT
  213   ORGANISM Artrfrc   ral sequence
  220   PEATURE:
  223.  OTHER INFORMATION    Synthetrc
  400   SEQUENCE   141
Glu   Ile Ser  Pro Ile Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                  5                       10                   15
Ser
  210   SEQ ID NO 142
  211   LENGTH 17
  212   TYPE PRT
  213   ORGAEISN Artrfrc   ral Sequence
  220   FEATURE
  223   OTHER INPORKATION    Synthetrc
  400   SEQUENCE   142
Glu   Ile Asn Pro Glu Hr    Gly  .'. g Tlr ann Tyr Asn Glu  Ly  Phe '
I                  5                       10                   15
Ser
  210   SEQ ID NO 143
  211   LENGTH 17
  212   TYPE PRT
  213 s ORGWIISM Artrfrc   ral  Sequence
  220.  FEATURE.
  223   OTHER INFORMATION    Syntlsetrc
  400   SEQUENCE   143
Glu   Ile Asn Pro Ser Glu Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
                   5                       10
Ser
  210   SEQ ID NO 144
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISN Artrfrc   ral Sequence
  220   FEATURE
  223   OTHER INFORMATION    Synthetrc
  400   SEQUENCE   144
Glu   Ile Asn Pro Trp Met Gly Arg Thr      A  n Tyr Asn Glu Lys Phe Lys
I                  5                       10                   15
Ser
  210   SEQ ID NO 145
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISM Artrfrc   ral Sequence
  220   FEATURE.
  223   OTHER INFORMATION    Synthetrc
                                                 US 8,080,243 B2
                            115
                                                  -continued
  400   SEQUENCE    145
Glu   Ile Asn Pro Gln Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                   5                   10                  15
Ser
  210   SEQ ID NO 14
  211   LENGTH 17
  212   TYPE PRT
  213   ORGAEISN Artzfrc   ral Sequence
  220   FEATURE
  223   OTHER INPORFZATION   Synthetzc
  400   SEQUENCE    146
Glu   Ile Aan Pro Val Lys Gly Arg Thr aan Tyr Asn Glu Lys Phe Ly-
I                   5                   10                  15
Ser
  210   SEQ ID NO 147
  211   LENGTH 17
  212   TYPE PRT
  213   ORGPIIISH Artrfzc  ral Sequence
  220   FEATURE.
  223   OTHER INPORHATION    Synthettc
  400   SEQUENCE    147
Glu   Ile Gly Pro Trp Gly Gly Arg Thr Psn Tyr Asn Glu Lys Phe Lys
I                   5                   10                  15
Ser
  210   SEQ ID NO 148
  211   LENGTH 17
  212   TYPE PRT
  213   ORGIZNISH .Artzftc tal Sequence
  220   FEATURE.
  223   OTHER INFORHATION    Synthetzc
  400   SEQUENCE    148
Glu   Ile Asn Pro   lie Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                   5                   10                  15
Ser
  210   SEQ ID NO 149
  211   LENGTH 17
  212   TYPE PRT
  213   ORG.AIISN AZtrfrC  ral Sequence
  220   PEATURR.
  223   OTHER INFORSIATION   Synthettc
  400   SEQUENCE    149
Glu   Ile Gln  Ile Ser  Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                                       10                  15
Ser
  210   SEQ ID I'10 150
  211   LENGTH 17
  212   TYPE PRT
  213   ORGANISE Artzftc   tal Sequence
  220   FEITURE
  223   OTHER INFORFIATION   Synthetzc
  400   SEQUENCE    150
Glu   Ile Asn Pro Gln Gly Thr Arg Thr F.cn Tyr Asn Glu Lys Phe Lys
I                   5                   10                  15
                                         US 8,080,243 B2
                            117
                                         -continued
Ser
  210  SEQ ID NO 151
e211   LENGTH 9
e212   TYPE PRT
  213  ORGANNSN    Artzfzc zal Sequence
  220  FEATURE.
  223  OTHER INFORMATION     Synthetzc
  400  SEQUENCE    151
Glu Arg Pro Leu Tyr Ala Ser Asp Ser
I                  5
  210  SEQ ID I'10 152
  211  LENGTH 9
  212e T'ZPE PRT
  213  ORGANISE Artzfzc zal Sequence
  220  FEZTURE
  223  OTHER INFORHATION Synthetzc
  400  SEQUENCE    152
Glu Arg Pro Leu Tyr Ala Ser 5 p Arg
I                  5
  210  SEQ ID NO 153
  211  LEI'GTH 9
  212  TYPE PRT
  213  ORGANISN Artzfzc zal Sequence
  220  FEATURE
e223   OTHER INPORNATION Synthetzc
  400  SEQUENCE    153
Glu Arg Pro Leu Tyr Ala Het Asp Arg
I                  5
  210  SEQ ID NO 154
  211  LEIZGTH   9
  212  TYPE PRT
  213  ORGANIS'N Artzfzc zal Sequence
  220. PEATURE.
  223. OTHER INFORNATION synthetzc
  400  SEQURNCE    154
Glu Arg Pro Leu Tyr Ala Asn Asp Ala
I                  5
  210  SEQ ID EO 155
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE Artzfzc zal Sequence
  220  FEATURE.
  223  OTHER INPORHATI014 Synthetzc
  400  SEQUENCE    155
Glu Arg Pro Leu Tyr Ala Asn Asp Val
I                  5
  210  SEQ ID I'10 156
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISE Artzfzc zal Sequence
  220  FEZTURE
  223  OTHER INFORFIATION Synthetzc
  400  SEQUENCE    156
Glu Arg Pro Leu Tyz Ala Hzs     A p Val
I                  5
                                         US 8,080,243 B2
                            119                         120
                                         -continued
  210  SEQ ID NO 157
  211  LENGTH    9
  212  TYPE PRT
s213   ORG.OIISN   AZtzfzC zal Sequence
s220   FEATURE:
  223  OTHER 11'IFORNATION   Synthetzc
  400  SEQUENCE    157
Glu Arg Pro Leu Tyr Ala Ser Asp Tyr
I
  210  SEQ ID NO 158
  211  LENGTH 9
  212  TYPE PRT
  213  ORGWIISN Artzfzc zal Sequence
  220. FEATURE.
  223  OTHER INFORN'ZION Synthetzc
  400  SEQUENCE    158
Glu Arg Pro Leu Tyr Ala Ser Asp Val
I                  5
  210  SEQ ID NO 159
  211  LENGTH 9
  212  TYPE PRT
  213  ORnaIIISH   Artzftc tal Sequence
  220  FEATURE
  223  OTHER INFORteATION    Synthetzc
s400   SEQUENCE    159
Glu Arg Pro Leu Tyr Ala Ser     A p Ala
I                  5
  210  SEQ ID NO 160
  211  LENGTH 9
  212  TYPE PRT
  213  ORGAEISH Artzfzc zal Sequence
  220  FEATURE.
  223  OTHER INFORHATION Synthetzc
  400. SEQUENCE    160
Glu Arg Pro Leu Tyr Ala Asn Asp Ser
                   5
  210  SEQ ID NO 161
  211  LENGTH 9
  212  TYPE PRT
  213  ORG.OIISN AZtzfzC zal Sequence
  220  PEATURR.
  223  OTHER INFORtZATION Synthetzc
  400  SEQUENCE    161
Glu Arg Pro Leu Tyr Ala Thr Asp Leu
I
  210  SEQ ID NO 162
  211  LENGTH 9
  212  TYPE PRT
  213  ORGANISN    Arttftc tal Sequence
  220  FEATURE
  223  OTHER INFORHATION     Synthetzc
  400  SEQUENCE    162
Glu Arg Pro Leu Tyr Ala Ser Asp Ser
I                  5
                                        US 8,080,243 B2
                           121                         122
                                        -continued
  210   SEQ ID NO 163
  211   LENGTH   9
  212   TYPE PRT
  213   ORGAEISN Artzfzc  tal Sequence
  220   FEATURE
a223    OTHER INFORHATION   Synthetzc
  400   SEQUENCE   163
Glu Arg Pro Leu Tyr Ala Asn Asp Net
I                  5
  210   SEQ ID NO 164
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzftc zal sequence
  220   PEATURE:
  223   OTHER INPORI4ATION synthetzc
  400   SEQUENCE   164
Glu Arg Pro Leu Tyr Ala Hts Asp Leu
I                  5
  210   SEQ ID NO 165
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzfzc zal Sequence
  220   FEATURE.
  223   OTHER INFORH'TION Synthetzc
  400   SEQUENCE   165
Glu   'rg Pro Leu Tyr Ala Hzs  A p Ile
I                  5
  210   SEQ ID NO 166
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE .Artzfzc tal Sequence
  220   FEATURE.
  223   OTHER INFORHATION   Synthetzc
  400   SEQUENCE   166
Glu Arg Pro Leu Tyr Ala Asn Asp Val
I                  5
  210   SEQ ID NO I 7
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISN Artzfzc zal Sequence
  220   FEATURE:
  223   OTHER INFORNATION Synthetzc
  400   SEQUENCE   167
Glu Arg Pro Leu Tyr Ala Ser Asp Tyr
I                  5
  210   SEQ ID NO 168
  211   LEI'GTH 9
  212   TYPE PRT
  213   ORGANISE Artzftc zal sequence
  220   PEATURE:
  223   OTHER INFORHATIOE Synthetzc
  400   SEQUENCE   168
Glu Arg Pro Leu Tyr Ala Ser Asp Arg
I                  5
  210   SEQ ID NO 169
  211   LENGTH 9
                                               US 8,080,243 B2
                              123                                 124
                                                -continued
  212   TYPE PRT
  213   ORGANISM     Artific ial Sequence
  220   FEATURE
  223   OTHER INFORHPTION      Synthetic
s400    SEQUENCE     169
Glu Arg Pro Leu Tyr Ala Ser 5 p Val
I                    5
  210   SEQ ID NO 170
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISN     Artific ial Sequence
  220   FEATURE.
  223   OTHER INFORffATION     Synthetic
  400   SEQUENCE     170
Glu Arg Pro Leu Tyr Ala Hls Asp Val
                     5
  210   SEQ ID NO 171
  211   LENGTH 9
  212   TYPE PRT
  213   ORGPIIISH    Artific ial Sequence
  220   FEATURE.
  223   OTHER INPORHATION      Synthetic
  400   SEQUENCE     171
Glu Arg Pro Leu Tyr Ala Asn Asp Net
1                    5
  210   SEQ ID NO 172
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISN     Artific ial Sequence
  220   FEATURE
  223   OTHER INFORMATION      Synthetic
  400   SEQUENCE     172
Glu Arg Pro Leu Tyr Ala His Asp Leu
1                    5
  210   SEQ ID NO 173
  211   LENGTH    17
  212   TYPE PRT
  213   ORGANISM     Artific ial Sequence
  220   FEATURE
  223   OTHER INFORMATION      Synthetic
  400   SEQUENCE     173
Glu   Ile Asn Pro Trp Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Ly
I                    5                    10              15
Ser
  210   SEQ ID NO 174
  211   LEI'GTH 17
  212   TYPE PRT
  213   ORGANISM     Artific ial sequence
  220   PEATURE:
  223   OTHER INFORHATION      Synthetic
  400   SEQUENCE     174
Glu   Ile Asn Pro Val Gln Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
1                    5                    10              15
Ser
                                                US 8,080,243 B2
                            125                                    126
                                                 -continued
  210   SEQ ID NO 175
  211   LENGTH    17
  212   TYPE PRT
  213   ORGANISN Artzfzc   tal Sequence
  220   FEATURE
r223    OTHER INFORHATION    Synthetzc
  400   SEQUENCE     175
Glu   Ile Ser  Pro Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                    5                  10                 15
Ser
  210   SEQ ID NO 174
  211   LENGTH 17
  212   TYPE PRT
  213   ORGWIISN Artzfzc zal Sequence
  220.  FEATURE.
  223   OTHER INFORN'TION Synthetzc
  400   SEQUENCE     17
Glu   Ile Gly Pro Trp Gly Gly Arg Thr Asn Tyr Asn Glu Zys Phe Ly-
I                    5                  10                 15
Ser
  210   SEQ ID NO 177
  211   LEI'GTH 9
  212   TYPE PRT
  213   ORGANISN Artzfzc zal Sequence
  220   FEATURE
r223    OTHER INPORNATION Synthetzc
  400   SEQUENCE     177
Gln Gln Arg Tyr Ser Asp Trp Arg Thr
I                    5
  210   SEQ ID NO 178
  211   LEIIGTH 9
  212   TYPE PRT
  213   ORGANIS'N Artzfzc zal Sequence
  220.  PEATURE.
  223.  OTHER INFORNATION synthetzc
  400   SEQURNCE     178
Gln Gln Arg Tyr Ser Ser Trp Arg Thr
I                    5
  210   SEQ ID EO 179
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzfzc zal Sequence
  220   FEATURE.
  223   OTHER INPORHATION Synthetzc
  400   SEQUENCE     179
Gln Gln Arg Tyr Ser Ala Glu Arg Thr
I                    5
  210   SEQ ID I'10 180
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzftc zal   Sequence
  220   FEITURE
  223   OTHER INFORFIATION   Synthetzc
  400   SEQUENCE     180
Gln Gln Arg Tyr Ser Leu Hzs Arg Thr
I                    5
                                                 US 8,080,243 B2
                             127
                                                  -continued
  210   SEQ ID NO 181
  211   LENGTH    9
  212   TYPE PRT
c213    ORG.SIISN   AZtzfzC zal Sequence
c220    FEATURE:
  223   OTHER 11'ZFORNATION   Synthetzc
  400   SEQUENCE    181
Gln Gln Arg Tyr Ser Ser Glu Arg Thr
I
  210   SEQ ID NO 182
  211   LENGTH 9
  212   TYPE PRT
  213   ORGWIISN Artzfzc zal Sequence
  220.  FEATURE.
  223   OTHER INFORN'ZION Synthetzc
  400   SEQUENCE    182
Gln Gln Azg Tyr Ser Leu Gln Azg Thr
I                   5
  210   SEQ ID NO 183
  211   LENGTH 9
  212   TYPE PRT
  213   ORG431ISH Artzfzc zal Sequence
  220   FEATURE
  223   OTHER INFORFZATION Synthetzc
c400    SEQUENCE    183
Gln Gln Arg Tyr Ser Thr      Zlzg  Arg Thr
I                   5
  210   SEQ ID NO 184
  211   LENGTH 9
  212   TYPE PRT
  213   ORGAEISH Artzfzc zal Sequence
  220   FEATURE.
  223   OTHER INFORHATION Synthetzc
  400.  SEQUENCE    184
Gln Gln Azg Tyr Ser Asp Trp Zlrg Thr
                    5
  210   SEQ ID NO 185
  211   LENGTH 17
  212   TYPE PRT
  213   ORG.SIISN   AZtzfzC zal Sequence
  220   PEATURR.
  223   OTHER INFORBZATION    Synthetzc
  400   SEQUENCE    185
Glu   Ile Ser Prc   Tyr Gly Gly Arg Thr Asn Tyr Asn Glu Lys Phe Lys
I                                          10               15
Ser
  210   SEQ ID I'10 186
  211   LENGTH 9
  212   TYPE PRT
  213   ORGANISE Artzfzc zal      Sequence
  220   FEITURE
  223   OTHER INFORFIATION    Synthetzc
  400   SEQUENCE    186
Gln Gln Arg Tyr Ser Arg Ser Arg Thr
I                   5
                                                        US 8,080,243 B2
                              129                                                              130
                                                          -continued
  210    SEQ ID No 187
  211    LENGTH     7
  212    TYPE PRT
a213     ORGAN11SN    ArtrfrCral  SequenCe
a220     FEATURE:
  223    OTHER INFORNATION      svntuetrc
  400    SEQUENCE     187
Asp Ala Ser       rsn Arg Ala Tar
1
   It is claimed:                                                    2. An Isolated antibody comprising a heavy clmin variable
    l. An Lso lated antibody which specifically binds to PCSK9    region (VI I) mid a light chain variable region (Vl h tvberein
and comprises a heavy clmtn venable regton (VII) comple-          the VI I region comprises the unulo actd sequence of SLQ ID
mentary determining region one (CORI) lmving the amino            NO: 54 and the VL region comprises the amino acid sequence
amd sequence shnw n in SI'Q ID NO g. 59. or 60, 0 Vl I CDR2     <U+201E><U+201E>of SFQ ID NO 53.
having the tuntno actd sequence sho~n in SFQ ID NO;9 or              3. A humalured anttbody compnstn a hatt chatn havtn
61, 0 VH ('DR3 havins the anlino acid sequence shown in           thc amino acid sequence of SFQ ID NO 14 and a hcaty clmin
Sl'.Q ID NO 10. a light chain varinble region (VL) ('DR I         havtng the amino acid sequence of SI',Q ID NO:15. wtth or
having the amino acid sequence shown in SL'Q ID NO:11, 0          without the (utenninal lysine of the amino acid sequence of
Vl, ('DR2 having tlm amino acid scqtmncc shown in SFQ ID          SFQ ID NO 15
NO 12. Snd a VI, CDR3 havulg the untno acid sequence
shown in SFQ 117 NO:13.
> 